HB0001 EngrossedLRB099 00249 HEP 20254 b

1    AN ACT concerning health.
 
2    Be it enacted by the People of the State of Illinois,
3represented in the General Assembly:
 
4
ARTICLE 1.

 
5    Section 1-1. This Article may be referred to as Lali's Law.
 
6    Section 1-5. The Pharmacy Practice Act is amended by adding
7Section 19.1 as follows:
 
8    (225 ILCS 85/19.1 new)
9    Sec. 19.1. Dispensing naloxone antidotes.
10    (a) Due to the recent rise in opioid-related deaths in
11Illinois and the existence of an opioid antagonist that can
12reverse the deadly effects of overdose, the General Assembly
13finds that in order to avoid further loss where possible, it is
14responsible to allow greater access of such an antagonist to
15those populations at risk of overdose.
16    (b) Notwithstanding any general or special law to the
17contrary, a licensed pharmacist may dispense an opioid
18antagonist in accordance with written, standardized procedures
19or protocols developed by the Department with the Department of
20Public Health and the Department of Human Services if the
21procedures or protocols are filed at the pharmacy before

 

 

HB0001 Engrossed- 2 -LRB099 00249 HEP 20254 b

1implementation and are available to the Department upon
2request.
3    (c) Before dispensing an opioid antagonist pursuant to this
4Section, a pharmacist shall complete a training program
5approved by the Department of Human Services pursuant to
6Section 5-23 of the Alcoholism and Other Drug Abuse and
7Dependency Act. The training program shall include, but not be
8limited to, proper documentation and quality assurance.
9    (d) For the purpose of this Section, "opioid antagonist"
10means a drug that binds to opioid receptors and blocks or
11inhibits the effect of opioids acting on those receptors,
12including, but not limited to, naloxone hydrochloride or any
13other similarly acting and equally safe drug approved by the
14U.S. Food and Drug Administration for the treatment of drug
15overdose.
 
16
ARTICLE 5.

 
17    Section 5-1. The Open Meetings Act is amended by changing
18Section 2 as follows:
 
19    (5 ILCS 120/2)  (from Ch. 102, par. 42)
20    Sec. 2. Open meetings.
21    (a) Openness required. All meetings of public bodies shall
22be open to the public unless excepted in subsection (c) and
23closed in accordance with Section 2a.

 

 

HB0001 Engrossed- 3 -LRB099 00249 HEP 20254 b

1    (b) Construction of exceptions. The exceptions contained
2in subsection (c) are in derogation of the requirement that
3public bodies meet in the open, and therefore, the exceptions
4are to be strictly construed, extending only to subjects
5clearly within their scope. The exceptions authorize but do not
6require the holding of a closed meeting to discuss a subject
7included within an enumerated exception.
8    (c) Exceptions. A public body may hold closed meetings to
9consider the following subjects:
10        (1) The appointment, employment, compensation,
11    discipline, performance, or dismissal of specific
12    employees of the public body or legal counsel for the
13    public body, including hearing testimony on a complaint
14    lodged against an employee of the public body or against
15    legal counsel for the public body to determine its
16    validity.
17        (2) Collective negotiating matters between the public
18    body and its employees or their representatives, or
19    deliberations concerning salary schedules for one or more
20    classes of employees.
21        (3) The selection of a person to fill a public office,
22    as defined in this Act, including a vacancy in a public
23    office, when the public body is given power to appoint
24    under law or ordinance, or the discipline, performance or
25    removal of the occupant of a public office, when the public
26    body is given power to remove the occupant under law or

 

 

HB0001 Engrossed- 4 -LRB099 00249 HEP 20254 b

1    ordinance.
2        (4) Evidence or testimony presented in open hearing, or
3    in closed hearing where specifically authorized by law, to
4    a quasi-adjudicative body, as defined in this Act, provided
5    that the body prepares and makes available for public
6    inspection a written decision setting forth its
7    determinative reasoning.
8        (5) The purchase or lease of real property for the use
9    of the public body, including meetings held for the purpose
10    of discussing whether a particular parcel should be
11    acquired.
12        (6) The setting of a price for sale or lease of
13    property owned by the public body.
14        (7) The sale or purchase of securities, investments, or
15    investment contracts. This exception shall not apply to the
16    investment of assets or income of funds deposited into the
17    Illinois Prepaid Tuition Trust Fund.
18        (8) Security procedures and the use of personnel and
19    equipment to respond to an actual, a threatened, or a
20    reasonably potential danger to the safety of employees,
21    students, staff, the public, or public property.
22        (9) Student disciplinary cases.
23        (10) The placement of individual students in special
24    education programs and other matters relating to
25    individual students.
26        (11) Litigation, when an action against, affecting or

 

 

HB0001 Engrossed- 5 -LRB099 00249 HEP 20254 b

1    on behalf of the particular public body has been filed and
2    is pending before a court or administrative tribunal, or
3    when the public body finds that an action is probable or
4    imminent, in which case the basis for the finding shall be
5    recorded and entered into the minutes of the closed
6    meeting.
7        (12) The establishment of reserves or settlement of
8    claims as provided in the Local Governmental and
9    Governmental Employees Tort Immunity Act, if otherwise the
10    disposition of a claim or potential claim might be
11    prejudiced, or the review or discussion of claims, loss or
12    risk management information, records, data, advice or
13    communications from or with respect to any insurer of the
14    public body or any intergovernmental risk management
15    association or self insurance pool of which the public body
16    is a member.
17        (13) Conciliation of complaints of discrimination in
18    the sale or rental of housing, when closed meetings are
19    authorized by the law or ordinance prescribing fair housing
20    practices and creating a commission or administrative
21    agency for their enforcement.
22        (14) Informant sources, the hiring or assignment of
23    undercover personnel or equipment, or ongoing, prior or
24    future criminal investigations, when discussed by a public
25    body with criminal investigatory responsibilities.
26        (15) Professional ethics or performance when

 

 

HB0001 Engrossed- 6 -LRB099 00249 HEP 20254 b

1    considered by an advisory body appointed to advise a
2    licensing or regulatory agency on matters germane to the
3    advisory body's field of competence.
4        (16) Self evaluation, practices and procedures or
5    professional ethics, when meeting with a representative of
6    a statewide association of which the public body is a
7    member.
8        (17) The recruitment, credentialing, discipline or
9    formal peer review of physicians or other health care
10    professionals for a hospital, or other institution
11    providing medical care, that is operated by the public
12    body.
13        (18) Deliberations for decisions of the Prisoner
14    Review Board.
15        (19) Review or discussion of applications received
16    under the Experimental Organ Transplantation Procedures
17    Act.
18        (20) The classification and discussion of matters
19    classified as confidential or continued confidential by
20    the State Government Suggestion Award Board.
21        (21) Discussion of minutes of meetings lawfully closed
22    under this Act, whether for purposes of approval by the
23    body of the minutes or semi-annual review of the minutes as
24    mandated by Section 2.06.
25        (22) Deliberations for decisions of the State
26    Emergency Medical Services Disciplinary Review Board.

 

 

HB0001 Engrossed- 7 -LRB099 00249 HEP 20254 b

1        (23) The operation by a municipality of a municipal
2    utility or the operation of a municipal power agency or
3    municipal natural gas agency when the discussion involves
4    (i) contracts relating to the purchase, sale, or delivery
5    of electricity or natural gas or (ii) the results or
6    conclusions of load forecast studies.
7        (24) Meetings of a residential health care facility
8    resident sexual assault and death review team or the
9    Executive Council under the Abuse Prevention Review Team
10    Act.
11        (25) Meetings of an independent team of experts under
12    Brian's Law.
13        (26) Meetings of a mortality review team appointed
14    under the Department of Juvenile Justice Mortality Review
15    Team Act.
16        (27) (Blank).
17        (28) Correspondence and records (i) that may not be
18    disclosed under Section 11-9 of the Public Aid Code or (ii)
19    that pertain to appeals under Section 11-8 of the Public
20    Aid Code.
21        (29) Meetings between internal or external auditors
22    and governmental audit committees, finance committees, and
23    their equivalents, when the discussion involves internal
24    control weaknesses, identification of potential fraud risk
25    areas, known or suspected frauds, and fraud interviews
26    conducted in accordance with generally accepted auditing

 

 

HB0001 Engrossed- 8 -LRB099 00249 HEP 20254 b

1    standards of the United States of America.
2        (30) Those meetings or portions of meetings of a
3    fatality review team or the Illinois Fatality Review Team
4    Advisory Council during which a review of the death of an
5    eligible adult in which abuse or neglect is suspected,
6    alleged, or substantiated is conducted pursuant to Section
7    15 of the Adult Protective Services Act.
8        (31) Meetings and deliberations for decisions of the
9    Concealed Carry Licensing Review Board under the Firearm
10    Concealed Carry Act.
11        (32) Meetings between the Regional Transportation
12    Authority Board and its Service Boards when the discussion
13    involves review by the Regional Transportation Authority
14    Board of employment contracts under Section 28d of the
15    Metropolitan Transit Authority Act and Sections 3A.18 and
16    3B.26 of the Regional Transportation Authority Act.
17        (33) Those meeting or portions of meetings of the
18    advisory committee and peer review subcommittee created
19    under Section 320 of the Illinois Controlled Substances Act
20    during which specific controlled substance prescriber,
21    dispenser, or patient information is discussed.
22    (d) Definitions. For purposes of this Section:
23    "Employee" means a person employed by a public body whose
24relationship with the public body constitutes an
25employer-employee relationship under the usual common law
26rules, and who is not an independent contractor.

 

 

HB0001 Engrossed- 9 -LRB099 00249 HEP 20254 b

1    "Public office" means a position created by or under the
2Constitution or laws of this State, the occupant of which is
3charged with the exercise of some portion of the sovereign
4power of this State. The term "public office" shall include
5members of the public body, but it shall not include
6organizational positions filled by members thereof, whether
7established by law or by a public body itself, that exist to
8assist the body in the conduct of its business.
9    "Quasi-adjudicative body" means an administrative body
10charged by law or ordinance with the responsibility to conduct
11hearings, receive evidence or testimony and make
12determinations based thereon, but does not include local
13electoral boards when such bodies are considering petition
14challenges.
15    (e) Final action. No final action may be taken at a closed
16meeting. Final action shall be preceded by a public recital of
17the nature of the matter being considered and other information
18that will inform the public of the business being conducted.
19(Source: P.A. 97-318, eff. 1-1-12; 97-333, eff. 8-12-11;
2097-452, eff. 8-19-11; 97-813, eff. 7-13-12; 97-876, eff.
218-1-12; 98-49, eff. 7-1-13; 98-63, eff. 7-9-13; 98-756, eff.
227-16-14; 98-1027, eff. 1-1-15; 98-1039, eff. 8-25-14; revised
2310-1-14.)
 
24    Section 5-10. The State Employees Group Insurance Act of
251971 is amended by changing Section 6.11 as follows:
 

 

 

HB0001 Engrossed- 10 -LRB099 00249 HEP 20254 b

1    (5 ILCS 375/6.11)
2    Sec. 6.11. Required health benefits; Illinois Insurance
3Code requirements. The program of health benefits shall provide
4the post-mastectomy care benefits required to be covered by a
5policy of accident and health insurance under Section 356t of
6the Illinois Insurance Code. The program of health benefits
7shall provide the coverage required under Sections 356g,
8356g.5, 356g.5-1, 356m, 356u, 356w, 356x, 356z.2, 356z.4,
9356z.6, 356z.8, 356z.9, 356z.10, 356z.11, 356z.12, 356z.13,
10356z.14, 356z.15, 356z.17, and 356z.22 of the Illinois
11Insurance Code. The program of health benefits must comply with
12Sections 155.22a, 155.37, 355b, and 356z.19, 370c, and 370c.1
13of the Illinois Insurance Code.
14    Rulemaking authority to implement Public Act 95-1045, if
15any, is conditioned on the rules being adopted in accordance
16with all provisions of the Illinois Administrative Procedure
17Act and all rules and procedures of the Joint Committee on
18Administrative Rules; any purported rule not so adopted, for
19whatever reason, is unauthorized.
20(Source: P.A. 97-282, eff. 8-9-11; 97-343, eff. 1-1-12; 97-813,
21eff. 7-13-12; 98-189, eff. 1-1-14; 98-1091, eff. 1-1-15.)
 
22    Section 5-15. The Alcoholism and Other Drug Abuse and
23Dependency Act is amended by changing Section 5-23 and adding
24Sections 5-24 and 20-20 as follows:
 

 

 

HB0001 Engrossed- 11 -LRB099 00249 HEP 20254 b

1    (20 ILCS 301/5-23)
2    Sec. 5-23. Drug Overdose Prevention Program.
3    (a) Reports of drug overdose.
4        (1) The Director of the Division of Alcoholism and
5    Substance Abuse shall may publish annually a report on drug
6    overdose trends statewide that reviews State death rates
7    from available data to ascertain changes in the causes or
8    rates of fatal and nonfatal drug overdose for the preceding
9    period of not less than 5 years. The report shall also
10    provide information on interventions that would be
11    effective in reducing the rate of fatal or nonfatal drug
12    overdose and shall include an analysis of drug overdose
13    information reported to the Department of Public Health
14    pursuant to subsection (e) of Section 3-3013 of the
15    Counties Code, Section 6.14g of the Hospital Licensing Act,
16    and subsection (j) of Section 22-30 of the School Code.
17        (2) The report may include:
18            (A) Trends in drug overdose death rates.
19            (B) Trends in emergency room utilization related
20        to drug overdose and the cost impact of emergency room
21        utilization.
22            (C) Trends in utilization of pre-hospital and
23        emergency services and the cost impact of emergency
24        services utilization.
25            (D) Suggested improvements in data collection.

 

 

HB0001 Engrossed- 12 -LRB099 00249 HEP 20254 b

1            (E) A description of other interventions effective
2        in reducing the rate of fatal or nonfatal drug
3        overdose.
4            (F) A description of efforts undertaken to educate
5        the public about unused medication and about how to
6        properly dispose of unused medication, including the
7        number of registered collection receptacles in this
8        State, mail-back programs, and drug take-back events.
9    (b) Programs; drug overdose prevention.
10        (1) The Director may establish a program to provide for
11    the production and publication, in electronic and other
12    formats, of drug overdose prevention, recognition, and
13    response literature. The Director may develop and
14    disseminate curricula for use by professionals,
15    organizations, individuals, or committees interested in
16    the prevention of fatal and nonfatal drug overdose,
17    including, but not limited to, drug users, jail and prison
18    personnel, jail and prison inmates, drug treatment
19    professionals, emergency medical personnel, hospital
20    staff, families and associates of drug users, peace
21    officers, firefighters, public safety officers, needle
22    exchange program staff, and other persons. In addition to
23    information regarding drug overdose prevention,
24    recognition, and response, literature produced by the
25    Department shall stress that drug use remains illegal and
26    highly dangerous and that complete abstinence from illegal

 

 

HB0001 Engrossed- 13 -LRB099 00249 HEP 20254 b

1    drug use is the healthiest choice. The literature shall
2    provide information and resources for substance abuse
3    treatment.
4        The Director may establish or authorize programs for
5    prescribing, dispensing, or distributing opioid
6    antagonists naloxone hydrochloride or any other similarly
7    acting and equally safe drug approved by the U.S. Food and
8    Drug Administration for the treatment of drug overdose.
9    Such programs may include the prescribing of opioid
10    antagonists naloxone hydrochloride or any other similarly
11    acting and equally safe drug approved by the U.S. Food and
12    Drug Administration for the treatment of drug overdose to a
13    person who is not at risk of opioid overdose but who, in
14    the judgment of the health care professional, may be in a
15    position to assist another individual during an
16    opioid-related drug overdose and who has received basic
17    instruction on how to administer an opioid antagonist and
18    education about administration by individuals who are not
19    personally at risk of opioid overdose.
20        (2) The Director may provide advice to State and local
21    officials on the growing drug overdose crisis, including
22    the prevalence of drug overdose incidents, programs
23    promoting the disposal of unused prescription drugs,
24    trends in drug overdose incidents, and solutions to the
25    drug overdose crisis.
26    (c) Grants.

 

 

HB0001 Engrossed- 14 -LRB099 00249 HEP 20254 b

1        (1) The Director may award grants, in accordance with
2    this subsection, to create or support local drug overdose
3    prevention, recognition, and response projects. Local
4    health departments, correctional institutions, hospitals,
5    universities, community-based organizations, and
6    faith-based organizations may apply to the Department for a
7    grant under this subsection at the time and in the manner
8    the Director prescribes.
9        (2) In awarding grants, the Director shall consider the
10    necessity for overdose prevention projects in various
11    settings and shall encourage all grant applicants to
12    develop interventions that will be effective and viable in
13    their local areas.
14        (3) The Director shall give preference for grants to
15    proposals that, in addition to providing life-saving
16    interventions and responses, provide information to drug
17    users on how to access drug treatment or other strategies
18    for abstaining from illegal drugs. The Director shall give
19    preference to proposals that include one or more of the
20    following elements:
21            (A) Policies and projects to encourage persons,
22        including drug users, to call 911 when they witness a
23        potentially fatal drug overdose.
24            (B) Drug overdose prevention, recognition, and
25        response education projects in drug treatment centers,
26        outreach programs, and other organizations that work

 

 

HB0001 Engrossed- 15 -LRB099 00249 HEP 20254 b

1        with, or have access to, drug users and their families
2        and communities.
3            (C) Drug overdose recognition and response
4        training, including rescue breathing, in drug
5        treatment centers and for other organizations that
6        work with, or have access to, drug users and their
7        families and communities.
8            (D) The production and distribution of targeted or
9        mass media materials on drug overdose prevention and
10        response, the potential dangers of keeping unused
11        prescription drugs in the home, and methods to properly
12        dispose of unused prescription drugs.
13            (E) Prescription and distribution of opioid
14        antagonists naloxone hydrochloride or any other
15        similarly acting and equally safe drug approved by the
16        U.S. Food and Drug Administration for the treatment of
17        drug overdose.
18            (F) The institution of education and training
19        projects on drug overdose response and treatment for
20        emergency services and law enforcement personnel.
21            (G) A system of parent, family, and survivor
22        education and mutual support groups.
23        (4) In addition to moneys appropriated by the General
24    Assembly, the Director may seek grants from private
25    foundations, the federal government, and other sources to
26    fund the grants under this Section and to fund an

 

 

HB0001 Engrossed- 16 -LRB099 00249 HEP 20254 b

1    evaluation of the programs supported by the grants.
2    (d) Health care professional prescription of opioid
3antagonists drug overdose treatment medication.
4        (1) A health care professional who, acting in good
5    faith, directly or by standing order, prescribes or
6    dispenses an opioid antagonist antidote to: (a) a patient
7    who, in the judgment of the health care professional, is
8    capable of administering the drug in an emergency, or (b) a
9    person who is not at risk of opioid overdose but who, in
10    the judgment of the health care professional, may be in a
11    position to assist another individual during an
12    opioid-related drug overdose and who has received basic
13    instruction on how to administer an opioid antagonist shall
14    not, as a result of his or her acts or omissions, be
15    subject to: (i) any disciplinary or other adverse action
16    under the Medical Practice Act of 1987, the Physician
17    Assistant Practice Act of 1987, the Nurse Practice Act, the
18    Pharmacy Practice Act, or any other professional licensing
19    statute or (ii) any criminal liability, except for willful
20    and wanton misconduct.
21        (2) A person who is not otherwise licensed to
22    administer an opioid antagonist antidote may in an
23    emergency administer without fee an opioid antagonist
24    antidote if the person has received the patient information
25    specified in paragraph (4) of this subsection and believes
26    in good faith that another person is experiencing a drug

 

 

HB0001 Engrossed- 17 -LRB099 00249 HEP 20254 b

1    overdose. The person shall not, as a result of his or her
2    acts or omissions, be (i) liable for any violation of the
3    Medical Practice Act of 1987, the Physician Assistant
4    Practice Act of 1987, the Nurse Practice Act, the Pharmacy
5    Practice Act, or any other professional licensing statute,
6    or (ii) subject to any criminal prosecution or civil
7    liability, except for willful and wanton misconduct
8    arising from or related to the unauthorized practice of
9    medicine or the possession of an opioid antidote.
10        (3) A health care professional prescribing an opioid
11    antagonist antidote to a patient shall ensure that the
12    patient receives the patient information specified in
13    paragraph (4) of this subsection. Patient information may
14    be provided by the health care professional or a
15    community-based organization, substance abuse program, or
16    other organization with which the health care professional
17    establishes a written agreement that includes a
18    description of how the organization will provide patient
19    information, how employees or volunteers providing
20    information will be trained, and standards for documenting
21    the provision of patient information to patients.
22    Provision of patient information shall be documented in the
23    patient's medical record or through similar means as
24    determined by agreement between the health care
25    professional and the organization. The Director of the
26    Division of Alcoholism and Substance Abuse, in

 

 

HB0001 Engrossed- 18 -LRB099 00249 HEP 20254 b

1    consultation with statewide organizations representing
2    physicians, pharmacists, advanced practice nurses,
3    physician assistants, substance abuse programs, and other
4    interested groups, shall develop and disseminate to health
5    care professionals, community-based organizations,
6    substance abuse programs, and other organizations training
7    materials in video, electronic, or other formats to
8    facilitate the provision of such patient information.
9        (4) For the purposes of this subsection:
10        "Opioid antagonist antidote" means a drug that binds to
11    opioid receptors and blocks or inhibits the effect of
12    opioids acting on those receptors, including, but not
13    limited to naloxone hydrochloride or any other similarly
14    acting and equally safe drug approved by the U.S. Food and
15    Drug Administration for the treatment of drug overdose.
16        "Health care professional" means a physician licensed
17    to practice medicine in all its branches, a physician
18    assistant who has been delegated prescriptive authority
19    the prescription or dispensation of an opioid antidote by
20    his or her supervising physician, an advanced practice
21    registered nurse who has a written collaborative agreement
22    with a collaborating physician that authorizes
23    prescriptive authority the prescription or dispensation of
24    an opioid antidote, or an advanced practice nurse or
25    physician assistant who practices in a hospital, hospital
26    affiliate, or ambulatory surgical treatment center and

 

 

HB0001 Engrossed- 19 -LRB099 00249 HEP 20254 b

1    possesses appropriate clinical privileges in accordance
2    with the Nurse Practice Act or a pharmacist licensed to
3    practice pharmacy under the Pharmacy Practice Act.
4        "Patient" includes a person who is not at risk of
5    opioid overdose but who, in the judgment of the physician,
6    may be in a position to assist another individual during an
7    overdose and who has received patient information as
8    required in paragraph (2) of this subsection on the
9    indications for and administration of an opioid antagonist
10    antidote.
11        "Patient information" includes information provided to
12    the patient on drug overdose prevention and recognition;
13    how to perform rescue breathing and resuscitation; opioid
14    antagonist antidote dosage and administration; the
15    importance of calling 911; care for the overdose victim
16    after administration of the overdose antagonist antidote;
17    and other issues as necessary.
18    (e) Drug overdose response policy.
19        (1) Every State and local government agency that
20    employs a law enforcement officer or fireman as those terms
21    are defined in the Line of Duty Compensation Act must
22    possess opioid antagonists and must establish a policy to
23    control the acquisition, storage, transportation, and
24    administration of such opioid antagonists and to provide
25    training in the administration of opioid antagonists. A
26    State or local government agency that employs a fireman as

 

 

HB0001 Engrossed- 20 -LRB099 00249 HEP 20254 b

1    defined in the Line of Duty Compensation Act but does not
2    respond to emergency medical calls or provide medical
3    services shall be exempt from this subsection.
4        (2) Every publicly or privately owned ambulance,
5    special emergency medical services vehicle, non-transport
6    vehicle, or ambulance assist vehicle, as described in the
7    Emergency Medical Services (EMS) Systems Act, which
8    responds to requests for emergency services or transports
9    patients between hospitals in emergency situations must
10    possess opioid antagonists.
11        (3) Entities that are required under paragraphs (1) and
12    (2) to possess opioid antagonists may also apply to the
13    Department for a grant to fund the acquisition of opioid
14    antagonists and training programs on the administration of
15    opioid antagonists.
16(Source: P.A. 96-361, eff. 1-1-10.)
 
17    (20 ILCS 301/5-24 new)
18    Sec. 5-24. Opiate prescriptions; educational materials.
19The Department shall develop educational materials to educate
20holders of opiate prescriptions about the dangers of children
21and teens gaining access to these medications. The materials
22shall include information regarding the means by which the
23abuse of opiate prescriptions can lead to the illegal use of
24heroin. The Department shall also develop a method of
25distribution for such educational materials.
 

 

 

HB0001 Engrossed- 21 -LRB099 00249 HEP 20254 b

1    (20 ILCS 301/20-20 new)
2    Sec. 20-20. Immunity from prosecution; drugs; public
3education program. The Department shall develop and implement a
4public education program to educate the public about the
5provisions set forth in Section 414 of the Illinois Controlled
6Substances Act granting immunity from prosecution for drug
7overdose victims or persons seeking help for drug overdose
8victims if the only evidence for the possession charge was
9obtained as a result of the person seeking or obtaining
10emergency medical assistance.
 
11    Section 5-25. The Department of State Police Law is amended
12by adding Section 2605-97 as follows:
 
13    (20 ILCS 2605/2605-97 new)
14    Sec. 2605-97. Training; opioid antagonists. The Department
15shall conduct or approve a training program for State police
16officers in the administration of opioid antagonists as defined
17in paragraph (1) of subsection (e) of Section 5-23 of the
18Alcoholism and Other Drug Abuse and Dependency Act that is in
19accordance with that Section. As used in this Section 2605-97,
20the term "State police officers" includes full-time or
21part-time State troopers, police officers, investigators, or
22any other employee of the Department exercising the powers of a
23peace officer.
 

 

 

HB0001 Engrossed- 22 -LRB099 00249 HEP 20254 b

1    Section 5-30. The Illinois Criminal Justice Information
2Act is amended by changing Section 9.3 as follows:
 
3    (20 ILCS 3930/9.3)
4    Sec. 9.3. The Prescription Pill and Drug Disposal Fund. The
5Prescription Pill and Drug Disposal Fund is created as a
6special fund in the State treasury. Moneys in the Fund shall be
7used for grants by the Illinois Criminal Justice Information
8Authority to local law enforcement agencies for the purpose of
9facilitating the collection, transportation, and incineration
10of pharmaceuticals from residential sources that are collected
11and transported by law enforcement agencies under Section 17.9A
12of the Environmental Protection Act; to municipalities or
13organizations that establish containers designated for the
14collection and disposal of unused controlled substances and
15conduct collection of unused controlled substances through
16mail-back programs; and for the publication or advertising of
17collection events or mail-back programs conducted by
18municipalities or organizations. Before awarding a grant from
19this Fund but no later than July 1, 2016 2012, the Authority
20shall adopt rules that (i) specify the conditions under which
21grants will be awarded from this Fund and (ii) otherwise
22provide for the implementation and administration of the grant
23program created by this Section. Interest attributable to
24moneys in the Fund shall be paid into the Fund.

 

 

HB0001 Engrossed- 23 -LRB099 00249 HEP 20254 b

1(Source: P.A. 97-545, eff. 1-1-12.)
 
2    Section 5-35. The State Finance Act is amended by adding
3Section 5.866 as follows:
 
4    (30 ILCS 105/5.866 new)
5    Sec. 5.866. The Parity Education Fund.
 
6    Section 5-40. The Illinois Police Training Act is amended
7by changing Section 7 and by adding Section 10.17 as follows:
 
8    (50 ILCS 705/7)  (from Ch. 85, par. 507)
9    Sec. 7. Rules and standards for schools. The Board shall
10adopt rules and minimum standards for such schools which shall
11include but not be limited to the following:
12    a. The curriculum for probationary police officers which
13shall be offered by all certified schools shall include but not
14be limited to courses of arrest, search and seizure, civil
15rights, human relations, cultural diversity, including racial
16and ethnic sensitivity, criminal law, law of criminal
17procedure, vehicle and traffic law including uniform and
18non-discriminatory enforcement of the Illinois Vehicle Code,
19traffic control and accident investigation, techniques of
20obtaining physical evidence, court testimonies, statements,
21reports, firearms training, training in the use of electronic
22control devices, including the psychological and physiological

 

 

HB0001 Engrossed- 24 -LRB099 00249 HEP 20254 b

1effects of the use of those devices on humans, first-aid
2(including cardiopulmonary resuscitation), training in the
3administration of opioid antagonists as defined in paragraph
4(1) of subsection (e) of Section 5-23 of the Alcoholism and
5Other Drug Abuse and Dependency Act, handling of juvenile
6offenders, recognition of mental conditions which require
7immediate assistance and methods to safeguard and provide
8assistance to a person in need of mental treatment, recognition
9of abuse, neglect, financial exploitation, and self-neglect of
10adults with disabilities and older adults, as defined in
11Section 2 of the Adult Protective Services Act, crimes against
12the elderly, law of evidence, the hazards of high-speed police
13vehicle chases with an emphasis on alternatives to the
14high-speed chase, and physical training. The curriculum shall
15include specific training in techniques for immediate response
16to and investigation of cases of domestic violence and of
17sexual assault of adults and children. The curriculum shall
18include training in techniques designed to promote effective
19communication at the initial contact with crime victims and
20ways to comprehensively explain to victims and witnesses their
21rights under the Rights of Crime Victims and Witnesses Act and
22the Crime Victims Compensation Act. The curriculum shall also
23include a block of instruction aimed at identifying and
24interacting with persons with autism and other developmental
25disabilities, reducing barriers to reporting crimes against
26persons with autism, and addressing the unique challenges

 

 

HB0001 Engrossed- 25 -LRB099 00249 HEP 20254 b

1presented by cases involving victims or witnesses with autism
2and other developmental disabilities. The curriculum for
3permanent police officers shall include but not be limited to
4(1) refresher and in-service training in any of the courses
5listed above in this subparagraph, (2) advanced courses in any
6of the subjects listed above in this subparagraph, (3) training
7for supervisory personnel, and (4) specialized training in
8subjects and fields to be selected by the board. The training
9in the use of electronic control devices shall be conducted for
10probationary police officers, including University police
11officers.
12    b. Minimum courses of study, attendance requirements and
13equipment requirements.
14    c. Minimum requirements for instructors.
15    d. Minimum basic training requirements, which a
16probationary police officer must satisfactorily complete
17before being eligible for permanent employment as a local law
18enforcement officer for a participating local governmental
19agency. Those requirements shall include training in first aid
20(including cardiopulmonary resuscitation).
21    e. Minimum basic training requirements, which a
22probationary county corrections officer must satisfactorily
23complete before being eligible for permanent employment as a
24county corrections officer for a participating local
25governmental agency.
26    f. Minimum basic training requirements which a

 

 

HB0001 Engrossed- 26 -LRB099 00249 HEP 20254 b

1probationary court security officer must satisfactorily
2complete before being eligible for permanent employment as a
3court security officer for a participating local governmental
4agency. The Board shall establish those training requirements
5which it considers appropriate for court security officers and
6shall certify schools to conduct that training.
7    A person hired to serve as a court security officer must
8obtain from the Board a certificate (i) attesting to his or her
9successful completion of the training course; (ii) attesting to
10his or her satisfactory completion of a training program of
11similar content and number of hours that has been found
12acceptable by the Board under the provisions of this Act; or
13(iii) attesting to the Board's determination that the training
14course is unnecessary because of the person's extensive prior
15law enforcement experience.
16    Individuals who currently serve as court security officers
17shall be deemed qualified to continue to serve in that capacity
18so long as they are certified as provided by this Act within 24
19months of the effective date of this amendatory Act of 1996.
20Failure to be so certified, absent a waiver from the Board,
21shall cause the officer to forfeit his or her position.
22    All individuals hired as court security officers on or
23after the effective date of this amendatory Act of 1996 shall
24be certified within 12 months of the date of their hire, unless
25a waiver has been obtained by the Board, or they shall forfeit
26their positions.

 

 

HB0001 Engrossed- 27 -LRB099 00249 HEP 20254 b

1    The Sheriff's Merit Commission, if one exists, or the
2Sheriff's Office if there is no Sheriff's Merit Commission,
3shall maintain a list of all individuals who have filed
4applications to become court security officers and who meet the
5eligibility requirements established under this Act. Either
6the Sheriff's Merit Commission, or the Sheriff's Office if no
7Sheriff's Merit Commission exists, shall establish a schedule
8of reasonable intervals for verification of the applicants'
9qualifications under this Act and as established by the Board.
10(Source: P.A. 97-815, eff. 1-1-13; 97-862, eff. 1-1-13; 98-49,
11eff. 7-1-13; 98-358, eff. 1-1-14; 98-463, eff. 8-16-13; 98-756,
12eff. 7-16-14.)
 
13    (50 ILCS 705/10.17 new)
14    Sec. 10.17. Training; administration of opioid
15antagonists. The Board shall conduct or approve an in-service
16training program for police officers in the administration of
17opioid antagonists as defined in paragraph (1) of subsection
18(e) of Section 5-23 of the Alcoholism and Other Drug Abuse and
19Dependency Act that is in accordance with that Section. As used
20in this Section 10.17, the term "police officers" includes
21full-time or part-time probationary police officers, permanent
22or part-time police officers, law enforcement officers,
23recruits, permanent or probationary county corrections
24officers, permanent or probationary county security officers,
25and court security officers. The term does not include

 

 

HB0001 Engrossed- 28 -LRB099 00249 HEP 20254 b

1auxiliary police officers as defined in Section 3.1-30-20 of
2the Illinois Municipal Code.
 
3    Section 5-45. The Illinois Fire Protection Training Act is
4amended by changing Section 8 and by adding Section 12.5 as
5follows:
 
6    (50 ILCS 740/8)  (from Ch. 85, par. 538)
7    Sec. 8. Rules and minimum standards for schools. The Office
8shall adopt rules and minimum standards for such schools which
9shall include but not be limited to the following:
10    a. Minimum courses of study, resources, facilities,
11apparatus, equipment, reference material, established records
12and procedures as determined by the Office.
13    b. Minimum requirements for instructors.
14    c. Minimum basic training requirements, which a trainee
15must satisfactorily complete before being eligible for
16permanent employment as a fire fighter in the fire department
17of a participating local governmental agency. Those
18requirements shall include training in first aid (including
19cardiopulmonary resuscitation) and training in the
20administration of opioid antagonists as defined in paragraph
21(1) of subsection (e) of Section 5-23 of the Alcoholism and
22Other Drug Abuse and Dependency Act.
23(Source: P.A. 88-661, eff. 1-1-95.)
 

 

 

HB0001 Engrossed- 29 -LRB099 00249 HEP 20254 b

1    (50 ILCS 740/12.5 new)
2    Sec. 12.5. In-service training; opioid antagonists. The
3Office shall distribute an in-service training program for fire
4fighters in the administration of opioid antagonists as defined
5in paragraph (1) of subsection (e) of Section 5-23 of the
6Alcoholism and Other Drug Abuse and Dependency Act that is
7developed by the Department of Human Services in accordance
8with that Section. As used in this Section 12.5, the term "fire
9fighters" includes full-time or part-time fire fighters, but
10does not include auxiliary, reserve, or volunteer
11firefighters.
 
12    Section 5-50. The Counties Code is amended by changing
13Sections 3-3013 and 5-1069.3 as follows:
 
14    (55 ILCS 5/3-3013)  (from Ch. 34, par. 3-3013)
15    Sec. 3-3013. Preliminary investigations; blood and urine
16analysis; summoning jury; reports. Every coroner, whenever, as
17soon as he knows or is informed that the dead body of any
18person is found, or lying within his county, whose death is
19suspected of being:
20        (a) A sudden or violent death, whether apparently
21    suicidal, homicidal or accidental, including but not
22    limited to deaths apparently caused or contributed to by
23    thermal, traumatic, chemical, electrical or radiational
24    injury, or a complication of any of them, or by drowning or

 

 

HB0001 Engrossed- 30 -LRB099 00249 HEP 20254 b

1    suffocation, or as a result of domestic violence as defined
2    in the Illinois Domestic Violence Act of 1986;
3        (b) A maternal or fetal death due to abortion, or any
4    death due to a sex crime or a crime against nature;
5        (c) A death where the circumstances are suspicious,
6    obscure, mysterious or otherwise unexplained or where, in
7    the written opinion of the attending physician, the cause
8    of death is not determined;
9        (d) A death where addiction to alcohol or to any drug
10    may have been a contributory cause; or
11        (e) A death where the decedent was not attended by a
12    licensed physician;
13shall go to the place where the dead body is, and take charge
14of the same and shall make a preliminary investigation into the
15circumstances of the death. In the case of death without
16attendance by a licensed physician the body may be moved with
17the coroner's consent from the place of death to a mortuary in
18the same county. Coroners in their discretion shall notify such
19physician as is designated in accordance with Section 3-3014 to
20attempt to ascertain the cause of death, either by autopsy or
21otherwise.
22    In cases of accidental death involving a motor vehicle in
23which the decedent was (1) the operator or a suspected operator
24of a motor vehicle, or (2) a pedestrian 16 years of age or
25older, the coroner shall require that a blood specimen of at
26least 30 cc., and if medically possible a urine specimen of at

 

 

HB0001 Engrossed- 31 -LRB099 00249 HEP 20254 b

1least 30 cc. or as much as possible up to 30 cc., be withdrawn
2from the body of the decedent in a timely fashion after the
3accident causing his death, by such physician as has been
4designated in accordance with Section 3-3014, or by the coroner
5or deputy coroner or a qualified person designated by such
6physician, coroner, or deputy coroner. If the county does not
7maintain laboratory facilities for making such analysis, the
8blood and urine so drawn shall be sent to the Department of
9State Police or any other accredited or State-certified
10laboratory for analysis of the alcohol, carbon monoxide, and
11dangerous or narcotic drug content of such blood and urine
12specimens. Each specimen submitted shall be accompanied by
13pertinent information concerning the decedent upon a form
14prescribed by such laboratory. Any person drawing blood and
15urine and any person making any examination of the blood and
16urine under the terms of this Division shall be immune from all
17liability, civil or criminal, that might otherwise be incurred
18or imposed.
19    In all other cases coming within the jurisdiction of the
20coroner and referred to in subparagraphs (a) through (e) above,
21blood, and whenever possible, urine samples shall be analyzed
22for the presence of alcohol and other drugs. When the coroner
23suspects that drugs may have been involved in the death, either
24directly or indirectly, a toxicological examination shall be
25performed which may include analyses of blood, urine, bile,
26gastric contents and other tissues. When the coroner suspects a

 

 

HB0001 Engrossed- 32 -LRB099 00249 HEP 20254 b

1death is due to toxic substances, other than drugs, the coroner
2shall consult with the toxicologist prior to collection of
3samples. Information submitted to the toxicologist shall
4include information as to height, weight, age, sex and race of
5the decedent as well as medical history, medications used by
6and the manner of death of decedent.
7    When the coroner or medical examiner finds that the cause
8of death is due to homicidal means, the coroner or medical
9examiner shall cause blood and buccal specimens (tissue may be
10submitted if no uncontaminated blood or buccal specimen can be
11obtained), whenever possible, to be withdrawn from the body of
12the decedent in a timely fashion. Within 45 days after the
13collection of the specimens, the coroner or medical examiner
14shall deliver those specimens, dried, to the Illinois
15Department of State Police, Division of Forensic Services, for
16analysis and categorizing into genetic marker groupings to be
17maintained by the Illinois Department of State Police in the
18State central repository in the same manner, and subject to the
19same conditions, as provided in Section 5-4-3 of the Unified
20Code of Corrections. The requirements of this paragraph are in
21addition to any other findings, specimens, or information that
22the coroner or medical examiner is required to provide during
23the conduct of a criminal investigation.
24    In all counties, in cases of apparent suicide, homicide, or
25accidental death or in other cases, within the discretion of
26the coroner, the coroner may summon 8 persons of lawful age

 

 

HB0001 Engrossed- 33 -LRB099 00249 HEP 20254 b

1from those persons drawn for petit jurors in the county. The
2summons shall command these persons to present themselves
3personally at such a place and time as the coroner shall
4determine, and may be in any form which the coroner shall
5determine and may incorporate any reasonable form of request
6for acknowledgement which the coroner deems practical and
7provides a reliable proof of service. The summons may be served
8by first class mail. From the 8 persons so summoned, the
9coroner shall select 6 to serve as the jury for the inquest.
10Inquests may be continued from time to time, as the coroner may
11deem necessary. The 6 jurors selected in a given case may view
12the body of the deceased. If at any continuation of an inquest
13one or more of the original jurors shall be unable to continue
14to serve, the coroner shall fill the vacancy or vacancies. A
15juror serving pursuant to this paragraph shall receive
16compensation from the county at the same rate as the rate of
17compensation that is paid to petit or grand jurors in the
18county. The coroner shall furnish to each juror without fee at
19the time of his discharge a certificate of the number of days
20in attendance at an inquest, and, upon being presented with
21such certificate, the county treasurer shall pay to the juror
22the sum provided for his services.
23    In counties which have a jury commission, in cases of
24apparent suicide or homicide or of accidental death, the
25coroner may conduct an inquest. The jury commission shall
26provide at least 8 jurors to the coroner, from whom the coroner

 

 

HB0001 Engrossed- 34 -LRB099 00249 HEP 20254 b

1shall select any 6 to serve as the jury for the inquest.
2Inquests may be continued from time to time as the coroner may
3deem necessary. The 6 jurors originally chosen in a given case
4may view the body of the deceased. If at any continuation of an
5inquest one or more of the 6 jurors originally chosen shall be
6unable to continue to serve, the coroner shall fill the vacancy
7or vacancies. At the coroner's discretion, additional jurors to
8fill such vacancies shall be supplied by the jury commission. A
9juror serving pursuant to this paragraph in such county shall
10receive compensation from the county at the same rate as the
11rate of compensation that is paid to petit or grand jurors in
12the county.
13    In every case in which a fire is determined to be a
14contributing factor in a death, the coroner shall report the
15death to the Office of the State Fire Marshal. The coroner
16shall provide a copy of the death certificate (i) within 30
17days after filing the permanent death certificate and (ii) in a
18manner that is agreed upon by the coroner and the State Fire
19Marshal.
20    In every case in which a drug overdose is determined to be
21the cause or a contributing factor in the death, the coroner or
22medical examiner shall report the death to the Department of
23Public Health. The Department of Public Health shall adopt
24rules regarding specific information that must be reported in
25the event of such a death. If possible, the coroner shall
26report the cause of the overdose. As used in this Section,

 

 

HB0001 Engrossed- 35 -LRB099 00249 HEP 20254 b

1"overdose" has the same meaning as it does in Section 414 of
2the Illinois Controlled Substances Act. The Department of
3Public Health shall issue a semiannual report to the General
4Assembly summarizing the reports received. The Department
5shall also provide on its website a monthly report of overdose
6death figures organized by location, age, and any other
7factors, the Department deems appropriate.
8    In addition, in every case in which domestic violence is
9determined to be a contributing factor in a death, the coroner
10shall report the death to the Department of State Police.
11    All deaths in State institutions and all deaths of wards of
12the State in private care facilities or in programs funded by
13the Department of Human Services under its powers relating to
14mental health and developmental disabilities or alcoholism and
15substance abuse or funded by the Department of Children and
16Family Services shall be reported to the coroner of the county
17in which the facility is located. If the coroner has reason to
18believe that an investigation is needed to determine whether
19the death was caused by maltreatment or negligent care of the
20ward of the State, the coroner may conduct a preliminary
21investigation of the circumstances of such death as in cases of
22death under circumstances set forth in paragraphs (a) through
23(e) of this Section.
24(Source: P.A. 95-484, eff. 6-1-08; 96-1059, eff. 7-14-10.)
 
25    (55 ILCS 5/5-1069.3)

 

 

HB0001 Engrossed- 36 -LRB099 00249 HEP 20254 b

1    Sec. 5-1069.3. Required health benefits. If a county,
2including a home rule county, is a self-insurer for purposes of
3providing health insurance coverage for its employees, the
4coverage shall include coverage for the post-mastectomy care
5benefits required to be covered by a policy of accident and
6health insurance under Section 356t and the coverage required
7under Sections 356g, 356g.5, 356g.5-1, 356u, 356w, 356x,
8356z.6, 356z.8, 356z.9, 356z.10, 356z.11, 356z.12, 356z.13,
9356z.14, 356z.15, and 356z.22 of the Illinois Insurance Code.
10The coverage shall comply with Sections 155.22a, 355b, and
11356z.19, and 370c of the Illinois Insurance Code. The
12requirement that health benefits be covered as provided in this
13Section is an exclusive power and function of the State and is
14a denial and limitation under Article VII, Section 6,
15subsection (h) of the Illinois Constitution. A home rule county
16to which this Section applies must comply with every provision
17of this Section.
18    Rulemaking authority to implement Public Act 95-1045, if
19any, is conditioned on the rules being adopted in accordance
20with all provisions of the Illinois Administrative Procedure
21Act and all rules and procedures of the Joint Committee on
22Administrative Rules; any purported rule not so adopted, for
23whatever reason, is unauthorized.
24(Source: P.A. 97-282, eff. 8-9-11; 97-343, eff. 1-1-12; 97-813,
25eff. 7-13-12; 98-189, eff. 1-1-14; 98-1091, eff. 1-1-15.)
 

 

 

HB0001 Engrossed- 37 -LRB099 00249 HEP 20254 b

1    Section 5-55. The Illinois Municipal Code is amended by
2changing Section 10-4-2.3 as follows:
 
3    (65 ILCS 5/10-4-2.3)
4    Sec. 10-4-2.3. Required health benefits. If a
5municipality, including a home rule municipality, is a
6self-insurer for purposes of providing health insurance
7coverage for its employees, the coverage shall include coverage
8for the post-mastectomy care benefits required to be covered by
9a policy of accident and health insurance under Section 356t
10and the coverage required under Sections 356g, 356g.5,
11356g.5-1, 356u, 356w, 356x, 356z.6, 356z.8, 356z.9, 356z.10,
12356z.11, 356z.12, 356z.13, 356z.14, 356z.15, and 356z.22 of the
13Illinois Insurance Code. The coverage shall comply with
14Sections 155.22a, 355b, and 356z.19, and 370c of the Illinois
15Insurance Code. The requirement that health benefits be covered
16as provided in this is an exclusive power and function of the
17State and is a denial and limitation under Article VII, Section
186, subsection (h) of the Illinois Constitution. A home rule
19municipality to which this Section applies must comply with
20every provision of this Section.
21    Rulemaking authority to implement Public Act 95-1045, if
22any, is conditioned on the rules being adopted in accordance
23with all provisions of the Illinois Administrative Procedure
24Act and all rules and procedures of the Joint Committee on
25Administrative Rules; any purported rule not so adopted, for

 

 

HB0001 Engrossed- 38 -LRB099 00249 HEP 20254 b

1whatever reason, is unauthorized.
2(Source: P.A. 97-282, eff. 8-9-11; 97-343, eff. 1-1-12; 97-813,
3eff. 7-13-12; 98-189, eff. 1-1-14; 98-1091, eff. 1-1-15.)
 
4    Section 5-60. The School Code is amended by changing
5Section 22-30 and adding Section 22-80 as follows:
 
6    (105 ILCS 5/22-30)
7    Sec. 22-30. Self-administration and self-carry of asthma
8medication and epinephrine auto-injectors; administration of
9undesignated epinephrine auto-injectors; administration of an
10opioid antagonist.
11    (a) For the purpose of this Section only, the following
12terms shall have the meanings set forth below:
13    "Asthma inhaler" means a quick reliever asthma inhaler.
14    "Epinephrine auto-injector" means a single-use device used
15for the automatic injection of a pre-measured dose of
16epinephrine into the human body.
17    "Asthma medication" means a medicine, prescribed by (i) a
18physician licensed to practice medicine in all its branches,
19(ii) a physician assistant who has been delegated prescriptive
20authority the authority to prescribe asthma medications by his
21or her supervising physician, or (iii) an advanced practice
22nurse who has a written collaborative agreement with a
23collaborating physician that delegates prescriptive authority
24the authority to prescribe asthma medications, for a pupil that

 

 

HB0001 Engrossed- 39 -LRB099 00249 HEP 20254 b

1pertains to the pupil's asthma and that has an individual
2prescription label.
3    "Opioid antagonist" means a drug that binds to opioid
4receptors and blocks or inhibits the effect of opioids acting
5on those receptors, including, but not limited to, naloxone
6hydrochloride or any other similarly acting drug approved by
7the U.S. Food and Drug Administration.
8    "School nurse" means a registered nurse working in a school
9with or without licensure endorsed in school nursing.
10    "Self-administration" means a pupil's discretionary use of
11his or her prescribed asthma medication or epinephrine
12auto-injector.
13    "Self-carry" means a pupil's ability to carry his or her
14prescribed asthma medication or epinephrine auto-injector.
15    "Standing protocol" may be issued by (i) a physician
16licensed to practice medicine in all its branches, (ii) a
17physician assistant who has been delegated prescriptive
18authority the authority to prescribe asthma medications or
19epinephrine auto-injectors by his or her supervising
20physician, or (iii) an advanced practice nurse who has a
21collaborative agreement with a collaborating physician that
22delegates prescriptive authority to issue a standing protocol
23for asthma medications or epinephrine auto-injectors.
24    "Trained personnel" means any school employee or volunteer
25personnel authorized in Sections 10-22.34, 10-22.34a, and
2610-22.34b of this Code who has completed training under

 

 

HB0001 Engrossed- 40 -LRB099 00249 HEP 20254 b

1subsection (g) of this Section to recognize and respond to
2anaphylaxis.
3    "Undesignated epinephrine auto-injector" means an
4epinephrine auto-injector prescribed in the name of a school
5district, public school, or nonpublic school.
6    (b) A school, whether public or nonpublic, must permit the
7self-administration and self-carry of asthma medication by a
8pupil with asthma or the self-administration and self-carry of
9an epinephrine auto-injector by a pupil, provided that:
10        (1) the parents or guardians of the pupil provide to
11    the school (i) written authorization from the parents or
12    guardians for (A) the self-administration and self-carry
13    of asthma medication or (B) the self-carry of asthma
14    medication or (ii) for (A) the self-administration and
15    self-carry of an epinephrine auto-injector or (B) the
16    self-carry of an epinephrine auto-injector, written
17    authorization from the pupil's physician, physician
18    assistant, or advanced practice nurse; and
19        (2) the parents or guardians of the pupil provide to
20    the school (i) the prescription label, which must contain
21    the name of the asthma medication, the prescribed dosage,
22    and the time at which or circumstances under which the
23    asthma medication is to be administered, or (ii) for the
24    self-administration or self-carry of an epinephrine
25    auto-injector, a written statement from the pupil's
26    physician, physician assistant, or advanced practice nurse

 

 

HB0001 Engrossed- 41 -LRB099 00249 HEP 20254 b

1    containing the following information:
2            (A) the name and purpose of the epinephrine
3        auto-injector;
4            (B) the prescribed dosage; and
5            (C) the time or times at which or the special
6        circumstances under which the epinephrine
7        auto-injector is to be administered.
8The information provided shall be kept on file in the office of
9the school nurse or, in the absence of a school nurse, the
10school's administrator.
11    (b-5) A school district, public school, or nonpublic school
12may authorize the provision of a student-specific or
13undesignated epinephrine auto-injector to a student or any
14personnel authorized under a student's Individual Health Care
15Action Plan, Illinois Food Allergy Emergency Action Plan and
16Treatment Authorization Form, or plan pursuant to Section 504
17of the federal Rehabilitation Act of 1973 to administer an
18epinephrine auto-injector to the student, that meets the
19student's prescription on file.
20    (b-10) The school district, public school, or nonpublic
21school may authorize a school nurse or trained personnel to do
22the following: (i) provide an undesignated epinephrine
23auto-injector to a student for self-administration only or any
24personnel authorized under a student's Individual Health Care
25Action Plan, Illinois Food Allergy Emergency Action Plan and
26Treatment Authorization Form, or plan pursuant to Section 504

 

 

HB0001 Engrossed- 42 -LRB099 00249 HEP 20254 b

1of the federal Rehabilitation Act of 1973 to administer to the
2student, that meets the student's prescription on file; (ii)
3administer an undesignated epinephrine auto-injector that
4meets the prescription on file to any student who has an
5Individual Health Care Action Plan, Illinois Food Allergy
6Emergency Action Plan and Treatment Authorization Form, or plan
7pursuant to Section 504 of the federal Rehabilitation Act of
81973 that authorizes the use of an epinephrine auto-injector;
9and (iii) administer an undesignated epinephrine auto-injector
10to any person that the school nurse or trained personnel in
11good faith believes is having an anaphylactic reaction; and
12(iv) administer an opioid antagonist to any person that the
13school nurse or trained personnel in good faith believes is
14having an opioid overdose.
15    (c) The school district, public school, or nonpublic school
16must inform the parents or guardians of the pupil, in writing,
17that the school district, public school, or nonpublic school
18and its employees and agents, including a physician, physician
19assistant, or advanced practice nurse providing standing
20protocol or prescription for school epinephrine
21auto-injectors, are to incur no liability or professional
22discipline, except for willful and wanton conduct, as a result
23of any injury arising from the administration of asthma
24medication, or of an epinephrine auto-injector, or an opioid
25antagonist regardless of whether authorization was given by the
26pupil's parents or guardians or by the pupil's physician,

 

 

HB0001 Engrossed- 43 -LRB099 00249 HEP 20254 b

1physician assistant, or advanced practice nurse. The parents or
2guardians of the pupil must sign a statement acknowledging that
3the school district, public school, or nonpublic school and its
4employees and agents are to incur no liability, except for
5willful and wanton conduct, as a result of any injury arising
6from the administration of asthma medication, or of an
7epinephrine auto-injector, or an opioid antagonist regardless
8of whether authorization was given by the pupil's parents or
9guardians or by the pupil's physician, physician assistant, or
10advanced practice nurse and that the parents or guardians must
11indemnify and hold harmless the school district, public school,
12or nonpublic school and its employees and agents against any
13claims, except a claim based on willful and wanton conduct,
14arising out of the administration of asthma medication, or of
15an epinephrine auto-injector, or an opioid antagonist
16regardless of whether authorization was given by the pupil's
17parents or guardians or by the pupil's physician, physician
18assistant, or advanced practice nurse.
19    (c-5) When Upon the effective date of this amendatory Act
20of the 98th General Assembly, when a school nurse or trained
21personnel administers an undesignated epinephrine
22auto-injector to a person whom the school nurse or trained
23personnel in good faith believes is having an anaphylactic
24reaction, or administers an opioid antagonist to a person whom
25the school nurse or trained personnel in good faith believes is
26having an opioid overdose, notwithstanding the lack of notice

 

 

HB0001 Engrossed- 44 -LRB099 00249 HEP 20254 b

1to the parents or guardians of the pupil or the absence of the
2parents or guardians signed statement acknowledging no
3liability, except for willful and wanton conduct, the school
4district, public school, or nonpublic school and its employees
5and agents, and a physician, a physician assistant, or an
6advanced practice nurse providing standing protocol or
7prescription for undesignated epinephrine auto-injectors, are
8to incur no liability or professional discipline, except for
9willful and wanton conduct, as a result of any injury arising
10from the use of an undesignated epinephrine auto-injector or
11the use of an opioid antagonist regardless of whether
12authorization was given by the pupil's parents or guardians or
13by the pupil's physician, physician assistant, or advanced
14practice nurse.
15    (d) The permission for self-administration and self-carry
16of asthma medication or the self-administration and self-carry
17of an epinephrine auto-injector is effective for the school
18year for which it is granted and shall be renewed each
19subsequent school year upon fulfillment of the requirements of
20this Section.
21    (e) Provided that the requirements of this Section are
22fulfilled, a pupil with asthma may self-administer and
23self-carry his or her asthma medication or a pupil may
24self-administer and self-carry an epinephrine auto-injector
25(i) while in school, (ii) while at a school-sponsored activity,
26(iii) while under the supervision of school personnel, or (iv)

 

 

HB0001 Engrossed- 45 -LRB099 00249 HEP 20254 b

1before or after normal school activities, such as while in
2before-school or after-school care on school-operated
3property.
4    (e-5) Provided that the requirements of this Section are
5fulfilled, a school nurse or trained personnel may administer
6an undesignated epinephrine auto-injector to any person whom
7the school nurse or trained personnel in good faith believes to
8be having an anaphylactic reaction (i) while in school, (ii)
9while at a school-sponsored activity, (iii) while under the
10supervision of school personnel, or (iv) before or after normal
11school activities, such as while in before-school or
12after-school care on school-operated property. A school nurse
13or trained personnel may carry undesignated epinephrine
14auto-injectors on his or her person while in school or at a
15school-sponsored activity.
16    (e-10) Provided that the requirements of this Section are
17fulfilled, a school nurse or trained personnel may administer
18an opioid antagonist to any person whom the school nurse or
19trained personnel in good faith believes to be having an opioid
20overdose (i) while in school, (ii) while at a school-sponsored
21activity, (iii) while under the supervision of school
22personnel, or (iv) before or after normal school activities,
23such as while in before-school or after-school care on
24school-operated property. A school nurse or trained personnel
25may carry an opioid antagonist on their person while in school
26or at a school-sponsored activity.

 

 

HB0001 Engrossed- 46 -LRB099 00249 HEP 20254 b

1    (f) The school district, public school, or nonpublic school
2may maintain a supply of undesignated epinephrine
3auto-injectors in any secure location where an allergic person
4is most at risk, including, but not limited to, classrooms and
5lunchrooms. A physician, a physician assistant who has been
6delegated prescriptive authority for asthma medication or
7epinephrine auto-injectors in accordance with Section 7.5 of
8the Physician Assistant Practice Act of 1987, or an advanced
9practice nurse who has been delegated prescriptive authority
10for asthma medication or epinephrine auto-injectors in
11accordance with Section 65-40 of the Nurse Practice Act may
12prescribe undesignated epinephrine auto-injectors in the name
13of the school district, public school, or nonpublic school to
14be maintained for use when necessary. Any supply of epinephrine
15auto-injectors shall be maintained in accordance with the
16manufacturer's instructions.
17    The school district, public school, or nonpublic school may
18maintain a supply of an opioid antagonist in any secure
19location where an individual may have an opioid overdose. A
20health care professional who has been delegated prescriptive
21authority for opioid antagonists in accordance with Section
225-23 of the Alcoholism and Other Drug Abuse and Dependency Act
23may prescribe opioid antagonists in the name of the school
24district, public school, or nonpublic school, to be maintained
25for use when necessary. Any supply of opioid antagonists shall
26be maintained in accordance with the manufacturer's

 

 

HB0001 Engrossed- 47 -LRB099 00249 HEP 20254 b

1instructions.
2    (f-5) Upon any administration of an epinephrine
3auto-injector, a school district, public school, or nonpublic
4school must immediately activate the EMS system and notify the
5student's parent, guardian, or emergency contact, if known.
6    Upon any administration of an opioid antagonist, a school
7district, public school, or nonpublic school must immediately
8activate the EMS system and notify the student's parent,
9guardian, or emergency contact, if known.
10    (f-10) Within 24 hours of the administration of an
11undesignated epinephrine auto-injector, a school district,
12public school, or nonpublic school must notify the physician,
13physician assistant, or advance practice nurse who provided the
14standing protocol or prescription for the undesignated
15epinephrine auto-injector of its use.
16    Within 24 hours after the administration of an opioid
17antagonist, a school district, public school, or nonpublic
18school must notify the health care professional who provided
19the prescription for the opioid antagonist of its use.
20    (g) Prior to the administration of an undesignated
21epinephrine auto-injector, trained personnel must submit to
22his or her school's administration proof of completion of a
23training curriculum to recognize and respond to anaphylaxis
24that meets the requirements of subsection (h) of this Section.
25Training must be completed annually. Trained personnel must
26also submit to his or her school's administration proof of

 

 

HB0001 Engrossed- 48 -LRB099 00249 HEP 20254 b

1cardiopulmonary resuscitation and automated external
2defibrillator certification. The school district, public
3school, or nonpublic school must maintain records related to
4the training curriculum and trained personnel.
5    Prior to the administration of an opioid antagonist,
6trained personnel must submit to their school's administration
7proof of completion of a training curriculum to recognize and
8respond to an opioid overdose, which curriculum must meet the
9requirements of subsection (h-5) of this Section. Training must
10be completed annually. Trained personnel must also submit to
11the school's administration proof of cardiopulmonary
12resuscitation and automated external defibrillator
13certification. The school district, public school, or
14nonpublic school must maintain records relating to the training
15curriculum and the trained personnel.
16    (h) A training curriculum to recognize and respond to
17anaphylaxis, including the administration of an undesignated
18epinephrine auto-injector, may be conducted online or in
19person. It must include, but is not limited to:
20        (1) how to recognize symptoms of an allergic reaction;
21        (2) a review of high-risk areas within the school and
22    its related facilities;
23        (3) steps to take to prevent exposure to allergens;
24        (4) how to respond to an emergency involving an
25    allergic reaction;
26        (5) how to administer an epinephrine auto-injector;

 

 

HB0001 Engrossed- 49 -LRB099 00249 HEP 20254 b

1        (6) how to respond to a student with a known allergy as
2    well as a student with a previously unknown allergy;
3        (7) a test demonstrating competency of the knowledge
4    required to recognize anaphylaxis and administer an
5    epinephrine auto-injector; and
6        (8) other criteria as determined in rules adopted
7    pursuant to this Section.
8    In consultation with statewide professional organizations
9representing physicians licensed to practice medicine in all of
10its branches, registered nurses, and school nurses, the State
11Board of Education shall make available resource materials
12consistent with criteria in this subsection (h) for educating
13trained personnel to recognize and respond to anaphylaxis. The
14State Board may take into consideration the curriculum on this
15subject developed by other states, as well as any other
16curricular materials suggested by medical experts and other
17groups that work on life-threatening allergy issues. The State
18Board is not required to create new resource materials. The
19State Board shall make these resource materials available on
20its Internet website.
21    (h-5) A training curriculum to recognize and respond to an
22opioid overdose, including the administration of an opioid
23antagonist, may be conducted online or in person. The training
24must comply with any training requirements under Section 5-23
25of the Alcoholism and Other Drug Abuse and Dependency Act and
26the corresponding rules. It must include, but is not limited

 

 

HB0001 Engrossed- 50 -LRB099 00249 HEP 20254 b

1to:
2        (1) how to recognize symptoms of an opioid overdose;
3        (2) information on drug overdose prevention and
4    recognition;
5        (3) how to perform rescue breathing and resuscitation;
6        (4) how to respond to an emergency involving an opioid
7    overdose;
8        (5) opioid antagonist dosage and administration;
9        (6) the importance of calling 911;
10        (7) care for the overdose victim after administration
11    of the overdose antagonist;
12        (8) a test demonstrating competency of the knowledge
13    required to recognize an opioid overdose and administer a
14    dose of an opioid antagonist; and
15        (9) other criteria as determined in rules adopted
16    pursuant to this Section.
17    (i) Within 3 days after the administration of an
18undesignated epinephrine auto-injector by a school nurse,
19trained personnel, or a student at a school or school-sponsored
20activity, the school must report to the Board in a form and
21manner prescribed by the Board the following information:
22        (1) age and type of person receiving epinephrine
23    (student, staff, visitor);
24        (2) any previously known diagnosis of a severe allergy;
25        (3) trigger that precipitated allergic episode;
26        (4) location where symptoms developed;

 

 

HB0001 Engrossed- 51 -LRB099 00249 HEP 20254 b

1        (5) number of doses administered;
2        (6) type of person administering epinephrine (school
3    nurse, trained personnel, student); and
4        (7) any other information required by the Board.
5    (i-5) Within 3 days after the administration of an opioid
6antagonist by a school nurse or trained personnel, the school
7must report to the Board, in a form and manner prescribed by
8the Board, the following information:
9        (1) the age and type of person receiving the opioid
10    antagonist (student, staff, or visitor);
11        (2) the location where symptoms developed;
12        (3) the type of person administering the opioid
13    antagonist (school nurse or trained personnel); and
14        (4) any other information required by the Board.
15    (j) By October 1, 2015 and every year thereafter, the Board
16shall submit a report to the General Assembly identifying the
17frequency and circumstances of epinephrine administration
18during the preceding academic year. This report shall be
19published on the Board's Internet website on the date the
20report is delivered to the General Assembly.
21    On or before October 1, 2016 and every year thereafter, the
22Board shall submit a report to the General Assembly and the
23Department of Public Health identifying the frequency and
24circumstances of opioid antagonist administration during the
25preceding academic year. This report shall be published on the
26State Board's Internet website on the date the report is

 

 

HB0001 Engrossed- 52 -LRB099 00249 HEP 20254 b

1delivered to the General Assembly.
2    (k) The Board may adopt rules necessary to implement this
3Section.
4(Source: P.A. 97-361, eff. 8-15-11; 98-795, eff. 8-1-14.)
 
5    (105 ILCS 5/22-80 new)
6    Sec. 22-80. Heroin and opioid prevention pilot program. By
7January 1, 2017, the State Board of Education and the
8Department of Human Services shall develop and establish a
93-year heroin and opioid drug prevention pilot program that
10offers educational materials and instruction on heroin and
11opioid abuse to all school districts in the State for use at
12their respective public elementary and secondary schools. A
13school district's participation in the pilot program shall be
14voluntary. Subject to appropriation, the Department of Human
15Services shall reimburse a school district that decides to
16participate in the pilot program for any costs it incurs in
17connection with its participation in the pilot program. Each
18school district that participates in the pilot program shall
19have the discretion to determine which grade levels the school
20district will instruct under the program.
21    The pilot program must use effective, research-proven,
22interactive teaching methods and technologies, and must
23provide students, parents, and school staff with scientific,
24social, and emotional learning content to help them understand
25the risk of drug use. Such learning content must specifically

 

 

HB0001 Engrossed- 53 -LRB099 00249 HEP 20254 b

1target the dangers of prescription pain medication and heroin
2abuse. The Department may contract with a health education
3organization to fulfill the requirements of the pilot program.
4    The State Board of Education, the Department of Human
5Services, and any contracted organization shall submit an
6annual report to the General Assembly that includes: (i) a list
7of school districts participating in the pilot program; (ii)
8the grade levels each school district instructs under the pilot
9program; and (iii) any findings regarding the effectiveness of
10the pilot program.
 
11    Section 5-65. The Emergency Medical Services (EMS) Systems
12Act is amended by changing Sections 3.30 and 3.50 as follows:
 
13    (210 ILCS 50/3.30)
14    Sec. 3.30. EMS Region Plan; Content.
15    (a) The EMS Medical Directors Committee shall address at
16least the following:
17        (1) Protocols for inter-System/inter-Region patient
18    transports, including identifying the conditions of
19    emergency patients which may not be transported to the
20    different levels of emergency department, based on their
21    Department classifications and relevant Regional
22    considerations (e.g. transport times and distances);
23        (2) Regional standing medical orders;
24        (3) Patient transfer patterns, including criteria for

 

 

HB0001 Engrossed- 54 -LRB099 00249 HEP 20254 b

1    determining whether a patient needs the specialized
2    services of a trauma center, along with protocols for the
3    bypassing of or diversion to any hospital, trauma center or
4    regional trauma center which are consistent with
5    individual System bypass or diversion protocols and
6    protocols for patient choice or refusal;
7        (4) Protocols for resolving Regional or Inter-System
8    conflict;
9        (5) An EMS disaster preparedness plan which includes
10    the actions and responsibilities of all EMS participants
11    within the Region. Within 90 days of the effective date of
12    this amendatory Act of 1996, an EMS System shall submit to
13    the Department for review an internal disaster plan. At a
14    minimum, the plan shall include contingency plans for the
15    transfer of patients to other facilities if an evacuation
16    of the hospital becomes necessary due to a catastrophe,
17    including but not limited to, a power failure;
18        (6) Regional standardization of continuing education
19    requirements;
20        (7) Regional standardization of Do Not Resuscitate
21    (DNR) policies, and protocols for power of attorney for
22    health care;
23        (8) Protocols for disbursement of Department grants;
24    and
25        (9) Protocols for the triage, treatment, and transport
26    of possible acute stroke patients; and .

 

 

HB0001 Engrossed- 55 -LRB099 00249 HEP 20254 b

1        (10) Regional standing medical orders for the
2    administration of opioid antagonists.
3    (b) The Trauma Center Medical Directors or Trauma Center
4Medical Directors Committee shall address at least the
5following:
6        (1) The identification of Regional Trauma Centers;
7        (2) Protocols for inter-System and inter-Region trauma
8    patient transports, including identifying the conditions
9    of emergency patients which may not be transported to the
10    different levels of emergency department, based on their
11    Department classifications and relevant Regional
12    considerations (e.g. transport times and distances);
13        (3) Regional trauma standing medical orders;
14        (4) Trauma patient transfer patterns, including
15    criteria for determining whether a patient needs the
16    specialized services of a trauma center, along with
17    protocols for the bypassing of or diversion to any
18    hospital, trauma center or regional trauma center which are
19    consistent with individual System bypass or diversion
20    protocols and protocols for patient choice or refusal;
21        (5) The identification of which types of patients can
22    be cared for by Level I and Level II Trauma Centers;
23        (6) Criteria for inter-hospital transfer of trauma
24    patients;
25        (7) The treatment of trauma patients in each trauma
26    center within the Region;

 

 

HB0001 Engrossed- 56 -LRB099 00249 HEP 20254 b

1        (8) A program for conducting a quarterly conference
2    which shall include at a minimum a discussion of morbidity
3    and mortality between all professional staff involved in
4    the care of trauma patients;
5        (9) The establishment of a Regional trauma quality
6    assurance and improvement subcommittee, consisting of
7    trauma surgeons, which shall perform periodic medical
8    audits of each trauma center's trauma services, and forward
9    tabulated data from such reviews to the Department; and
10        (10) The establishment, within 90 days of the effective
11    date of this amendatory Act of 1996, of an internal
12    disaster plan, which shall include, at a minimum,
13    contingency plans for the transfer of patients to other
14    facilities if an evacuation of the hospital becomes
15    necessary due to a catastrophe, including but not limited
16    to, a power failure.
17    (c) The Region's EMS Medical Directors and Trauma Center
18Medical Directors Committees shall appoint any subcommittees
19which they deem necessary to address specific issues concerning
20Region activities.
21(Source: P.A. 96-514, eff. 1-1-10.)
 
22    (210 ILCS 50/3.50)
23    Sec. 3.50. Emergency Medical Services personnel licensure
24levels.
25    (a) "Emergency Medical Technician" or "EMT" means a person

 

 

HB0001 Engrossed- 57 -LRB099 00249 HEP 20254 b

1who has successfully completed a course in basic life support
2as approved by the Department, is currently licensed by the
3Department in accordance with standards prescribed by this Act
4and rules adopted by the Department pursuant to this Act, and
5practices within an EMS System. A valid Emergency Medical
6Technician-Basic (EMT-B) license issued under this Act shall
7continue to be valid and shall be recognized as an Emergency
8Medical Technician (EMT) license until the Emergency Medical
9Technician-Basic (EMT-B) license expires.
10    (b) "Emergency Medical Technician-Intermediate" or "EMT-I"
11means a person who has successfully completed a course in
12intermediate life support as approved by the Department, is
13currently licensed by the Department in accordance with
14standards prescribed by this Act and rules adopted by the
15Department pursuant to this Act, and practices within an
16Intermediate or Advanced Life Support EMS System.
17    (b-5) "Advanced Emergency Medical Technician" or "A-EMT"
18means a person who has successfully completed a course in basic
19and limited advanced emergency medical care as approved by the
20Department, is currently licensed by the Department in
21accordance with standards prescribed by this Act and rules
22adopted by the Department pursuant to this Act, and practices
23within an Intermediate or Advanced Life Support EMS System.
24    (c) "Paramedic (EMT-P)" means a person who has successfully
25completed a course in advanced life support care as approved by
26the Department, is licensed by the Department in accordance

 

 

HB0001 Engrossed- 58 -LRB099 00249 HEP 20254 b

1with standards prescribed by this Act and rules adopted by the
2Department pursuant to this Act, and practices within an
3Advanced Life Support EMS System. A valid Emergency Medical
4Technician-Paramedic (EMT-P) license issued under this Act
5shall continue to be valid and shall be recognized as a
6Paramedic license until the Emergency Medical
7Technician-Paramedic (EMT-P) license expires.
8    (c-5) "Emergency Medical Responder" or "EMR (First
9Responder)" means a person who has successfully completed a
10course in emergency medical response as approved by the
11Department and provides emergency medical response services
12prior to the arrival of an ambulance or specialized emergency
13medical services vehicle, in accordance with the level of care
14established by the National EMS Educational Standards
15Emergency Medical Responder course as modified by the
16Department. An Emergency Medical Responder who provides
17services as part of an EMS System response plan shall comply
18with the applicable sections of the Program Plan, as approved
19by the Department, of that EMS System. The Department shall
20have the authority to adopt rules governing the curriculum,
21practice, and necessary equipment applicable to Emergency
22Medical Responders.
23    On the effective date of this amendatory Act of the 98th
24General Assembly, a person who is licensed by the Department as
25a First Responder and has completed a Department-approved
26course in first responder defibrillator training based on, or

 

 

HB0001 Engrossed- 59 -LRB099 00249 HEP 20254 b

1equivalent to, the National EMS Educational Standards or other
2standards previously recognized by the Department shall be
3eligible for licensure as an Emergency Medical Responder upon
4meeting the licensure requirements and submitting an
5application to the Department. A valid First Responder license
6issued under this Act shall continue to be valid and shall be
7recognized as an Emergency Medical Responder license until the
8First Responder license expires.
9    (c-10) All EMS Systems and licensees shall be fully
10compliant with the National EMS Education Standards, as
11modified by the Department in administrative rules, within 24
12months after the adoption of the administrative rules.
13    (d) The Department shall have the authority and
14responsibility to:
15        (1) Prescribe education and training requirements,
16    which includes training in the use of epinephrine, for all
17    levels of EMS personnel except for EMRs, based on the
18    National EMS Educational Standards and any modifications
19    to those curricula specified by the Department through
20    rules adopted pursuant to this Act.
21        (2) Prescribe licensure testing requirements for all
22    levels of EMS personnel, which shall include a requirement
23    that all phases of instruction, training, and field
24    experience be completed before taking the appropriate
25    licensure examination. Candidates may elect to take the
26    appropriate National Registry examination in lieu of the

 

 

HB0001 Engrossed- 60 -LRB099 00249 HEP 20254 b

1    Department's examination, but are responsible for making
2    their own arrangements for taking the National Registry
3    examination. In prescribing licensure testing requirements
4    for honorably discharged members of the armed forces of the
5    United States under this paragraph (2), the Department
6    shall ensure that a candidate's military emergency medical
7    training, emergency medical curriculum completed, and
8    clinical experience, as described in paragraph (2.5), are
9    recognized.
10        (2.5) Review applications for EMS personnel licensure
11    from honorably discharged members of the armed forces of
12    the United States with military emergency medical
13    training. Applications shall be filed with the Department
14    within one year after military discharge and shall contain:
15    (i) proof of successful completion of military emergency
16    medical training; (ii) a detailed description of the
17    emergency medical curriculum completed; and (iii) a
18    detailed description of the applicant's clinical
19    experience. The Department may request additional and
20    clarifying information. The Department shall evaluate the
21    application, including the applicant's training and
22    experience, consistent with the standards set forth under
23    subsections (a), (b), (c), and (d) of Section 3.10. If the
24    application clearly demonstrates that the training and
25    experience meets such standards, the Department shall
26    offer the applicant the opportunity to successfully

 

 

HB0001 Engrossed- 61 -LRB099 00249 HEP 20254 b

1    complete a Department-approved EMS personnel examination
2    for the level of license for which the applicant is
3    qualified. Upon passage of an examination, the Department
4    shall issue a license, which shall be subject to all
5    provisions of this Act that are otherwise applicable to the
6    level of EMS personnel license issued.
7        (3) License individuals as an EMR, EMT, EMT-I, A-EMT,
8    or Paramedic who have met the Department's education,
9    training and examination requirements.
10        (4) Prescribe annual continuing education and
11    relicensure requirements for all EMS personnel licensure
12    levels.
13        (5) Relicense individuals as an EMD, EMR, EMT, EMT-I,
14    A-EMT, or Paramedic every 4 years, based on their
15    compliance with continuing education and relicensure
16    requirements as required by the Department pursuant to this
17    Act. Every 4 years, a Paramedic shall have 100 hours of
18    approved continuing education, an EMT-I and an advanced EMT
19    shall have 80 hours of approved continuing education, and
20    an EMT shall have 60 hours of approved continuing
21    education. An Illinois licensed EMR, EMD, EMT, EMT-I,
22    A-EMT, Paramedic, ECRN, or PHRN whose license has been
23    expired for less than 36 months may apply for reinstatement
24    by the Department. Reinstatement shall require that the
25    applicant (i) submit satisfactory proof of completion of
26    continuing medical education and clinical requirements to

 

 

HB0001 Engrossed- 62 -LRB099 00249 HEP 20254 b

1    be prescribed by the Department in an administrative rule;
2    (ii) submit a positive recommendation from an Illinois EMS
3    Medical Director attesting to the applicant's
4    qualifications for retesting; and (iii) pass a Department
5    approved test for the level of EMS personnel license sought
6    to be reinstated.
7        (6) Grant inactive status to any EMR, EMD, EMT, EMT-I,
8    A-EMT, Paramedic, ECRN, or PHRN who qualifies, based on
9    standards and procedures established by the Department in
10    rules adopted pursuant to this Act.
11        (7) Charge a fee for EMS personnel examination,
12    licensure, and license renewal.
13        (8) Suspend, revoke, or refuse to issue or renew the
14    license of any licensee, after an opportunity for an
15    impartial hearing before a neutral administrative law
16    judge appointed by the Director, where the preponderance of
17    the evidence shows one or more of the following:
18            (A) The licensee has not met continuing education
19        or relicensure requirements as prescribed by the
20        Department;
21            (B) The licensee has failed to maintain
22        proficiency in the level of skills for which he or she
23        is licensed;
24            (C) The licensee, during the provision of medical
25        services, engaged in dishonorable, unethical, or
26        unprofessional conduct of a character likely to

 

 

HB0001 Engrossed- 63 -LRB099 00249 HEP 20254 b

1        deceive, defraud, or harm the public;
2            (D) The licensee has failed to maintain or has
3        violated standards of performance and conduct as
4        prescribed by the Department in rules adopted pursuant
5        to this Act or his or her EMS System's Program Plan;
6            (E) The licensee is physically impaired to the
7        extent that he or she cannot physically perform the
8        skills and functions for which he or she is licensed,
9        as verified by a physician, unless the person is on
10        inactive status pursuant to Department regulations;
11            (F) The licensee is mentally impaired to the extent
12        that he or she cannot exercise the appropriate
13        judgment, skill and safety for performing the
14        functions for which he or she is licensed, as verified
15        by a physician, unless the person is on inactive status
16        pursuant to Department regulations;
17            (G) The licensee has violated this Act or any rule
18        adopted by the Department pursuant to this Act; or
19            (H) The licensee has been convicted (or entered a
20        plea of guilty or nolo-contendere) by a court of
21        competent jurisdiction of a Class X, Class 1, or Class
22        2 felony in this State or an out-of-state equivalent
23        offense.
24        (9) Prescribe education and training requirements in
25    the administration and use of opioid antagonists for all
26    levels of EMS personnel based on the National EMS

 

 

HB0001 Engrossed- 64 -LRB099 00249 HEP 20254 b

1    Educational Standards and any modifications to those
2    curricula specified by the Department through rules
3    adopted pursuant to this Act.
4    (d-5) An EMR, EMD, EMT, EMT-I, A-EMT, Paramedic, ECRN, or
5PHRN who is a member of the Illinois National Guard or an
6Illinois State Trooper or who exclusively serves as a volunteer
7for units of local government with a population base of less
8than 5,000 or as a volunteer for a not-for-profit organization
9that serves a service area with a population base of less than
105,000 may submit an application to the Department for a waiver
11of the fees described under paragraph (7) of subsection (d) of
12this Section on a form prescribed by the Department.
13    The education requirements prescribed by the Department
14under this Section must allow for the suspension of those
15requirements in the case of a member of the armed services or
16reserve forces of the United States or a member of the Illinois
17National Guard who is on active duty pursuant to an executive
18order of the President of the United States, an act of the
19Congress of the United States, or an order of the Governor at
20the time that the member would otherwise be required to fulfill
21a particular education requirement. Such a person must fulfill
22the education requirement within 6 months after his or her
23release from active duty.
24    (e) In the event that any rule of the Department or an EMS
25Medical Director that requires testing for drug use as a
26condition of the applicable EMS personnel license conflicts

 

 

HB0001 Engrossed- 65 -LRB099 00249 HEP 20254 b

1with or duplicates a provision of a collective bargaining
2agreement that requires testing for drug use, that rule shall
3not apply to any person covered by the collective bargaining
4agreement.
5(Source: P.A. 97-333, eff. 8-12-11; 97-509, eff. 8-23-11;
697-813, eff. 7-13-12; 97-1014, eff. 1-1-13; 98-53, eff. 1-1-14;
798-463, eff. 8-16-13; 98-973, eff. 8-15-14.)
 
8    Section 5-70. The Hospital Licensing Act is amended by
9adding Section 6.14g as follows:
 
10    (210 ILCS 85/6.14g new)
11    Sec. 6.14g. Reports to the Department; opioid overdoses.
12    (a) As used in this Section:
13    "Overdose" has the same meaning as provided in Section 414
14of the Illinois Controlled Substances Act.
15    "Health care professional" includes a physician licensed
16to practice medicine in all its branches, a physician
17assistant, or an advanced practice nurse licensed in the State.
18    (b) When treatment is provided in a hospital's emergency
19department, a health care professional who treats a drug
20overdose or hospital administrator or designee shall report the
21case to the Department of Public Health within 48 hours of
22providing treatment for the drug overdose or at such time the
23drug overdose is confirmed. The Department shall by rule create
24a form for this purpose which requires the following

 

 

HB0001 Engrossed- 66 -LRB099 00249 HEP 20254 b

1information, if known: (1) whether an opioid antagonist was
2administered; (2) the cause of the overdose; and (3) the
3demographic information of the person treated. The Department
4shall create the form with input from the statewide association
5representing a majority of hospitals in Illinois. The person
6completing the form may not disclose the name, address, or any
7other personal information of the individual experiencing the
8overdose.
9    (c) The identity of the person and entity reporting under
10this subsection shall not be disclosed to the subject of the
11report. For the purposes of this subsection, the health care
12professional, hospital administrator, or designee making the
13report and his or her employer shall not be held criminally,
14civilly, or professionally liable for reporting under this
15subsection, except for willful or wanton misconduct.
16    (d) The Department shall provide a semiannual report to the
17General Assembly summarizing the reports received. The
18Department shall also provide on its website a monthly report
19of drug overdose figures. The figures shall be organized by the
20overdose location, the age of the victim, the cause of the
21overdose, and any other factors the Department deems
22appropriate.
 
23    Section 5-72. The Safe Pharmaceutical Disposal Act is
24amended by changing Section 17 as follows:
 

 

 

HB0001 Engrossed- 67 -LRB099 00249 HEP 20254 b

1    (210 ILCS 150/17)
2    Sec. 17. Pharmaceutical disposal. Notwithstanding any
3provision of law, any city, village, or municipality may
4authorize the use of its city hall or police department to
5display a container suitable for use as a receptacle for used,
6expired, or unwanted pharmaceuticals. These used, expired, or
7unwanted pharmaceuticals may include unused medication and
8prescription drugs, as well as controlled substances if
9collected in accordance with federal law. This receptacle shall
10only permit the deposit of items, and the contents shall be
11locked and secured. The container shall be accessible to the
12public and shall have posted clearly legible signage indicating
13that expired or unwanted prescription drugs may be disposed of
14in the receptacle.
15(Source: P.A. 97-546, eff. 1-1-12.)
 
16    Section 5-75. The Illinois Insurance Code is amended by
17changing Sections 352, 370c, and 370c.1 and by adding Section
18356z.23 as follows:
 
19    (215 ILCS 5/352)  (from Ch. 73, par. 964)
20    Sec. 352. Scope of Article.
21    (a) Except as provided in subsections (b), (c), (d), and
22(e), this Article shall apply to all companies transacting in
23this State the kinds of business enumerated in clause (b) of
24Class 1 and clause (a) of Class 2 of section 4. Nothing in this

 

 

HB0001 Engrossed- 68 -LRB099 00249 HEP 20254 b

1Article shall apply to, or in any way affect policies or
2contracts described in clause (a) of Class 1 of Section 4;
3however, this Article shall apply to policies and contracts
4which contain benefits providing reimbursement for the
5expenses of long term health care which are certified or
6ordered by a physician including but not limited to
7professional nursing care, custodial nursing care, and
8non-nursing custodial care provided in a nursing home or at a
9residence of the insured.
10    (b) (Blank). This Article does not apply to policies of
11accident and health insurance issued in compliance with Article
12XIXB of this Code.
13    (c) A policy issued and delivered in this State that
14provides coverage under that policy for certificate holders who
15are neither residents of nor employed in this State does not
16need to provide to those nonresident certificate holders who
17are not employed in this State the coverages or services
18mandated by this Article.
19    (d) Stop-loss insurance is exempt from all Sections of this
20Article, except this Section and Sections 353a, 354, 357.30,
21and 370. For purposes of this exemption, stop-loss insurance is
22further defined as follows:
23        (1) The policy must be issued to and insure an
24    employer, trustee, or other sponsor of the plan, or the
25    plan itself, but not employees, members, or participants.
26        (2) Payments by the insurer must be made to the

 

 

HB0001 Engrossed- 69 -LRB099 00249 HEP 20254 b

1    employer, trustee, or other sponsors of the plan, or the
2    plan itself, but not to the employees, members,
3    participants, or health care providers.
4    (e) A policy issued or delivered in this State to the
5Department of Healthcare and Family Services (formerly
6Illinois Department of Public Aid) and providing coverage,
7under clause (b) of Class 1 or clause (a) of Class 2 as
8described in Section 4, to persons who are enrolled under
9Article V of the Illinois Public Aid Code or under the
10Children's Health Insurance Program Act is exempt from all
11restrictions, limitations, standards, rules, or regulations
12respecting benefits imposed by or under authority of this Code,
13except those specified by subsection (1) of Section 143,
14Section 370c, and Section 370c.1. Nothing in this subsection,
15however, affects the total medical services available to
16persons eligible for medical assistance under the Illinois
17Public Aid Code.
18(Source: P.A. 95-331, eff. 8-21-07.)
 
19    (215 ILCS 5/356z.23 new)
20    Sec. 356z.23. Coverage for opioid antagonists.
21    (a) An individual or group policy of accident and health
22insurance amended, delivered, issued, or renewed in this State
23after the effective date of this amendatory Act of the 99th
24General Assembly that provides coverage for prescription drugs
25must provide coverage for at least one opioid antagonist,

 

 

HB0001 Engrossed- 70 -LRB099 00249 HEP 20254 b

1including the medication product, administration devices, and
2any pharmacy administration fees related to the dispensing of
3the opioid antagonist. This coverage must include refills for
4expired or utilized opioid antagonists.
5    (b) As used in this Section, "opioid antagonist" means a
6drug that binds to opioid receptors and blocks or inhibits the
7effect of opioids acting on those receptors, including, but not
8limited to, naloxone hydrochloride or any other similarly
9acting drug approved by the U.S. Food and Drug Administration.
 
10    (215 ILCS 5/370c)  (from Ch. 73, par. 982c)
11    Sec. 370c. Mental and emotional disorders.
12    (a) (1) On and after the effective date of this amendatory
13Act of the 97th General Assembly, every insurer which amends,
14delivers, issues, or renews group accident and health policies
15providing coverage for hospital or medical treatment or
16services for illness on an expense-incurred basis shall offer
17to the applicant or group policyholder subject to the insurer's
18standards of insurability, coverage for reasonable and
19necessary treatment and services for mental, emotional or
20nervous disorders or conditions, other than serious mental
21illnesses as defined in item (2) of subsection (b), consistent
22with the parity requirements of Section 370c.1 of this Code.
23    (2) Each insured that is covered for mental, emotional,
24nervous, or substance use disorders or conditions shall be free
25to select the physician licensed to practice medicine in all

 

 

HB0001 Engrossed- 71 -LRB099 00249 HEP 20254 b

1its branches, licensed clinical psychologist, licensed
2clinical social worker, licensed clinical professional
3counselor, licensed marriage and family therapist, licensed
4speech-language pathologist, or other licensed or certified
5professional at a program licensed pursuant to the Illinois
6Alcoholism and Other Drug Abuse and Dependency Act of his
7choice to treat such disorders, and the insurer shall pay the
8covered charges of such physician licensed to practice medicine
9in all its branches, licensed clinical psychologist, licensed
10clinical social worker, licensed clinical professional
11counselor, licensed marriage and family therapist, licensed
12speech-language pathologist, or other licensed or certified
13professional at a program licensed pursuant to the Illinois
14Alcoholism and Other Drug Abuse and Dependency Act up to the
15limits of coverage, provided (i) the disorder or condition
16treated is covered by the policy, and (ii) the physician,
17licensed psychologist, licensed clinical social worker,
18licensed clinical professional counselor, licensed marriage
19and family therapist, licensed speech-language pathologist, or
20other licensed or certified professional at a program licensed
21pursuant to the Illinois Alcoholism and Other Drug Abuse and
22Dependency Act is authorized to provide said services under the
23statutes of this State and in accordance with accepted
24principles of his profession.
25    (3) Insofar as this Section applies solely to licensed
26clinical social workers, licensed clinical professional

 

 

HB0001 Engrossed- 72 -LRB099 00249 HEP 20254 b

1counselors, licensed marriage and family therapists, licensed
2speech-language pathologists, and other licensed or certified
3professionals at programs licensed pursuant to the Illinois
4Alcoholism and Other Drug Abuse and Dependency Act, those
5persons who may provide services to individuals shall do so
6after the licensed clinical social worker, licensed clinical
7professional counselor, licensed marriage and family
8therapist, licensed speech-language pathologist, or other
9licensed or certified professional at a program licensed
10pursuant to the Illinois Alcoholism and Other Drug Abuse and
11Dependency Act has informed the patient of the desirability of
12the patient conferring with the patient's primary care
13physician and the licensed clinical social worker, licensed
14clinical professional counselor, licensed marriage and family
15therapist, licensed speech-language pathologist, or other
16licensed or certified professional at a program licensed
17pursuant to the Illinois Alcoholism and Other Drug Abuse and
18Dependency Act has provided written notification to the
19patient's primary care physician, if any, that services are
20being provided to the patient. That notification may, however,
21be waived by the patient on a written form. Those forms shall
22be retained by the licensed clinical social worker, licensed
23clinical professional counselor, licensed marriage and family
24therapist, licensed speech-language pathologist, or other
25licensed or certified professional at a program licensed
26pursuant to the Illinois Alcoholism and Other Drug Abuse and

 

 

HB0001 Engrossed- 73 -LRB099 00249 HEP 20254 b

1Dependency Act for a period of not less than 5 years.
2    (b) (1) An insurer that provides coverage for hospital or
3medical expenses under a group policy of accident and health
4insurance or health care plan amended, delivered, issued, or
5renewed on or after the effective date of this amendatory Act
6of the 97th General Assembly shall provide coverage under the
7policy for treatment of serious mental illness and substance
8use disorders consistent with the parity requirements of
9Section 370c.1 of this Code. This subsection does not apply to
10any group policy of accident and health insurance or health
11care plan for any plan year of a small employer as defined in
12Section 5 of the Illinois Health Insurance Portability and
13Accountability Act.
14    (2) "Serious mental illness" means the following
15psychiatric illnesses as defined in the most current edition of
16the Diagnostic and Statistical Manual (DSM) published by the
17American Psychiatric Association:
18        (A) schizophrenia;
19        (B) paranoid and other psychotic disorders;
20        (C) bipolar disorders (hypomanic, manic, depressive,
21    and mixed);
22        (D) major depressive disorders (single episode or
23    recurrent);
24        (E) schizoaffective disorders (bipolar or depressive);
25        (F) pervasive developmental disorders;
26        (G) obsessive-compulsive disorders;

 

 

HB0001 Engrossed- 74 -LRB099 00249 HEP 20254 b

1        (H) depression in childhood and adolescence;
2        (I) panic disorder;
3        (J) post-traumatic stress disorders (acute, chronic,
4    or with delayed onset); and
5        (K) anorexia nervosa and bulimia nervosa.
6    (2.5) "Substance use disorder" means the following mental
7disorders as defined in the most current edition of the
8Diagnostic and Statistical Manual (DSM) published by the
9American Psychiatric Association:
10        (A) substance abuse disorders;
11        (B) substance dependence disorders; and
12        (C) substance induced disorders.
13    (3) Unless otherwise prohibited by federal law and
14consistent with the parity requirements of Section 370c.1 of
15this Code, the reimbursing insurer, a provider of treatment of
16serious mental illness or substance use disorder shall furnish
17medical records or other necessary data that substantiate that
18initial or continued treatment is at all times medically
19necessary. An insurer shall provide a mechanism for the timely
20review by a provider holding the same license and practicing in
21the same specialty as the patient's provider, who is
22unaffiliated with the insurer, jointly selected by the patient
23(or the patient's next of kin or legal representative if the
24patient is unable to act for himself or herself), the patient's
25provider, and the insurer in the event of a dispute between the
26insurer and patient's provider regarding the medical necessity

 

 

HB0001 Engrossed- 75 -LRB099 00249 HEP 20254 b

1of a treatment proposed by a patient's provider. If the
2reviewing provider determines the treatment to be medically
3necessary, the insurer shall provide reimbursement for the
4treatment. Future contractual or employment actions by the
5insurer regarding the patient's provider may not be based on
6the provider's participation in this procedure. Nothing
7prevents the insured from agreeing in writing to continue
8treatment at his or her expense. When making a determination of
9the medical necessity for a treatment modality for serious
10mental illness or substance use disorder, an insurer must make
11the determination in a manner that is consistent with the
12manner used to make that determination with respect to other
13diseases or illnesses covered under the policy, including an
14appeals process. Medical necessity determinations for
15substance use disorders shall be made in accordance with
16appropriate patient placement criteria established by the
17American Society of Addiction Medicine. No additional criteria
18may be used to make medical necessity determinations for
19substance use disorders.
20    (4) A group health benefit plan amended, delivered, issued,
21or renewed on or after the effective date of this amendatory
22Act of the 97th General Assembly:
23        (A) shall provide coverage based upon medical
24    necessity for the treatment of mental illness and substance
25    use disorders consistent with the parity requirements of
26    Section 370c.1 of this Code; provided, however, that in

 

 

HB0001 Engrossed- 76 -LRB099 00249 HEP 20254 b

1    each calendar year coverage shall not be less than the
2    following:
3            (i) 45 days of inpatient treatment; and
4            (ii) beginning on June 26, 2006 (the effective date
5        of Public Act 94-921), 60 visits for outpatient
6        treatment including group and individual outpatient
7        treatment; and
8            (iii) for plans or policies delivered, issued for
9        delivery, renewed, or modified after January 1, 2007
10        (the effective date of Public Act 94-906), 20
11        additional outpatient visits for speech therapy for
12        treatment of pervasive developmental disorders that
13        will be in addition to speech therapy provided pursuant
14        to item (ii) of this subparagraph (A); and
15        (B) may not include a lifetime limit on the number of
16    days of inpatient treatment or the number of outpatient
17    visits covered under the plan.
18        (C) (Blank).
19    (5) An issuer of a group health benefit plan may not count
20toward the number of outpatient visits required to be covered
21under this Section an outpatient visit for the purpose of
22medication management and shall cover the outpatient visits
23under the same terms and conditions as it covers outpatient
24visits for the treatment of physical illness.
25    (5.5) An individual or group health benefit plan amended,
26delivered, issued, or renewed on or after the effective date of

 

 

HB0001 Engrossed- 77 -LRB099 00249 HEP 20254 b

1this amendatory Act of the 99th General Assembly shall offer
2coverage for medically necessary acute treatment services and
3medically necessary clinical stabilization services. The
4treating provider shall base all treatment recommendations and
5the health benefit plan shall base all medical necessity
6determinations for substance use disorders in accordance with
7the most current edition of the American Society of Addiction
8Medicine Patient Placement Criteria.
9    As used in this subsection:
10    "Acute treatment services" means 24-hour medically
11supervised addiction treatment that provides evaluation and
12withdrawal management and may include biopsychosocial
13assessment, individual and group counseling, psychoeducational
14groups, and discharge planning.
15    "Clinical stabilization services" means 24-hour treatment,
16usually following acute treatment services for substance
17abuse, which may include intensive education and counseling
18regarding the nature of addiction and its consequences, relapse
19prevention, outreach to families and significant others, and
20aftercare planning for individuals beginning to engage in
21recovery from addiction.
22    (6) An issuer of a group health benefit plan may provide or
23offer coverage required under this Section through a managed
24care plan.
25    (7) (Blank).
26    (8) (Blank).

 

 

HB0001 Engrossed- 78 -LRB099 00249 HEP 20254 b

1    (9) With respect to substance use disorders, coverage for
2inpatient treatment shall include coverage for treatment in a
3residential treatment center licensed by the Department of
4Public Health or the Department of Human Services, Division of
5Alcoholism and Substance Abuse.
6    (c) This Section shall not be interpreted to require
7coverage for speech therapy or other habilitative services for
8those individuals covered under Section 356z.15 of this Code.
9    (d) The Department shall enforce the requirements of State
10and federal parity law, which includes ensuring compliance by
11individual and group policies; detecting violations of the law
12by individual and group policies proactively monitoring
13discriminatory practices; accepting, evaluating, and
14responding to complaints regarding such violations; and
15ensuring violations are appropriately remedied and deterred.
16    (e) Availability of plan information.
17        (1) The criteria for medical necessity determinations
18    made under a group health plan with respect to mental
19    health or substance use disorder benefits (or health
20    insurance coverage offered in connection with the plan with
21    respect to such benefits) must be made available by the
22    plan administrator (or the health insurance issuer
23    offering such coverage) to any current or potential
24    participant, beneficiary, or contracting provider upon
25    request.
26        (2) The reason for any denial under a group health plan

 

 

HB0001 Engrossed- 79 -LRB099 00249 HEP 20254 b

1    (or health insurance coverage offered in connection with
2    such plan) of reimbursement or payment for services with
3    respect to mental health or substance use disorder benefits
4    in the case of any participant or beneficiary must be made
5    available within a reasonable time and in a reasonable
6    manner by the plan administrator (or the health insurance
7    issuer offering such coverage) to the participant or
8    beneficiary upon request.
9    (f) As used in this Section, "group policy of accident and
10health insurance" and "group health benefit plan" includes (1)
11State-regulated employer-sponsored group health insurance
12plans written in Illinois and (2) State employee health plans.
13(Source: P.A. 96-328, eff. 8-11-09; 96-1000, eff. 7-2-10;
1497-437, eff. 8-18-11.)
 
15    (215 ILCS 5/370c.1)
16    Sec. 370c.1. Mental health and addiction parity.
17    (a) On and after the effective date of this amendatory Act
18of the 99th General Assembly this amendatory Act of the 97th
19General Assembly, every insurer that amends, delivers, issues,
20or renews a group or individual policy of accident and health
21insurance or a qualified health plan offered through the Health
22Insurance Marketplace policy of accident and health insurance
23in this State providing coverage for hospital or medical
24treatment and for the treatment of mental, emotional, nervous,
25or substance use disorders or conditions shall ensure that:

 

 

HB0001 Engrossed- 80 -LRB099 00249 HEP 20254 b

1        (1) the financial requirements applicable to such
2    mental, emotional, nervous, or substance use disorder or
3    condition benefits are no more restrictive than the
4    predominant financial requirements applied to
5    substantially all hospital and medical benefits covered by
6    the policy and that there are no separate cost-sharing
7    requirements that are applicable only with respect to
8    mental, emotional, nervous, or substance use disorder or
9    condition benefits; and
10        (2) the treatment limitations applicable to such
11    mental, emotional, nervous, or substance use disorder or
12    condition benefits are no more restrictive than the
13    predominant treatment limitations applied to substantially
14    all hospital and medical benefits covered by the policy and
15    that there are no separate treatment limitations that are
16    applicable only with respect to mental, emotional,
17    nervous, or substance use disorder or condition benefits.
18    (b) The following provisions shall apply concerning
19aggregate lifetime limits:
20        (1) In the case of a group or individual policy of
21    accident and health insurance or a qualified health plan
22    offered through the Health Insurance Marketplace policy of
23    accident and health insurance amended, delivered, issued,
24    or renewed in this State on or after the effective date of
25    this amendatory Act of the 99th General Assembly this
26    amendatory Act of the 97th General Assembly that provides

 

 

HB0001 Engrossed- 81 -LRB099 00249 HEP 20254 b

1    coverage for hospital or medical treatment and for the
2    treatment of mental, emotional, nervous, or substance use
3    disorders or conditions the following provisions shall
4    apply:
5            (A) if the policy does not include an aggregate
6        lifetime limit on substantially all hospital and
7        medical benefits, then the policy may not impose any
8        aggregate lifetime limit on mental, emotional,
9        nervous, or substance use disorder or condition
10        benefits; or
11            (B) if the policy includes an aggregate lifetime
12        limit on substantially all hospital and medical
13        benefits (in this subsection referred to as the
14        "applicable lifetime limit"), then the policy shall
15        either:
16                (i) apply the applicable lifetime limit both
17            to the hospital and medical benefits to which it
18            otherwise would apply and to mental, emotional,
19            nervous, or substance use disorder or condition
20            benefits and not distinguish in the application of
21            the limit between the hospital and medical
22            benefits and mental, emotional, nervous, or
23            substance use disorder or condition benefits; or
24                (ii) not include any aggregate lifetime limit
25            on mental, emotional, nervous, or substance use
26            disorder or condition benefits that is less than

 

 

HB0001 Engrossed- 82 -LRB099 00249 HEP 20254 b

1            the applicable lifetime limit.
2        (2) In the case of a policy that is not described in
3    paragraph (1) of subsection (b) of this Section and that
4    includes no or different aggregate lifetime limits on
5    different categories of hospital and medical benefits, the
6    Director shall establish rules under which subparagraph
7    (B) of paragraph (1) of subsection (b) of this Section is
8    applied to such policy with respect to mental, emotional,
9    nervous, or substance use disorder or condition benefits by
10    substituting for the applicable lifetime limit an average
11    aggregate lifetime limit that is computed taking into
12    account the weighted average of the aggregate lifetime
13    limits applicable to such categories.
14    (c) The following provisions shall apply concerning annual
15limits:
16        (1) In the case of a group or individual policy of
17    accident and health insurance or a qualified health plan
18    offered through the Health Insurance Marketplace policy of
19    accident and health insurance amended, delivered, issued,
20    or renewed in this State on or after the effective date of
21    this amendatory Act of the 99th General Assembly this
22    amendatory Act of the 97th General Assembly that provides
23    coverage for hospital or medical treatment and for the
24    treatment of mental, emotional, nervous, or substance use
25    disorders or conditions the following provisions shall
26    apply:

 

 

HB0001 Engrossed- 83 -LRB099 00249 HEP 20254 b

1            (A) if the policy does not include an annual limit
2        on substantially all hospital and medical benefits,
3        then the policy may not impose any annual limits on
4        mental, emotional, nervous, or substance use disorder
5        or condition benefits; or
6            (B) if the policy includes an annual limit on
7        substantially all hospital and medical benefits (in
8        this subsection referred to as the "applicable annual
9        limit"), then the policy shall either:
10                (i) apply the applicable annual limit both to
11            the hospital and medical benefits to which it
12            otherwise would apply and to mental, emotional,
13            nervous, or substance use disorder or condition
14            benefits and not distinguish in the application of
15            the limit between the hospital and medical
16            benefits and mental, emotional, nervous, or
17            substance use disorder or condition benefits; or
18                (ii) not include any annual limit on mental,
19            emotional, nervous, or substance use disorder or
20            condition benefits that is less than the
21            applicable annual limit.
22        (2) In the case of a policy that is not described in
23    paragraph (1) of subsection (c) of this Section and that
24    includes no or different annual limits on different
25    categories of hospital and medical benefits, the Director
26    shall establish rules under which subparagraph (B) of

 

 

HB0001 Engrossed- 84 -LRB099 00249 HEP 20254 b

1    paragraph (1) of subsection (c) of this Section is applied
2    to such policy with respect to mental, emotional, nervous,
3    or substance use disorder or condition benefits by
4    substituting for the applicable annual limit an average
5    annual limit that is computed taking into account the
6    weighted average of the annual limits applicable to such
7    categories.
8    (d) With respect to substance use disorders, an insurer
9shall use policies and procedures for the election and
10placement of substance abuse treatment drugs on their formulary
11that are no less favorable to the insured as those policies and
12procedures the insurer uses for the selection and placement of
13other drugs and shall follow the expedited coverage
14determination requirements for substance abuse treatment drugs
15set forth in Section 45.2 of the Managed Care Reform and
16Patient Rights Act.
17    (e) (d) This Section shall be interpreted in a manner
18consistent with all applicable federal parity regulations
19including, but not limited to, the Mental Health Parity and
20Addiction Equity Act of 2008 at 78 FR 68240. the interim final
21regulations promulgated by the U.S. Department of Health and
22Human Services at 75 FR 5410, including the prohibition against
23applying a cumulative financial requirement or cumulative
24quantitative treatment limitation for mental, emotional,
25nervous, or substance use disorder benefits that accumulates
26separately from any cumulative financial requirement or

 

 

HB0001 Engrossed- 85 -LRB099 00249 HEP 20254 b

1cumulative quantitative treatment limitation established for
2hospital and medical benefits in the same classification.
3    (f) (e) The provisions of subsections (b) and (c) of this
4Section shall not be interpreted to allow the use of lifetime
5or annual limits otherwise prohibited by State or federal law.
6    (f) This Section shall not apply to individual health
7insurance coverage as defined in Section 5 of the Illinois
8Health Insurance Portability and Accountability Act.
9    (g) As used in this Section:
10    "Financial requirement" includes deductibles, copayments,
11coinsurance, and out-of-pocket maximums, but does not include
12an aggregate lifetime limit or an annual limit subject to
13subsections (b) and (c).
14    "Treatment limitation" includes limits on benefits based
15on the frequency of treatment, number of visits, days of
16coverage, days in a waiting period, or other similar limits on
17the scope or duration of treatment. "Treatment limitation"
18includes both quantitative treatment limitations, which are
19expressed numerically (such as 50 outpatient visits per year),
20and nonquantitative treatment limitations, which otherwise
21limit the scope or duration of treatment. A permanent exclusion
22of all benefits for a particular condition or disorder shall
23not be considered a treatment limitation. "Nonquantitative
24treatment" means those limitations as described under federal
25regulations (26 CFR 54.9812-1).
26    (h) The Department of Insurance shall implement the

 

 

HB0001 Engrossed- 86 -LRB099 00249 HEP 20254 b

1following education initiatives:
2        (1) By January 1, 2016, the Department shall develop a
3    plan for a Consumer Education Campaign on parity. The
4    Consumer Education Campaign shall focus its efforts
5    throughout the State and include trainings in the northern,
6    southern, and central regions of the State, as defined by
7    the Department, as well as each of the 5 managed care
8    regions of the State as identified by the Department of
9    Healthcare and Family Services. Under this Consumer
10    Education Campaign, the Department shall: (1) by January 1,
11    2017, provide at least one live training in each region on
12    parity for consumers and providers and one webinar training
13    to be posted on the Department website and (2) establish a
14    consumer hotline to assist consumers in navigating the
15    parity process by March 1, 2016. By January 1, 2018 the
16    Department shall issue a report to the General Assembly on
17    the success of the Consumer Education Campaign, which shall
18    indicate whether additional training is necessary or would
19    be recommended.
20        (2) The Department, in coordination with the
21    Department of Human Services and the Department of
22    Healthcare and Family Services, shall convene a working
23    group of health care insurance carriers, mental health
24    advocacy groups, substance abuse patient advocacy groups,
25    and mental health physician groups for the purpose of
26    discussing issues related to the treatment and coverage of

 

 

HB0001 Engrossed- 87 -LRB099 00249 HEP 20254 b

1    substance abuse disorders and mental illness. The working
2    group shall meet once before January 1, 2016 and shall meet
3    semiannually thereafter. The Department shall issue an
4    annual report to the General Assembly that includes a list
5    of the health care insurance carriers, mental health
6    advocacy groups, substance abuse patient advocacy groups,
7    and mental health physician groups that participated in the
8    working group meetings, details on the issues and topics
9    covered, and any legislative recommendations.
10    (i) The Parity Education Fund is created as a special fund
11in the State treasury. Moneys deposited into the Fund for
12appropriation by the General Assembly to the Department of
13Insurance shall be used for the purpose of providing financial
14support of the Consumer Education Campaign.
15(Source: P.A. 97-437, eff. 8-18-11.)
 
16    Section 5-80. The Health Carrier External Review Act is
17amended by changing Sections 20 and 35 as follows:
 
18    (215 ILCS 180/20)
19    Sec. 20. Notice of right to external review.
20    (a) At the same time the health carrier sends written
21notice of a covered person's right to appeal a coverage
22decision upon an adverse determination or a final adverse
23determination, a health carrier shall notify a covered person,
24the covered person's authorized representative, if any, and a

 

 

HB0001 Engrossed- 88 -LRB099 00249 HEP 20254 b

1covered person's health care provider in writing of the covered
2person's right to request an external review as provided by
3this Act. The written notice required shall include the
4following, or substantially equivalent, language: "We have
5denied your request for the provision of or payment for a
6health care service or course of treatment. You have the right
7to have our decision reviewed by an independent review
8organization not associated with us by submitting a written
9request for an external review to the Department of Insurance,
10Office of Consumer Health Information, 320 West Washington
11Street, 4th Floor, Springfield, Illinois, 62767.". The written
12notice shall include a copy of the Department's Request for
13External Review form.
14    (a-5) The Department may prescribe the form and content of
15the notice required under this Section.
16    (b) In addition to the notice required in subsection (a),
17for a notice related to an adverse determination, the health
18carrier shall include a statement informing the covered person
19of all of the following:
20        (1) If the covered person has a medical condition where
21    the timeframe for completion of (A) an expedited internal
22    review of an appeal involving an adverse determination, (B)
23    a final adverse determination, or (C) a standard external
24    review as established in this Act, would seriously
25    jeopardize the life or health of the covered person or
26    would jeopardize the covered person's ability to regain

 

 

HB0001 Engrossed- 89 -LRB099 00249 HEP 20254 b

1    maximum function, then the covered person or the covered
2    person's authorized representative may file a request for
3    an expedited external review.
4        (2) The covered person or the covered person's
5    authorized representative may file an appeal under the
6    health carrier's internal appeal process, but if the health
7    carrier has not issued a written decision to the covered
8    person or the covered person's authorized representative
9    30 days following the date the covered person or the
10    covered person's authorized representative files an appeal
11    of an adverse determination that involves a concurrent or
12    prospective review request or 60 days following the date
13    the covered person or the covered person's authorized
14    representative files an appeal of an adverse determination
15    that involves a retrospective review request with the
16    health carrier and the covered person or the covered
17    person's authorized representative has not requested or
18    agreed to a delay, then the covered person or the covered
19    person's authorized representative may file a request for
20    external review and shall be considered to have exhausted
21    the health carrier's internal appeal process for purposes
22    of this Act.
23        (3) If the covered person or the covered person's
24    authorized representative filed a request for an expedited
25    internal review of an adverse determination and has not
26    received a decision on such request from the health carrier

 

 

HB0001 Engrossed- 90 -LRB099 00249 HEP 20254 b

1    within 48 hours, except to the extent the covered person or
2    the covered person's authorized representative requested
3    or agreed to a delay, then the covered person or the
4    covered person's authorized representative may file a
5    request for external review and shall be considered to have
6    exhausted the health carrier's internal appeal process for
7    the purposes of this Act.
8        (4) If an adverse determination concerns a denial of
9    coverage based on a determination that the recommended or
10    requested health care service or treatment is experimental
11    or investigational and the covered person's health care
12    provider certifies in writing that the recommended or
13    requested health care service or treatment that is the
14    subject of the request would be significantly less
15    effective if not promptly initiated, then the covered
16    person or the covered person's authorized representative
17    may request an expedited external review at the same time
18    the covered person or the covered person's authorized
19    representative files a request for an expedited internal
20    appeal involving an adverse determination. The independent
21    review organization assigned to conduct the expedited
22    external review shall determine whether the covered person
23    is required to complete the expedited review of the appeal
24    prior to conducting the expedited external review.
25    (c) In addition to the notice required in subsection (a),
26for a notice related to a final adverse determination, the

 

 

HB0001 Engrossed- 91 -LRB099 00249 HEP 20254 b

1health carrier shall include a statement informing the covered
2person of all of the following:
3        (1) if the covered person has a medical condition where
4    the timeframe for completion of a standard external review
5    would seriously jeopardize the life or health of the
6    covered person or would jeopardize the covered person's
7    ability to regain maximum function, then the covered person
8    or the covered person's authorized representative may file
9    a request for an expedited external review; or
10        (2) if a final adverse determination concerns an
11    admission, availability of care, continued stay, or health
12    care service for which the covered person received
13    emergency services, but has not been discharged from a
14    facility, then the covered person, or the covered person's
15    authorized representative, may request an expedited
16    external review; or
17        (3) if a final adverse determination concerns a denial
18    of coverage based on a determination that the recommended
19    or requested health care service or treatment is
20    experimental or investigational, and the covered person's
21    health care provider certifies in writing that the
22    recommended or requested health care service or treatment
23    that is the subject of the request would be significantly
24    less effective if not promptly initiated, then the covered
25    person or the covered person's authorized representative
26    may request an expedited external review.

 

 

HB0001 Engrossed- 92 -LRB099 00249 HEP 20254 b

1    (d) In addition to the information to be provided pursuant
2to subsections (a), (b), and (c) of this Section, the health
3carrier shall include a copy of the description of both the
4required standard and expedited external review procedures.
5The description shall highlight the external review procedures
6that give the covered person or the covered person's authorized
7representative the opportunity to submit additional
8information, including any forms used to process an external
9review.
10    (e) As part of any forms provided under subsection (d) of
11this Section, the health carrier shall include an authorization
12form, or other document approved by the Director, by which the
13covered person, for purposes of conducting an external review
14under this Act, authorizes the health carrier and the covered
15person's treating health care provider to disclose protected
16health information, including medical records, concerning the
17covered person that is pertinent to the external review, as
18provided in the Illinois Insurance Code.
19(Source: P.A. 96-857, eff. 7-1-10; 97-574, eff. 8-26-11.)
 
20    (215 ILCS 180/35)
21    Sec. 35. Standard external review.
22    (a) Within 4 months after the date of receipt of a notice
23of an adverse determination or final adverse determination, a
24covered person or the covered person's authorized
25representative may file a request for an external review with

 

 

HB0001 Engrossed- 93 -LRB099 00249 HEP 20254 b

1the Director. Within one business day after the date of receipt
2of a request for external review, the Director shall send a
3copy of the request to the health carrier.
4    (b) Within 5 business days following the date of receipt of
5the external review request, the health carrier shall complete
6a preliminary review of the request to determine whether:
7        (1) the individual is or was a covered person in the
8    health benefit plan at the time the health care service was
9    requested or at the time the health care service was
10    provided;
11        (2) the health care service that is the subject of the
12    adverse determination or the final adverse determination
13    is a covered service under the covered person's health
14    benefit plan, but the health carrier has determined that
15    the health care service is not covered;
16        (3) the covered person has exhausted the health
17    carrier's internal appeal process unless the covered
18    person is not required to exhaust the health carrier's
19    internal appeal process pursuant to this Act;
20        (4) (blank); and
21        (5) the covered person has provided all the information
22    and forms required to process an external review, as
23    specified in this Act.
24    (c) Within one business day after completion of the
25preliminary review, the health carrier shall notify the
26Director and covered person and, if applicable, the covered

 

 

HB0001 Engrossed- 94 -LRB099 00249 HEP 20254 b

1person's authorized representative in writing whether the
2request is complete and eligible for external review. If the
3request:
4        (1) is not complete, the health carrier shall inform
5    the Director and covered person and, if applicable, the
6    covered person's authorized representative in writing and
7    include in the notice what information or materials are
8    required by this Act to make the request complete; or
9        (2) is not eligible for external review, the health
10    carrier shall inform the Director and covered person and,
11    if applicable, the covered person's authorized
12    representative in writing and include in the notice the
13    reasons for its ineligibility.
14    The Department may specify the form for the health
15carrier's notice of initial determination under this
16subsection (c) and any supporting information to be included in
17the notice.
18    The notice of initial determination of ineligibility shall
19include a statement informing the covered person and, if
20applicable, the covered person's authorized representative
21that a health carrier's initial determination that the external
22review request is ineligible for review may be appealed to the
23Director by filing a complaint with the Director.
24    Notwithstanding a health carrier's initial determination
25that the request is ineligible for external review, the
26Director may determine that a request is eligible for external

 

 

HB0001 Engrossed- 95 -LRB099 00249 HEP 20254 b

1review and require that it be referred for external review. In
2making such determination, the Director's decision shall be in
3accordance with the terms of the covered person's health
4benefit plan, unless such terms are inconsistent with
5applicable law, and shall be subject to all applicable
6provisions of this Act.
7    (d) Whenever the Director receives notice that a request is
8eligible for external review following the preliminary review
9conducted pursuant to this Section, within one business day
10after the date of receipt of the notice, the Director shall:
11        (1) assign an independent review organization from the
12    list of approved independent review organizations compiled
13    and maintained by the Director pursuant to this Act and
14    notify the health carrier of the name of the assigned
15    independent review organization; and
16        (2) notify in writing the covered person and, if
17    applicable, the covered person's authorized representative
18    of the request's eligibility and acceptance for external
19    review and the name of the independent review organization.
20    The Director shall include in the notice provided to the
21covered person and, if applicable, the covered person's
22authorized representative a statement that the covered person
23or the covered person's authorized representative may, within 5
24business days following the date of receipt of the notice
25provided pursuant to item (2) of this subsection (d), submit in
26writing to the assigned independent review organization

 

 

HB0001 Engrossed- 96 -LRB099 00249 HEP 20254 b

1additional information that the independent review
2organization shall consider when conducting the external
3review. The independent review organization is not required to,
4but may, accept and consider additional information submitted
5after 5 business days.
6    (e) The assignment by the Director of an approved
7independent review organization to conduct an external review
8in accordance with this Section shall be done on a random basis
9among those independent review organizations approved by the
10Director pursuant to this Act.
11    (f) Within 5 business days after the date of receipt of the
12notice provided pursuant to item (1) of subsection (d) of this
13Section, the health carrier or its designee utilization review
14organization shall provide to the assigned independent review
15organization the documents and any information considered in
16making the adverse determination or final adverse
17determination; in such cases, the following provisions shall
18apply:
19        (1) Except as provided in item (2) of this subsection
20    (f), failure by the health carrier or its utilization
21    review organization to provide the documents and
22    information within the specified time frame shall not delay
23    the conduct of the external review.
24        (2) If the health carrier or its utilization review
25    organization fails to provide the documents and
26    information within the specified time frame, the assigned

 

 

HB0001 Engrossed- 97 -LRB099 00249 HEP 20254 b

1    independent review organization may terminate the external
2    review and make a decision to reverse the adverse
3    determination or final adverse determination.
4        (3) Within one business day after making the decision
5    to terminate the external review and make a decision to
6    reverse the adverse determination or final adverse
7    determination under item (2) of this subsection (f), the
8    independent review organization shall notify the Director,
9    the health carrier, the covered person and, if applicable,
10    the covered person's authorized representative, of its
11    decision to reverse the adverse determination.
12    (g) Upon receipt of the information from the health carrier
13or its utilization review organization, the assigned
14independent review organization shall review all of the
15information and documents and any other information submitted
16in writing to the independent review organization by the
17covered person and the covered person's authorized
18representative.
19    (h) Upon receipt of any information submitted by the
20covered person or the covered person's authorized
21representative, the independent review organization shall
22forward the information to the health carrier within 1 business
23day.
24        (1) Upon receipt of the information, if any, the health
25    carrier may reconsider its adverse determination or final
26    adverse determination that is the subject of the external

 

 

HB0001 Engrossed- 98 -LRB099 00249 HEP 20254 b

1    review.
2        (2) Reconsideration by the health carrier of its
3    adverse determination or final adverse determination shall
4    not delay or terminate the external review.
5        (3) The external review may only be terminated if the
6    health carrier decides, upon completion of its
7    reconsideration, to reverse its adverse determination or
8    final adverse determination and provide coverage or
9    payment for the health care service that is the subject of
10    the adverse determination or final adverse determination.
11    In such cases, the following provisions shall apply:
12            (A) Within one business day after making the
13        decision to reverse its adverse determination or final
14        adverse determination, the health carrier shall notify
15        the Director, the covered person and, if applicable,
16        the covered person's authorized representative, and
17        the assigned independent review organization in
18        writing of its decision.
19            (B) Upon notice from the health carrier that the
20        health carrier has made a decision to reverse its
21        adverse determination or final adverse determination,
22        the assigned independent review organization shall
23        terminate the external review.
24    (i) In addition to the documents and information provided
25by the health carrier or its utilization review organization
26and the covered person and the covered person's authorized

 

 

HB0001 Engrossed- 99 -LRB099 00249 HEP 20254 b

1representative, if any, the independent review organization,
2to the extent the information or documents are available and
3the independent review organization considers them
4appropriate, shall consider the following in reaching a
5decision:
6        (1) the covered person's pertinent medical records;
7        (2) the covered person's health care provider's
8    recommendation;
9        (3) consulting reports from appropriate health care
10    providers and other documents submitted by the health
11    carrier or its designee utilization review organization,
12    the covered person, the covered person's authorized
13    representative, or the covered person's treating provider;
14        (4) the terms of coverage under the covered person's
15    health benefit plan with the health carrier to ensure that
16    the independent review organization's decision is not
17    contrary to the terms of coverage under the covered
18    person's health benefit plan with the health carrier,
19    unless the terms are inconsistent with applicable law;
20        (5) the most appropriate practice guidelines, which
21    shall include applicable evidence-based standards and may
22    include any other practice guidelines developed by the
23    federal government, national or professional medical
24    societies, boards, and associations;
25        (6) any applicable clinical review criteria developed
26    and used by the health carrier or its designee utilization

 

 

HB0001 Engrossed- 100 -LRB099 00249 HEP 20254 b

1    review organization;
2        (7) the opinion of the independent review
3    organization's clinical reviewer or reviewers after
4    considering items (1) through (6) of this subsection (i) to
5    the extent the information or documents are available and
6    the clinical reviewer or reviewers considers the
7    information or documents appropriate; and
8        (8) (blank); and .
9        (9) in the case of medically necessary determinations
10    for substance use disorders, the patient placement
11    criteria established by the American Society of Addiction
12    Medicine.
13    (j) Within 5 days after the date of receipt of all
14necessary information, but in no event more than 45 days after
15the date of receipt of the request for an external review, the
16assigned independent review organization shall provide written
17notice of its decision to uphold or reverse the adverse
18determination or the final adverse determination to the
19Director, the health carrier, the covered person, and, if
20applicable, the covered person's authorized representative. In
21reaching a decision, the assigned independent review
22organization is not bound by any claim determinations reached
23prior to the submission of information to the independent
24review organization. In such cases, the following provisions
25shall apply:
26        (1) The independent review organization shall include

 

 

HB0001 Engrossed- 101 -LRB099 00249 HEP 20254 b

1    in the notice:
2            (A) a general description of the reason for the
3        request for external review;
4            (B) the date the independent review organization
5        received the assignment from the Director to conduct
6        the external review;
7            (C) the time period during which the external
8        review was conducted;
9            (D) references to the evidence or documentation,
10        including the evidence-based standards, considered in
11        reaching its decision;
12            (E) the date of its decision;
13            (F) the principal reason or reasons for its
14        decision, including what applicable, if any,
15        evidence-based standards that were a basis for its
16        decision; and
17            (G) the rationale for its decision.
18        (2) (Blank).
19        (3) (Blank).
20        (4) Upon receipt of a notice of a decision reversing
21    the adverse determination or final adverse determination,
22    the health carrier immediately shall approve the coverage
23    that was the subject of the adverse determination or final
24    adverse determination.
25(Source: P.A. 96-857, eff. 7-1-10; 96-967, eff. 1-1-11; 97-574,
26eff. 8-26-11.)
 

 

 

HB0001 Engrossed- 102 -LRB099 00249 HEP 20254 b

1    Section 5-85. The Illinois Public Aid Code is amended by
2changing Sections 5-5 and 5-16.8 as follows:
 
3    (305 ILCS 5/5-5)  (from Ch. 23, par. 5-5)
4    Sec. 5-5. Medical services. The Illinois Department, by
5rule, shall determine the quantity and quality of and the rate
6of reimbursement for the medical assistance for which payment
7will be authorized, and the medical services to be provided,
8which may include all or part of the following: (1) inpatient
9hospital services; (2) outpatient hospital services; (3) other
10laboratory and X-ray services; (4) skilled nursing home
11services; (5) physicians' services whether furnished in the
12office, the patient's home, a hospital, a skilled nursing home,
13or elsewhere; (6) medical care, or any other type of remedial
14care furnished by licensed practitioners; (7) home health care
15services; (8) private duty nursing service; (9) clinic
16services; (10) dental services, including prevention and
17treatment of periodontal disease and dental caries disease for
18pregnant women, provided by an individual licensed to practice
19dentistry or dental surgery; for purposes of this item (10),
20"dental services" means diagnostic, preventive, or corrective
21procedures provided by or under the supervision of a dentist in
22the practice of his or her profession; (11) physical therapy
23and related services; (12) prescribed drugs, dentures, and
24prosthetic devices; and eyeglasses prescribed by a physician

 

 

HB0001 Engrossed- 103 -LRB099 00249 HEP 20254 b

1skilled in the diseases of the eye, or by an optometrist,
2whichever the person may select; (13) other diagnostic,
3screening, preventive, and rehabilitative services, including
4to ensure that the individual's need for intervention or
5treatment of mental disorders or substance use disorders or
6co-occurring mental health and substance use disorders is
7determined using a uniform screening, assessment, and
8evaluation process inclusive of criteria, for children and
9adults; for purposes of this item (13), a uniform screening,
10assessment, and evaluation process refers to a process that
11includes an appropriate evaluation and, as warranted, a
12referral; "uniform" does not mean the use of a singular
13instrument, tool, or process that all must utilize; (14)
14transportation and such other expenses as may be necessary;
15(15) medical treatment of sexual assault survivors, as defined
16in Section 1a of the Sexual Assault Survivors Emergency
17Treatment Act, for injuries sustained as a result of the sexual
18assault, including examinations and laboratory tests to
19discover evidence which may be used in criminal proceedings
20arising from the sexual assault; (16) the diagnosis and
21treatment of sickle cell anemia; and (17) any other medical
22care, and any other type of remedial care recognized under the
23laws of this State, but not including abortions, or induced
24miscarriages or premature births, unless, in the opinion of a
25physician, such procedures are necessary for the preservation
26of the life of the woman seeking such treatment, or except an

 

 

HB0001 Engrossed- 104 -LRB099 00249 HEP 20254 b

1induced premature birth intended to produce a live viable child
2and such procedure is necessary for the health of the mother or
3her unborn child. The Illinois Department, by rule, shall
4prohibit any physician from providing medical assistance to
5anyone eligible therefor under this Code where such physician
6has been found guilty of performing an abortion procedure in a
7wilful and wanton manner upon a woman who was not pregnant at
8the time such abortion procedure was performed. The term "any
9other type of remedial care" shall include nursing care and
10nursing home service for persons who rely on treatment by
11spiritual means alone through prayer for healing.
12    Notwithstanding any other provision of this Section, a
13comprehensive tobacco use cessation program that includes
14purchasing prescription drugs or prescription medical devices
15approved by the Food and Drug Administration shall be covered
16under the medical assistance program under this Article for
17persons who are otherwise eligible for assistance under this
18Article.
19    Notwithstanding any other provision of this Code, the
20Illinois Department may not require, as a condition of payment
21for any laboratory test authorized under this Article, that a
22physician's handwritten signature appear on the laboratory
23test order form. The Illinois Department may, however, impose
24other appropriate requirements regarding laboratory test order
25documentation.
26    Upon receipt of federal approval of an amendment to the

 

 

HB0001 Engrossed- 105 -LRB099 00249 HEP 20254 b

1Illinois Title XIX State Plan for this purpose, the Department
2shall authorize the Chicago Public Schools (CPS) to procure a
3vendor or vendors to manufacture eyeglasses for individuals
4enrolled in a school within the CPS system. CPS shall ensure
5that its vendor or vendors are enrolled as providers in the
6medical assistance program and in any capitated Medicaid
7managed care entity (MCE) serving individuals enrolled in a
8school within the CPS system. Under any contract procured under
9this provision, the vendor or vendors must serve only
10individuals enrolled in a school within the CPS system. Claims
11for services provided by CPS's vendor or vendors to recipients
12of benefits in the medical assistance program under this Code,
13the Children's Health Insurance Program, or the Covering ALL
14KIDS Health Insurance Program shall be submitted to the
15Department or the MCE in which the individual is enrolled for
16payment and shall be reimbursed at the Department's or the
17MCE's established rates or rate methodologies for eyeglasses.
18    On and after July 1, 2012, the Department of Healthcare and
19Family Services may provide the following services to persons
20eligible for assistance under this Article who are
21participating in education, training or employment programs
22operated by the Department of Human Services as successor to
23the Department of Public Aid:
24        (1) dental services provided by or under the
25    supervision of a dentist; and
26        (2) eyeglasses prescribed by a physician skilled in the

 

 

HB0001 Engrossed- 106 -LRB099 00249 HEP 20254 b

1    diseases of the eye, or by an optometrist, whichever the
2    person may select.
3    Notwithstanding any other provision of this Code and
4subject to federal approval, the Department may adopt rules to
5allow a dentist who is volunteering his or her service at no
6cost to render dental services through an enrolled
7not-for-profit health clinic without the dentist personally
8enrolling as a participating provider in the medical assistance
9program. A not-for-profit health clinic shall include a public
10health clinic or Federally Qualified Health Center or other
11enrolled provider, as determined by the Department, through
12which dental services covered under this Section are performed.
13The Department shall establish a process for payment of claims
14for reimbursement for covered dental services rendered under
15this provision.
16    The Illinois Department, by rule, may distinguish and
17classify the medical services to be provided only in accordance
18with the classes of persons designated in Section 5-2.
19    The Department of Healthcare and Family Services must
20provide coverage and reimbursement for amino acid-based
21elemental formulas, regardless of delivery method, for the
22diagnosis and treatment of (i) eosinophilic disorders and (ii)
23short bowel syndrome when the prescribing physician has issued
24a written order stating that the amino acid-based elemental
25formula is medically necessary.
26    The Illinois Department shall authorize the provision of,

 

 

HB0001 Engrossed- 107 -LRB099 00249 HEP 20254 b

1and shall authorize payment for, screening by low-dose
2mammography for the presence of occult breast cancer for women
335 years of age or older who are eligible for medical
4assistance under this Article, as follows:
5        (A) A baseline mammogram for women 35 to 39 years of
6    age.
7        (B) An annual mammogram for women 40 years of age or
8    older.
9        (C) A mammogram at the age and intervals considered
10    medically necessary by the woman's health care provider for
11    women under 40 years of age and having a family history of
12    breast cancer, prior personal history of breast cancer,
13    positive genetic testing, or other risk factors.
14        (D) A comprehensive ultrasound screening of an entire
15    breast or breasts if a mammogram demonstrates
16    heterogeneous or dense breast tissue, when medically
17    necessary as determined by a physician licensed to practice
18    medicine in all of its branches.
19    All screenings shall include a physical breast exam,
20instruction on self-examination and information regarding the
21frequency of self-examination and its value as a preventative
22tool. For purposes of this Section, "low-dose mammography"
23means the x-ray examination of the breast using equipment
24dedicated specifically for mammography, including the x-ray
25tube, filter, compression device, and image receptor, with an
26average radiation exposure delivery of less than one rad per

 

 

HB0001 Engrossed- 108 -LRB099 00249 HEP 20254 b

1breast for 2 views of an average size breast. The term also
2includes digital mammography.
3    On and after January 1, 2012, providers participating in a
4quality improvement program approved by the Department shall be
5reimbursed for screening and diagnostic mammography at the same
6rate as the Medicare program's rates, including the increased
7reimbursement for digital mammography.
8    The Department shall convene an expert panel including
9representatives of hospitals, free-standing mammography
10facilities, and doctors, including radiologists, to establish
11quality standards.
12    Subject to federal approval, the Department shall
13establish a rate methodology for mammography at federally
14qualified health centers and other encounter-rate clinics.
15These clinics or centers may also collaborate with other
16hospital-based mammography facilities.
17    The Department shall establish a methodology to remind
18women who are age-appropriate for screening mammography, but
19who have not received a mammogram within the previous 18
20months, of the importance and benefit of screening mammography.
21    The Department shall establish a performance goal for
22primary care providers with respect to their female patients
23over age 40 receiving an annual mammogram. This performance
24goal shall be used to provide additional reimbursement in the
25form of a quality performance bonus to primary care providers
26who meet that goal.

 

 

HB0001 Engrossed- 109 -LRB099 00249 HEP 20254 b

1    The Department shall devise a means of case-managing or
2patient navigation for beneficiaries diagnosed with breast
3cancer. This program shall initially operate as a pilot program
4in areas of the State with the highest incidence of mortality
5related to breast cancer. At least one pilot program site shall
6be in the metropolitan Chicago area and at least one site shall
7be outside the metropolitan Chicago area. An evaluation of the
8pilot program shall be carried out measuring health outcomes
9and cost of care for those served by the pilot program compared
10to similarly situated patients who are not served by the pilot
11program.
12    Any medical or health care provider shall immediately
13recommend, to any pregnant woman who is being provided prenatal
14services and is suspected of drug abuse or is addicted as
15defined in the Alcoholism and Other Drug Abuse and Dependency
16Act, referral to a local substance abuse treatment provider
17licensed by the Department of Human Services or to a licensed
18hospital which provides substance abuse treatment services.
19The Department of Healthcare and Family Services shall assure
20coverage for the cost of treatment of the drug abuse or
21addiction for pregnant recipients in accordance with the
22Illinois Medicaid Program in conjunction with the Department of
23Human Services.
24    All medical providers providing medical assistance to
25pregnant women under this Code shall receive information from
26the Department on the availability of services under the Drug

 

 

HB0001 Engrossed- 110 -LRB099 00249 HEP 20254 b

1Free Families with a Future or any comparable program providing
2case management services for addicted women, including
3information on appropriate referrals for other social services
4that may be needed by addicted women in addition to treatment
5for addiction.
6    The Illinois Department, in cooperation with the
7Departments of Human Services (as successor to the Department
8of Alcoholism and Substance Abuse) and Public Health, through a
9public awareness campaign, may provide information concerning
10treatment for alcoholism and drug abuse and addiction, prenatal
11health care, and other pertinent programs directed at reducing
12the number of drug-affected infants born to recipients of
13medical assistance.
14    Neither the Department of Healthcare and Family Services
15nor the Department of Human Services shall sanction the
16recipient solely on the basis of her substance abuse.
17    The Illinois Department shall establish such regulations
18governing the dispensing of health services under this Article
19as it shall deem appropriate. The Department should seek the
20advice of formal professional advisory committees appointed by
21the Director of the Illinois Department for the purpose of
22providing regular advice on policy and administrative matters,
23information dissemination and educational activities for
24medical and health care providers, and consistency in
25procedures to the Illinois Department.
26    The Illinois Department may develop and contract with

 

 

HB0001 Engrossed- 111 -LRB099 00249 HEP 20254 b

1Partnerships of medical providers to arrange medical services
2for persons eligible under Section 5-2 of this Code.
3Implementation of this Section may be by demonstration projects
4in certain geographic areas. The Partnership shall be
5represented by a sponsor organization. The Department, by rule,
6shall develop qualifications for sponsors of Partnerships.
7Nothing in this Section shall be construed to require that the
8sponsor organization be a medical organization.
9    The sponsor must negotiate formal written contracts with
10medical providers for physician services, inpatient and
11outpatient hospital care, home health services, treatment for
12alcoholism and substance abuse, and other services determined
13necessary by the Illinois Department by rule for delivery by
14Partnerships. Physician services must include prenatal and
15obstetrical care. The Illinois Department shall reimburse
16medical services delivered by Partnership providers to clients
17in target areas according to provisions of this Article and the
18Illinois Health Finance Reform Act, except that:
19        (1) Physicians participating in a Partnership and
20    providing certain services, which shall be determined by
21    the Illinois Department, to persons in areas covered by the
22    Partnership may receive an additional surcharge for such
23    services.
24        (2) The Department may elect to consider and negotiate
25    financial incentives to encourage the development of
26    Partnerships and the efficient delivery of medical care.

 

 

HB0001 Engrossed- 112 -LRB099 00249 HEP 20254 b

1        (3) Persons receiving medical services through
2    Partnerships may receive medical and case management
3    services above the level usually offered through the
4    medical assistance program.
5    Medical providers shall be required to meet certain
6qualifications to participate in Partnerships to ensure the
7delivery of high quality medical services. These
8qualifications shall be determined by rule of the Illinois
9Department and may be higher than qualifications for
10participation in the medical assistance program. Partnership
11sponsors may prescribe reasonable additional qualifications
12for participation by medical providers, only with the prior
13written approval of the Illinois Department.
14    Nothing in this Section shall limit the free choice of
15practitioners, hospitals, and other providers of medical
16services by clients. In order to ensure patient freedom of
17choice, the Illinois Department shall immediately promulgate
18all rules and take all other necessary actions so that provided
19services may be accessed from therapeutically certified
20optometrists to the full extent of the Illinois Optometric
21Practice Act of 1987 without discriminating between service
22providers.
23    The Department shall apply for a waiver from the United
24States Health Care Financing Administration to allow for the
25implementation of Partnerships under this Section.
26    The Illinois Department shall require health care

 

 

HB0001 Engrossed- 113 -LRB099 00249 HEP 20254 b

1providers to maintain records that document the medical care
2and services provided to recipients of Medical Assistance under
3this Article. Such records must be retained for a period of not
4less than 6 years from the date of service or as provided by
5applicable State law, whichever period is longer, except that
6if an audit is initiated within the required retention period
7then the records must be retained until the audit is completed
8and every exception is resolved. The Illinois Department shall
9require health care providers to make available, when
10authorized by the patient, in writing, the medical records in a
11timely fashion to other health care providers who are treating
12or serving persons eligible for Medical Assistance under this
13Article. All dispensers of medical services shall be required
14to maintain and retain business and professional records
15sufficient to fully and accurately document the nature, scope,
16details and receipt of the health care provided to persons
17eligible for medical assistance under this Code, in accordance
18with regulations promulgated by the Illinois Department. The
19rules and regulations shall require that proof of the receipt
20of prescription drugs, dentures, prosthetic devices and
21eyeglasses by eligible persons under this Section accompany
22each claim for reimbursement submitted by the dispenser of such
23medical services. No such claims for reimbursement shall be
24approved for payment by the Illinois Department without such
25proof of receipt, unless the Illinois Department shall have put
26into effect and shall be operating a system of post-payment

 

 

HB0001 Engrossed- 114 -LRB099 00249 HEP 20254 b

1audit and review which shall, on a sampling basis, be deemed
2adequate by the Illinois Department to assure that such drugs,
3dentures, prosthetic devices and eyeglasses for which payment
4is being made are actually being received by eligible
5recipients. Within 90 days after the effective date of this
6amendatory Act of 1984, the Illinois Department shall establish
7a current list of acquisition costs for all prosthetic devices
8and any other items recognized as medical equipment and
9supplies reimbursable under this Article and shall update such
10list on a quarterly basis, except that the acquisition costs of
11all prescription drugs shall be updated no less frequently than
12every 30 days as required by Section 5-5.12.
13    The rules and regulations of the Illinois Department shall
14require that a written statement including the required opinion
15of a physician shall accompany any claim for reimbursement for
16abortions, or induced miscarriages or premature births. This
17statement shall indicate what procedures were used in providing
18such medical services.
19    Notwithstanding any other law to the contrary, the Illinois
20Department shall, within 365 days after July 22, 2013, (the
21effective date of Public Act 98-104), establish procedures to
22permit skilled care facilities licensed under the Nursing Home
23Care Act to submit monthly billing claims for reimbursement
24purposes. Following development of these procedures, the
25Department shall have an additional 365 days to test the
26viability of the new system and to ensure that any necessary

 

 

HB0001 Engrossed- 115 -LRB099 00249 HEP 20254 b

1operational or structural changes to its information
2technology platforms are implemented.
3    Notwithstanding any other law to the contrary, the Illinois
4Department shall, within 365 days after August 15, 2014 (the
5effective date of Public Act 98-963) this amendatory Act of the
698th General Assembly, establish procedures to permit ID/DD
7facilities licensed under the ID/DD Community Care Act to
8submit monthly billing claims for reimbursement purposes.
9Following development of these procedures, the Department
10shall have an additional 365 days to test the viability of the
11new system and to ensure that any necessary operational or
12structural changes to its information technology platforms are
13implemented.
14    The Illinois Department shall require all dispensers of
15medical services, other than an individual practitioner or
16group of practitioners, desiring to participate in the Medical
17Assistance program established under this Article to disclose
18all financial, beneficial, ownership, equity, surety or other
19interests in any and all firms, corporations, partnerships,
20associations, business enterprises, joint ventures, agencies,
21institutions or other legal entities providing any form of
22health care services in this State under this Article.
23    The Illinois Department may require that all dispensers of
24medical services desiring to participate in the medical
25assistance program established under this Article disclose,
26under such terms and conditions as the Illinois Department may

 

 

HB0001 Engrossed- 116 -LRB099 00249 HEP 20254 b

1by rule establish, all inquiries from clients and attorneys
2regarding medical bills paid by the Illinois Department, which
3inquiries could indicate potential existence of claims or liens
4for the Illinois Department.
5    Enrollment of a vendor shall be subject to a provisional
6period and shall be conditional for one year. During the period
7of conditional enrollment, the Department may terminate the
8vendor's eligibility to participate in, or may disenroll the
9vendor from, the medical assistance program without cause.
10Unless otherwise specified, such termination of eligibility or
11disenrollment is not subject to the Department's hearing
12process. However, a disenrolled vendor may reapply without
13penalty.
14    The Department has the discretion to limit the conditional
15enrollment period for vendors based upon category of risk of
16the vendor.
17    Prior to enrollment and during the conditional enrollment
18period in the medical assistance program, all vendors shall be
19subject to enhanced oversight, screening, and review based on
20the risk of fraud, waste, and abuse that is posed by the
21category of risk of the vendor. The Illinois Department shall
22establish the procedures for oversight, screening, and review,
23which may include, but need not be limited to: criminal and
24financial background checks; fingerprinting; license,
25certification, and authorization verifications; unscheduled or
26unannounced site visits; database checks; prepayment audit

 

 

HB0001 Engrossed- 117 -LRB099 00249 HEP 20254 b

1reviews; audits; payment caps; payment suspensions; and other
2screening as required by federal or State law.
3    The Department shall define or specify the following: (i)
4by provider notice, the "category of risk of the vendor" for
5each type of vendor, which shall take into account the level of
6screening applicable to a particular category of vendor under
7federal law and regulations; (ii) by rule or provider notice,
8the maximum length of the conditional enrollment period for
9each category of risk of the vendor; and (iii) by rule, the
10hearing rights, if any, afforded to a vendor in each category
11of risk of the vendor that is terminated or disenrolled during
12the conditional enrollment period.
13    To be eligible for payment consideration, a vendor's
14payment claim or bill, either as an initial claim or as a
15resubmitted claim following prior rejection, must be received
16by the Illinois Department, or its fiscal intermediary, no
17later than 180 days after the latest date on the claim on which
18medical goods or services were provided, with the following
19exceptions:
20        (1) In the case of a provider whose enrollment is in
21    process by the Illinois Department, the 180-day period
22    shall not begin until the date on the written notice from
23    the Illinois Department that the provider enrollment is
24    complete.
25        (2) In the case of errors attributable to the Illinois
26    Department or any of its claims processing intermediaries

 

 

HB0001 Engrossed- 118 -LRB099 00249 HEP 20254 b

1    which result in an inability to receive, process, or
2    adjudicate a claim, the 180-day period shall not begin
3    until the provider has been notified of the error.
4        (3) In the case of a provider for whom the Illinois
5    Department initiates the monthly billing process.
6        (4) In the case of a provider operated by a unit of
7    local government with a population exceeding 3,000,000
8    when local government funds finance federal participation
9    for claims payments.
10    For claims for services rendered during a period for which
11a recipient received retroactive eligibility, claims must be
12filed within 180 days after the Department determines the
13applicant is eligible. For claims for which the Illinois
14Department is not the primary payer, claims must be submitted
15to the Illinois Department within 180 days after the final
16adjudication by the primary payer.
17    In the case of long term care facilities, within 5 days of
18receipt by the facility of required prescreening information,
19data for new admissions shall be entered into the Medical
20Electronic Data Interchange (MEDI) or the Recipient
21Eligibility Verification (REV) System or successor system, and
22within 15 days of receipt by the facility of required
23prescreening information, admission documents shall be
24submitted through MEDI or REV or shall be submitted directly to
25the Department of Human Services using required admission
26forms. Effective September 1, 2014, admission documents,

 

 

HB0001 Engrossed- 119 -LRB099 00249 HEP 20254 b

1including all prescreening information, must be submitted
2through MEDI or REV. Confirmation numbers assigned to an
3accepted transaction shall be retained by a facility to verify
4timely submittal. Once an admission transaction has been
5completed, all resubmitted claims following prior rejection
6are subject to receipt no later than 180 days after the
7admission transaction has been completed.
8    Claims that are not submitted and received in compliance
9with the foregoing requirements shall not be eligible for
10payment under the medical assistance program, and the State
11shall have no liability for payment of those claims.
12    To the extent consistent with applicable information and
13privacy, security, and disclosure laws, State and federal
14agencies and departments shall provide the Illinois Department
15access to confidential and other information and data necessary
16to perform eligibility and payment verifications and other
17Illinois Department functions. This includes, but is not
18limited to: information pertaining to licensure;
19certification; earnings; immigration status; citizenship; wage
20reporting; unearned and earned income; pension income;
21employment; supplemental security income; social security
22numbers; National Provider Identifier (NPI) numbers; the
23National Practitioner Data Bank (NPDB); program and agency
24exclusions; taxpayer identification numbers; tax delinquency;
25corporate information; and death records.
26    The Illinois Department shall enter into agreements with

 

 

HB0001 Engrossed- 120 -LRB099 00249 HEP 20254 b

1State agencies and departments, and is authorized to enter into
2agreements with federal agencies and departments, under which
3such agencies and departments shall share data necessary for
4medical assistance program integrity functions and oversight.
5The Illinois Department shall develop, in cooperation with
6other State departments and agencies, and in compliance with
7applicable federal laws and regulations, appropriate and
8effective methods to share such data. At a minimum, and to the
9extent necessary to provide data sharing, the Illinois
10Department shall enter into agreements with State agencies and
11departments, and is authorized to enter into agreements with
12federal agencies and departments, including but not limited to:
13the Secretary of State; the Department of Revenue; the
14Department of Public Health; the Department of Human Services;
15and the Department of Financial and Professional Regulation.
16    Beginning in fiscal year 2013, the Illinois Department
17shall set forth a request for information to identify the
18benefits of a pre-payment, post-adjudication, and post-edit
19claims system with the goals of streamlining claims processing
20and provider reimbursement, reducing the number of pending or
21rejected claims, and helping to ensure a more transparent
22adjudication process through the utilization of: (i) provider
23data verification and provider screening technology; and (ii)
24clinical code editing; and (iii) pre-pay, pre- or
25post-adjudicated predictive modeling with an integrated case
26management system with link analysis. Such a request for

 

 

HB0001 Engrossed- 121 -LRB099 00249 HEP 20254 b

1information shall not be considered as a request for proposal
2or as an obligation on the part of the Illinois Department to
3take any action or acquire any products or services.
4    The Illinois Department shall establish policies,
5procedures, standards and criteria by rule for the acquisition,
6repair and replacement of orthotic and prosthetic devices and
7durable medical equipment. Such rules shall provide, but not be
8limited to, the following services: (1) immediate repair or
9replacement of such devices by recipients; and (2) rental,
10lease, purchase or lease-purchase of durable medical equipment
11in a cost-effective manner, taking into consideration the
12recipient's medical prognosis, the extent of the recipient's
13needs, and the requirements and costs for maintaining such
14equipment. Subject to prior approval, such rules shall enable a
15recipient to temporarily acquire and use alternative or
16substitute devices or equipment pending repairs or
17replacements of any device or equipment previously authorized
18for such recipient by the Department.
19    The Department shall execute, relative to the nursing home
20prescreening project, written inter-agency agreements with the
21Department of Human Services and the Department on Aging, to
22effect the following: (i) intake procedures and common
23eligibility criteria for those persons who are receiving
24non-institutional services; and (ii) the establishment and
25development of non-institutional services in areas of the State
26where they are not currently available or are undeveloped; and

 

 

HB0001 Engrossed- 122 -LRB099 00249 HEP 20254 b

1(iii) notwithstanding any other provision of law, subject to
2federal approval, on and after July 1, 2012, an increase in the
3determination of need (DON) scores from 29 to 37 for applicants
4for institutional and home and community-based long term care;
5if and only if federal approval is not granted, the Department
6may, in conjunction with other affected agencies, implement
7utilization controls or changes in benefit packages to
8effectuate a similar savings amount for this population; and
9(iv) no later than July 1, 2013, minimum level of care
10eligibility criteria for institutional and home and
11community-based long term care; and (v) no later than October
121, 2013, establish procedures to permit long term care
13providers access to eligibility scores for individuals with an
14admission date who are seeking or receiving services from the
15long term care provider. In order to select the minimum level
16of care eligibility criteria, the Governor shall establish a
17workgroup that includes affected agency representatives and
18stakeholders representing the institutional and home and
19community-based long term care interests. This Section shall
20not restrict the Department from implementing lower level of
21care eligibility criteria for community-based services in
22circumstances where federal approval has been granted.
23    The Illinois Department shall develop and operate, in
24cooperation with other State Departments and agencies and in
25compliance with applicable federal laws and regulations,
26appropriate and effective systems of health care evaluation and

 

 

HB0001 Engrossed- 123 -LRB099 00249 HEP 20254 b

1programs for monitoring of utilization of health care services
2and facilities, as it affects persons eligible for medical
3assistance under this Code.
4    The Illinois Department shall report annually to the
5General Assembly, no later than the second Friday in April of
61979 and each year thereafter, in regard to:
7        (a) actual statistics and trends in utilization of
8    medical services by public aid recipients;
9        (b) actual statistics and trends in the provision of
10    the various medical services by medical vendors;
11        (c) current rate structures and proposed changes in
12    those rate structures for the various medical vendors; and
13        (d) efforts at utilization review and control by the
14    Illinois Department.
15    The period covered by each report shall be the 3 years
16ending on the June 30 prior to the report. The report shall
17include suggested legislation for consideration by the General
18Assembly. The filing of one copy of the report with the
19Speaker, one copy with the Minority Leader and one copy with
20the Clerk of the House of Representatives, one copy with the
21President, one copy with the Minority Leader and one copy with
22the Secretary of the Senate, one copy with the Legislative
23Research Unit, and such additional copies with the State
24Government Report Distribution Center for the General Assembly
25as is required under paragraph (t) of Section 7 of the State
26Library Act shall be deemed sufficient to comply with this

 

 

HB0001 Engrossed- 124 -LRB099 00249 HEP 20254 b

1Section.
2    Rulemaking authority to implement Public Act 95-1045, if
3any, is conditioned on the rules being adopted in accordance
4with all provisions of the Illinois Administrative Procedure
5Act and all rules and procedures of the Joint Committee on
6Administrative Rules; any purported rule not so adopted, for
7whatever reason, is unauthorized.
8    On and after July 1, 2012, the Department shall reduce any
9rate of reimbursement for services or other payments or alter
10any methodologies authorized by this Code to reduce any rate of
11reimbursement for services or other payments in accordance with
12Section 5-5e.
13    Because kidney transplantation can be an appropriate, cost
14effective alternative to renal dialysis when medically
15necessary and notwithstanding the provisions of Section 1-11 of
16this Code, beginning October 1, 2014, the Department shall
17cover kidney transplantation for noncitizens with end-stage
18renal disease who are not eligible for comprehensive medical
19benefits, who meet the residency requirements of Section 5-3 of
20this Code, and who would otherwise meet the financial
21requirements of the appropriate class of eligible persons under
22Section 5-2 of this Code. To qualify for coverage of kidney
23transplantation, such person must be receiving emergency renal
24dialysis services covered by the Department. Providers under
25this Section shall be prior approved and certified by the
26Department to perform kidney transplantation and the services

 

 

HB0001 Engrossed- 125 -LRB099 00249 HEP 20254 b

1under this Section shall be limited to services associated with
2kidney transplantation.
3    Notwithstanding any other provision of this Code to the
4contrary, on or after July 1, 2015, all FDA approved forms of
5medication assisted treatment prescribed for the treatment of
6alcohol dependence or treatment of opioid dependence shall be
7covered under both fee for service and managed care medical
8assistance programs for persons who are otherwise eligible for
9medical assistance under this Article and shall not be subject
10to any (1) utilization control, other than those established
11under the American Society of Addiction Medicine patient
12placement criteria, (2) prior authorization mandate, or (3)
13lifetime restriction limit mandate.
14    On or after July 1, 2015, opioid antagonists prescribed for
15the treatment of an opioid overdose, including the medication
16product, administration devices, and any pharmacy fees related
17to the dispensing and administration of the opioid antagonist,
18shall be covered under the medical assistance program for
19persons who are otherwise eligible for medical assistance under
20this Article. As used in this Section, "opioid antagonist"
21means a drug that binds to opioid receptors and blocks or
22inhibits the effect of opioids acting on those receptors,
23including, but not limited to, naloxone hydrochloride or any
24other similarly acting drug approved by the U.S. Food and Drug
25Administration.
26(Source: P.A. 97-48, eff. 6-28-11; 97-638, eff. 1-1-12; 97-689,

 

 

HB0001 Engrossed- 126 -LRB099 00249 HEP 20254 b

1eff. 6-14-12; 97-1061, eff. 8-24-12; 98-104, Article 9, Section
29-5, eff. 7-22-13; 98-104, Article 12, Section 12-20, eff.
37-22-13; 98-303, eff. 8-9-13; 98-463, eff. 8-16-13; 98-651,
4eff. 6-16-14; 98-756, eff. 7-16-14; 98-963, eff. 8-15-14;
5revised 10-2-14.)
 
6    (305 ILCS 5/5-16.8)
7    Sec. 5-16.8. Required health benefits. The medical
8assistance program shall (i) provide the post-mastectomy care
9benefits required to be covered by a policy of accident and
10health insurance under Section 356t and the coverage required
11under Sections 356g.5, 356u, 356w, 356x, and 356z.6 of the
12Illinois Insurance Code and (ii) be subject to the provisions
13of Sections 356z.19, and 364.01, 370c, and 370c.1 of the
14Illinois Insurance Code.
15    On and after July 1, 2012, the Department shall reduce any
16rate of reimbursement for services or other payments or alter
17any methodologies authorized by this Code to reduce any rate of
18reimbursement for services or other payments in accordance with
19Section 5-5e.
20(Source: P.A. 97-282, eff. 8-9-11; 97-689, eff. 6-14-12.)
 
21    Section 5-88. The Environmental Protection Act is amended
22by changing Section 22.55 as follows:
 
23    (415 ILCS 5/22.55)

 

 

HB0001 Engrossed- 127 -LRB099 00249 HEP 20254 b

1    Sec. 22.55. Household Waste Drop-off Points.
2    (a) Findings; Purpose and Intent.
3        (1) The General Assembly finds that protection of human
4    health and the environment can be enhanced if certain
5    commonly generated household wastes are managed separately
6    from the general household waste stream.
7        (2) The purpose of this Section is to provide, to the
8    extent allowed under federal law, a method for managing
9    certain types of household waste separately from the
10    general household waste stream.
11    (b) Definitions. For the purposes of this Section:
12        "Controlled substance" means a controlled substance as
13    defined in the Illinois Controlled Substances Act.
14        "Household waste" means waste generated from a single
15    residence or multiple residences.
16        "Household waste drop-off point" means the portion of a
17    site or facility used solely for the receipt and temporary
18    storage of household waste.
19        "One-day household waste collection event" means a
20    household waste drop-off point approved by the Agency under
21    subsection (d) of this Section.
22        "Personal care product" means an item other than a
23    pharmaceutical product that is consumed or applied by an
24    individual for personal health, hygiene, or cosmetic
25    reasons. Personal care products include, but are not
26    limited to, items used in bathing, dressing, or grooming.

 

 

HB0001 Engrossed- 128 -LRB099 00249 HEP 20254 b

1        "Pharmaceutical product" means medicine or a product
2    containing medicine. A pharmaceutical product may be sold
3    by prescription or over the counter. "Pharmaceutical
4    product" does not include (i) medicine that contains a
5    radioactive component or a product that contains a
6    radioactive component or (ii) a controlled substance.
7    (c) Except as otherwise provided in Agency rules, the
8following requirements apply to each household waste drop-off
9point other than a one-day household waste collection event:
10        (1) A household waste drop-off point must not accept
11    waste other than the following types of household waste:
12    pharmaceutical products, personal care products, batteries
13    other than lead-acid batteries, paints, automotive fluids,
14    compact fluorescent lightbulbs, mercury thermometers, and
15    mercury thermostats. A household waste drop-off point may
16    accept controlled substances in accordance with federal
17    law.
18        (2) Except as provided in subdivision (c)(2) of this
19    Section, household waste drop-off points must be located at
20    a site or facility where the types of products accepted at
21    the household waste drop-off point are lawfully sold,
22    distributed, or dispensed. For example, household waste
23    drop-off points that accept prescription pharmaceutical
24    products must be located at a site or facility where
25    prescription pharmaceutical products are sold,
26    distributed, or dispensed.

 

 

HB0001 Engrossed- 129 -LRB099 00249 HEP 20254 b

1            (A) Subdivision (c)(2) of this Section does not
2        apply to household waste drop-off points operated by a
3        government or school entity, or by an association or
4        other organization of government or school entities.
5            (B) Household waste drop-off points that accept
6        mercury thermometers can be located at any site or
7        facility where non-mercury thermometers are sold,
8        distributed, or dispensed.
9            (C) Household waste drop-off points that accept
10        mercury thermostats can be located at any site or
11        facility where non-mercury thermostats are sold,
12        distributed, or dispensed.
13        (3) The location of acceptance for each type of waste
14    accepted at the household waste drop-off point must be
15    clearly identified. Locations where pharmaceutical
16    products are accepted must also include a copy of the sign
17    required under subsection (j) of this Section.
18        (4) Household waste must be accepted only from private
19    individuals. Waste must not be accepted from other persons,
20    including, but not limited to, owners and operators of
21    rented or leased residences where the household waste was
22    generated, commercial haulers, and other commercial,
23    industrial, agricultural, and government operations or
24    entities.
25        (5) If more than one type of household waste is
26    accepted, each type of household waste must be managed

 

 

HB0001 Engrossed- 130 -LRB099 00249 HEP 20254 b

1    separately prior to its packaging for off-site transfer.
2        (6) Household waste must not be stored for longer than
3    90 days after its receipt, except as otherwise approved by
4    the Agency in writing.
5        (7) Household waste must be managed in a manner that
6    protects against releases of the waste, prevents
7    nuisances, and otherwise protects human health and the
8    environment. Household waste must also be properly secured
9    to prevent unauthorized public access to the waste,
10    including, but not limited to, preventing access to the
11    waste during the non-business hours of the site or facility
12    on which the household waste drop-off point is located.
13    Containers in which pharmaceutical products are collected
14    must be clearly marked "No Controlled Substances", unless
15    the household waste drop-off point accepts controlled
16    substances in accordance with federal law.
17        (8) Management of the household waste must be limited
18    to the following: (i) acceptance of the waste, (ii)
19    temporary storage of the waste prior to transfer, and (iii)
20    off-site transfer of the waste and packaging for off-site
21    transfer.
22        (9) Off-site transfer of the household waste must
23    comply with federal and State laws and regulations.
24    (d) One-day household waste collection events. To further
25aid in the collection of certain household wastes, the Agency
26may approve the operation of one-day household waste collection

 

 

HB0001 Engrossed- 131 -LRB099 00249 HEP 20254 b

1events. The Agency shall not approve a one-day household waste
2collection event at the same site or facility for more than one
3day each calendar quarter. Requests for approval must be
4submitted on forms prescribed by the Agency. The Agency must
5issue its approval in writing, and it may impose conditions as
6necessary to protect human health and the environment and to
7otherwise accomplish the purposes of this Act. One-day
8household waste collection events must be operated in
9accordance with the Agency's approval, including all
10conditions contained in the approval. The following
11requirements apply to all one-day household waste collection
12events, in addition to the conditions contained in the Agency's
13approval:
14        (1) Waste accepted at the event must be limited to
15    household waste and must not include garbage, landscape
16    waste, controlled substances, or other waste excluded by
17    the Agency in the Agency's approval or any conditions
18    contained in the approval. A one-day household waste
19    collection event may accept controlled substances in
20    accordance with federal law.
21        (2) Household waste must be accepted only from private
22    individuals. Waste must not be accepted from other persons,
23    including, but not limited to, owners and operators of
24    rented or leased residences where the household waste was
25    generated, commercial haulers, and other commercial,
26    industrial, agricultural, and government operations or

 

 

HB0001 Engrossed- 132 -LRB099 00249 HEP 20254 b

1    entities.
2        (3) Household waste must be managed in a manner that
3    protects against releases of the waste, prevents
4    nuisances, and otherwise protects human health and the
5    environment. Household waste must also be properly secured
6    to prevent public access to the waste, including, but not
7    limited to, preventing access to the waste during the
8    event's non-business hours.
9        (4) Management of the household waste must be limited
10    to the following: (i) acceptance of the waste, (ii)
11    temporary storage of the waste before transfer, and (iii)
12    off-site transfer of the waste or packaging for off-site
13    transfer.
14        (5) Except as otherwise approved by the Agency, all
15    household waste received at the collection event must be
16    transferred off-site by the end of the day following the
17    collection event.
18        (6) The transfer and ultimate disposition of household
19    waste received at the collection event must comply with the
20    Agency's approval, including all conditions contained in
21    the approval.
22    (e) The Agency may adopt rules governing the operation of
23household waste drop-off points other than one-day household
24waste collection events. Those rules must be designed to
25protect against releases of waste to the environment, prevent
26nuisances, and otherwise protect human health and the

 

 

HB0001 Engrossed- 133 -LRB099 00249 HEP 20254 b

1environment. As necessary to address different circumstances,
2the regulations may contain different requirements for
3different types of household waste and different types of
4household waste drop-off points, and the regulations may modify
5the requirements set forth in subsection (c) of this Section.
6The regulations may include, but are not limited to, the
7following: (i) identification of additional types of household
8waste that can be collected at household waste drop-off points,
9(ii) identification of the different types of household wastes
10that can be received at different household waste drop-off
11points, (iii) the maximum amounts of each type of household
12waste that can be stored at household waste drop-off points at
13any one time, and (iv) the maximum time periods each type of
14household waste can be stored at household waste drop-off
15points.
16    (f) Prohibitions.
17        (1) Except as authorized in a permit issued by the
18    Agency, no person shall cause or allow the operation of a
19    household waste drop-off point other than a one-day
20    household waste collection event in violation of this
21    Section or any regulations adopted under this Section.
22        (2) No person shall cause or allow the operation of a
23    one-day household waste collection event in violation of
24    this Section or the Agency's approval issued under
25    subsection (d) of this Section, including all conditions
26    contained in the approval.

 

 

HB0001 Engrossed- 134 -LRB099 00249 HEP 20254 b

1    (g) Permit exemptions.
2        (1) No permit is required under subdivision (d)(1) of
3    Section 21 of this Act for the operation of a household
4    waste drop-off point other than a one-day household waste
5    collection event if the household waste drop-off point is
6    operated in accordance with this Section and all
7    regulations adopted under this Section.
8        (2) No permit is required under subdivision (d)(1) of
9    Section 21 of this Act for the operation of a one-day
10    household waste collection event if the event is operated
11    in accordance with this Section and the Agency's approval
12    issued under subsection (d) of this Section, including all
13    conditions contained in the approval, or for the operation
14    of a household waste collection event by the Agency.
15    (h) This Section does not apply to the following:
16        (1) Persons accepting household waste that they are
17    authorized to accept under a permit issued by the Agency.
18        (2) Sites or facilities operated pursuant to an
19    intergovernmental agreement entered into with the Agency
20    under Section 22.16b(d) of this Act.
21    (i) The Agency, in consultation with the Department of
22Public Health, must develop and implement a public information
23program regarding household waste drop-off points that accept
24pharmaceutical products, as well as mail-back programs
25authorized under federal law.
26    (j) The Agency must develop a sign that provides

 

 

HB0001 Engrossed- 135 -LRB099 00249 HEP 20254 b

1information on the proper disposal of unused pharmaceutical
2products. The sign shall include information on approved
3drop-off sites or list a website where updated information on
4drop-off sites can be accessed. The sign shall also include
5information on mail-back programs and self-disposal. The
6Agency shall make a copy of the sign available for downloading
7from its website. Every pharmacy shall display the sign in the
8area where medications are dispensed and shall also display any
9signs the Agency develops regarding local take-back programs or
10household waste collection events. These signs shall be no
11larger than 8.5 inches by 11 inches.
12    (k) If an entity chooses to participate as a household
13waste drop-off point, then it must follow the provisions of
14this Section and any rules the Agency may adopt governing
15household waste drop-off points.
16    (l) The Agency shall establish, by rule, a statewide
17medication take-back program by June 1, 2016 to ensure that
18there are pharmaceutical product disposal options regularly
19available for residents across the State. No private entity may
20be compelled to serve as or fund a take-back location or
21program. Medications collected and disposed of under the
22program shall include controlled substances approved for
23collection by federal law. All medications collected and
24disposed of under the program must be managed in accordance
25with all applicable federal and State laws and regulations. The
26Agency shall issue a report to the General Assembly by June 1,

 

 

HB0001 Engrossed- 136 -LRB099 00249 HEP 20254 b

12019 detailing the amount of pharmaceutical products annually
2collected under the program, as well as any legislative
3recommendations.
4(Source: P.A. 96-121, eff. 8-4-09.)
 
5    Section 5-90. The Criminal Code of 2012 is amended by
6changing Section 29B-1 as follows:
 
7    (720 ILCS 5/29B-1)  (from Ch. 38, par. 29B-1)
8    Sec. 29B-1. (a) A person commits the offense of money
9laundering:
10        (1) when, knowing that the property involved in a
11    financial transaction represents the proceeds of some form
12    of unlawful activity, he or she conducts or attempts to
13    conduct such a financial transaction which in fact involves
14    criminally derived property:
15            (A) with the intent to promote the carrying on of
16        the unlawful activity from which the criminally
17        derived property was obtained; or
18            (B) where he or she knows or reasonably should know
19        that the financial transaction is designed in whole or
20        in part:
21                (i) to conceal or disguise the nature, the
22            location, the source, the ownership or the control
23            of the criminally derived property; or
24                (ii) to avoid a transaction reporting

 

 

HB0001 Engrossed- 137 -LRB099 00249 HEP 20254 b

1            requirement under State law; or
2        (1.5) when he or she transports, transmits, or
3    transfers, or attempts to transport, transmit, or transfer
4    a monetary instrument:
5            (A) with the intent to promote the carrying on of
6        the unlawful activity from which the criminally
7        derived property was obtained; or
8            (B) knowing, or having reason to know, that the
9        financial transaction is designed in whole or in part:
10                (i) to conceal or disguise the nature, the
11            location, the source, the ownership or the control
12            of the criminally derived property; or
13                (ii) to avoid a transaction reporting
14            requirement under State law; or
15        (2) when, with the intent to:
16            (A) promote the carrying on of a specified criminal
17        activity as defined in this Article; or
18            (B) conceal or disguise the nature, location,
19        source, ownership, or control of property believed to
20        be the proceeds of a specified criminal activity as
21        defined by subdivision (b)(6); or
22            (C) avoid a transaction reporting requirement
23        under State law,
24    he or she conducts or attempts to conduct a financial
25    transaction involving property he or she believes to be the
26    proceeds of specified criminal activity as defined by

 

 

HB0001 Engrossed- 138 -LRB099 00249 HEP 20254 b

1    subdivision (b)(6) or property used to conduct or
2    facilitate specified criminal activity as defined by
3    subdivision (b)(6).
4    (b) As used in this Section:
5        (0.5) "Knowing that the property involved in a
6    financial transaction represents the proceeds of some form
7    of unlawful activity" means that the person knew the
8    property involved in the transaction represented proceeds
9    from some form, though not necessarily which form, of
10    activity that constitutes a felony under State, federal, or
11    foreign law.
12        (1) "Financial transaction" means a purchase, sale,
13    loan, pledge, gift, transfer, delivery or other
14    disposition utilizing criminally derived property, and
15    with respect to financial institutions, includes a
16    deposit, withdrawal, transfer between accounts, exchange
17    of currency, loan, extension of credit, purchase or sale of
18    any stock, bond, certificate of deposit or other monetary
19    instrument, use of safe deposit box, or any other payment,
20    transfer or delivery by, through, or to a financial
21    institution. For purposes of clause (a)(2) of this Section,
22    the term "financial transaction" also means a transaction
23    which without regard to whether the funds, monetary
24    instruments, or real or personal property involved in the
25    transaction are criminally derived, any transaction which
26    in any way or degree: (1) involves the movement of funds by

 

 

HB0001 Engrossed- 139 -LRB099 00249 HEP 20254 b

1    wire or any other means; (2) involves one or more monetary
2    instruments; or (3) the transfer of title to any real or
3    personal property. The receipt by an attorney of bona fide
4    fees for the purpose of legal representation is not a
5    financial transaction for purposes of this Section.
6        (2) "Financial institution" means any bank; saving and
7    loan association; trust company; agency or branch of a
8    foreign bank in the United States; currency exchange;
9    credit union, mortgage banking institution; pawnbroker;
10    loan or finance company; operator of a credit card system;
11    issuer, redeemer or cashier of travelers checks, checks or
12    money orders; dealer in precious metals, stones or jewels;
13    broker or dealer in securities or commodities; investment
14    banker; or investment company.
15        (3) "Monetary instrument" means United States coins
16    and currency; coins and currency of a foreign country;
17    travelers checks; personal checks, bank checks, and money
18    orders; investment securities; bearer negotiable
19    instruments; bearer investment securities; or bearer
20    securities and certificates of stock in such form that
21    title thereto passes upon delivery.
22        (4) "Criminally derived property" means: (A) any
23    property, real or personal, constituting or derived from
24    proceeds obtained, directly or indirectly, from activity
25    that constitutes a felony under State, federal, or foreign
26    law; or (B) any property represented to be property

 

 

HB0001 Engrossed- 140 -LRB099 00249 HEP 20254 b

1    constituting or derived from proceeds obtained, directly
2    or indirectly, from activity that constitutes a felony
3    under State, federal, or foreign law.
4        (5) "Conduct" or "conducts" includes, in addition to
5    its ordinary meaning, initiating, concluding, or
6    participating in initiating or concluding a transaction.
7        (6) "Specified criminal activity" means any violation
8    of Section 29D-15.1 (720 ILCS 5/29D-15.1) and any violation
9    of Article 29D of this Code.
10        (7) "Director" means the Director of State Police or
11    his or her designated agents.
12        (8) "Department" means the Department of State Police
13    of the State of Illinois or its successor agency.
14        (9) "Transaction reporting requirement under State
15    law" means any violation as defined under the Currency
16    Reporting Act.
17    (c) Sentence.
18        (1) Laundering of criminally derived property of a
19    value not exceeding $10,000 is a Class 3 felony;
20        (2) Laundering of criminally derived property of a
21    value exceeding $10,000 but not exceeding $100,000 is a
22    Class 2 felony;
23        (3) Laundering of criminally derived property of a
24    value exceeding $100,000 but not exceeding $500,000 is a
25    Class 1 felony;
26        (4) Money laundering in violation of subsection (a)(2)

 

 

HB0001 Engrossed- 141 -LRB099 00249 HEP 20254 b

1    of this Section is a Class X felony;
2        (5) Laundering of criminally derived property of a
3    value exceeding $500,000 is a Class 1 non-probationable
4    felony;
5        (6) In a prosecution under clause (a)(1.5)(B)(ii) of
6    this Section, the sentences are as follows:
7            (A) Laundering of property of a value not exceeding
8        $10,000 is a Class 3 felony;
9            (B) Laundering of property of a value exceeding
10        $10,000 but not exceeding $100,000 is a Class 2 felony;
11            (C) Laundering of property of a value exceeding
12        $100,000 but not exceeding $500,000 is a Class 1
13        felony;
14            (D) Laundering of property of a value exceeding
15        $500,000 is a Class 1 non-probationable felony.
16    (d) Evidence. In a prosecution under this Article, either
17party may introduce the following evidence pertaining to the
18issue of whether the property or proceeds were known to be some
19form of criminally derived property or from some form of
20unlawful activity:
21        (1) A financial transaction was conducted or
22    structured or attempted in violation of the reporting
23    requirements of any State or federal law; or
24        (2) A financial transaction was conducted or attempted
25    with the use of a false or fictitious name or a forged
26    instrument; or

 

 

HB0001 Engrossed- 142 -LRB099 00249 HEP 20254 b

1        (3) A falsely altered or completed written instrument
2    or a written instrument that contains any materially false
3    personal identifying information was made, used, offered
4    or presented, whether accepted or not, in connection with a
5    financial transaction; or
6        (4) A financial transaction was structured or
7    attempted to be structured so as to falsely report the
8    actual consideration or value of the transaction; or
9        (5) A money transmitter, a person engaged in a trade or
10    business or any employee of a money transmitter or a person
11    engaged in a trade or business, knows or reasonably should
12    know that false personal identifying information has been
13    presented and incorporates the false personal identifying
14    information into any report or record; or
15        (6) The criminally derived property is transported or
16    possessed in a fashion inconsistent with the ordinary or
17    usual means of transportation or possession of such
18    property and where the property is discovered in the
19    absence of any documentation or other indicia of legitimate
20    origin or right to such property; or
21        (7) A person pays or receives substantially less than
22    face value for one or more monetary instruments; or
23        (8) A person engages in a transaction involving one or
24    more monetary instruments, where the physical condition or
25    form of the monetary instrument or instruments makes it
26    apparent that they are not the product of bona fide

 

 

HB0001 Engrossed- 143 -LRB099 00249 HEP 20254 b

1    business or financial transactions.
2    (e) Duty to enforce this Article.
3        (1) It is the duty of the Department of State Police,
4    and its agents, officers, and investigators, to enforce all
5    provisions of this Article, except those specifically
6    delegated, and to cooperate with all agencies charged with
7    the enforcement of the laws of the United States, or of any
8    state, relating to money laundering. Only an agent,
9    officer, or investigator designated by the Director may be
10    authorized in accordance with this Section to serve seizure
11    notices, warrants, subpoenas, and summonses under the
12    authority of this State.
13        (2) Any agent, officer, investigator, or peace officer
14    designated by the Director may: (A) make seizure of
15    property pursuant to the provisions of this Article; and
16    (B) perform such other law enforcement duties as the
17    Director designates. It is the duty of all State's
18    Attorneys to prosecute violations of this Article and
19    institute legal proceedings as authorized under this
20    Article.
21    (f) Protective orders.
22        (1) Upon application of the State, the court may enter
23    a restraining order or injunction, require the execution of
24    a satisfactory performance bond, or take any other action
25    to preserve the availability of property described in
26    subsection (h) for forfeiture under this Article:

 

 

HB0001 Engrossed- 144 -LRB099 00249 HEP 20254 b

1            (A) upon the filing of an indictment, information,
2        or complaint charging a violation of this Article for
3        which forfeiture may be ordered under this Article and
4        alleging that the property with respect to which the
5        order is sought would be subject to forfeiture under
6        this Article; or
7            (B) prior to the filing of such an indictment,
8        information, or complaint, if, after notice to persons
9        appearing to have an interest in the property and
10        opportunity for a hearing, the court determines that:
11                (i) there is probable cause to believe that the
12            State will prevail on the issue of forfeiture and
13            that failure to enter the order will result in the
14            property being destroyed, removed from the
15            jurisdiction of the court, or otherwise made
16            unavailable for forfeiture; and
17                (ii) the need to preserve the availability of
18            the property through the entry of the requested
19            order outweighs the hardship on any party against
20            whom the order is to be entered.
21            Provided, however, that an order entered pursuant
22        to subparagraph (B) shall be effective for not more
23        than 90 days, unless extended by the court for good
24        cause shown or unless an indictment, information,
25        complaint, or administrative notice has been filed.
26        (2) A temporary restraining order under this

 

 

HB0001 Engrossed- 145 -LRB099 00249 HEP 20254 b

1    subsection may be entered upon application of the State
2    without notice or opportunity for a hearing when an
3    indictment, information, complaint, or administrative
4    notice has not yet been filed with respect to the property,
5    if the State demonstrates that there is probable cause to
6    believe that the property with respect to which the order
7    is sought would be subject to forfeiture under this Section
8    and that provision of notice will jeopardize the
9    availability of the property for forfeiture. Such a
10    temporary order shall expire not more than 30 days after
11    the date on which it is entered, unless extended for good
12    cause shown or unless the party against whom it is entered
13    consents to an extension for a longer period. A hearing
14    requested concerning an order entered under this paragraph
15    shall be held at the earliest possible time and prior to
16    the expiration of the temporary order.
17        (3) The court may receive and consider, at a hearing
18    held pursuant to this subsection (f), evidence and
19    information that would be inadmissible under the Illinois
20    rules of evidence.
21        (4) Order to repatriate and deposit.
22            (A) In general. Pursuant to its authority to enter
23        a pretrial restraining order under this Section, the
24        court may order a defendant to repatriate any property
25        that may be seized and forfeited and to deposit that
26        property pending trial with the Illinois State Police

 

 

HB0001 Engrossed- 146 -LRB099 00249 HEP 20254 b

1        or another law enforcement agency designated by the
2        Illinois State Police.
3            (B) Failure to comply. Failure to comply with an
4        order under this subsection (f) is punishable as a
5        civil or criminal contempt of court.
6    (g) Warrant of seizure. The State may request the issuance
7of a warrant authorizing the seizure of property described in
8subsection (h) in the same manner as provided for a search
9warrant. If the court determines that there is probable cause
10to believe that the property to be seized would be subject to
11forfeiture, the court shall issue a warrant authorizing the
12seizure of such property.
13    (h) Forfeiture.
14        (1) The following are subject to forfeiture:
15            (A) any property, real or personal, constituting,
16        derived from, or traceable to any proceeds the person
17        obtained directly or indirectly, as a result of a
18        violation of this Article;
19            (B) any of the person's property used, or intended
20        to be used, in any manner or part, to commit, or to
21        facilitate the commission of, a violation of this
22        Article;
23            (C) all conveyances, including aircraft, vehicles
24        or vessels, which are used, or intended for use, to
25        transport, or in any manner to facilitate the
26        transportation, sale, receipt, possession, or

 

 

HB0001 Engrossed- 147 -LRB099 00249 HEP 20254 b

1        concealment of property described in subparagraphs (A)
2        and (B), but:
3                (i) no conveyance used by any person as a
4            common carrier in the transaction of business as a
5            common carrier is subject to forfeiture under this
6            Section unless it appears that the owner or other
7            person in charge of the conveyance is a consenting
8            party or privy to a violation of this Article;
9                (ii) no conveyance is subject to forfeiture
10            under this Section by reason of any act or omission
11            which the owner proves to have been committed or
12            omitted without his or her knowledge or consent;
13                (iii) a forfeiture of a conveyance encumbered
14            by a bona fide security interest is subject to the
15            interest of the secured party if he or she neither
16            had knowledge of nor consented to the act or
17            omission;
18            (D) all real property, including any right, title,
19        and interest (including, but not limited to, any
20        leasehold interest or the beneficial interest in a land
21        trust) in the whole of any lot or tract of land and any
22        appurtenances or improvements, which is used or
23        intended to be used, in any manner or part, to commit,
24        or in any manner to facilitate the commission of, any
25        violation of this Article or that is the proceeds of
26        any violation or act that constitutes a violation of

 

 

HB0001 Engrossed- 148 -LRB099 00249 HEP 20254 b

1        this Article.
2        (2) Property subject to forfeiture under this Article
3    may be seized by the Director or any peace officer upon
4    process or seizure warrant issued by any court having
5    jurisdiction over the property. Seizure by the Director or
6    any peace officer without process may be made:
7            (A) if the seizure is incident to a seizure
8        warrant;
9            (B) if the property subject to seizure has been the
10        subject of a prior judgment in favor of the State in a
11        criminal proceeding, or in an injunction or forfeiture
12        proceeding based upon this Article;
13            (C) if there is probable cause to believe that the
14        property is directly or indirectly dangerous to health
15        or safety;
16            (D) if there is probable cause to believe that the
17        property is subject to forfeiture under this Article
18        and the property is seized under circumstances in which
19        a warrantless seizure or arrest would be reasonable; or
20            (E) in accordance with the Code of Criminal
21        Procedure of 1963.
22        (3) In the event of seizure pursuant to paragraph (2),
23    forfeiture proceedings shall be instituted in accordance
24    with subsections (i) through (r).
25        (4) Property taken or detained under this Section shall
26    not be subject to replevin, but is deemed to be in the

 

 

HB0001 Engrossed- 149 -LRB099 00249 HEP 20254 b

1    custody of the Director subject only to the order and
2    judgments of the circuit court having jurisdiction over the
3    forfeiture proceedings and the decisions of the State's
4    Attorney under this Article. When property is seized under
5    this Article, the seizing agency shall promptly conduct an
6    inventory of the seized property and estimate the
7    property's value and shall forward a copy of the inventory
8    of seized property and the estimate of the property's value
9    to the Director. Upon receiving notice of seizure, the
10    Director may:
11            (A) place the property under seal;
12            (B) remove the property to a place designated by
13        the Director;
14            (C) keep the property in the possession of the
15        seizing agency;
16            (D) remove the property to a storage area for
17        safekeeping or, if the property is a negotiable
18        instrument or money and is not needed for evidentiary
19        purposes, deposit it in an interest bearing account;
20            (E) place the property under constructive seizure
21        by posting notice of pending forfeiture on it, by
22        giving notice of pending forfeiture to its owners and
23        interest holders, or by filing notice of pending
24        forfeiture in any appropriate public record relating
25        to the property; or
26            (F) provide for another agency or custodian,

 

 

HB0001 Engrossed- 150 -LRB099 00249 HEP 20254 b

1        including an owner, secured party, or lienholder, to
2        take custody of the property upon the terms and
3        conditions set by the Director.
4        (5) When property is forfeited under this Article, the
5    Director shall sell all such property unless such property
6    is required by law to be destroyed or is harmful to the
7    public, and shall distribute the proceeds of the sale,
8    together with any moneys forfeited or seized, in accordance
9    with paragraph (6). However, upon the application of the
10    seizing agency or prosecutor who was responsible for the
11    investigation, arrest or arrests and prosecution which
12    lead to the forfeiture, the Director may return any item of
13    forfeited property to the seizing agency or prosecutor for
14    official use in the enforcement of laws, if the agency or
15    prosecutor can demonstrate that the item requested would be
16    useful to the agency or prosecutor in its enforcement
17    efforts. When any real property returned to the seizing
18    agency is sold by the agency or its unit of government, the
19    proceeds of the sale shall be delivered to the Director and
20    distributed in accordance with paragraph (6).
21        (6) All monies and the sale proceeds of all other
22    property forfeited and seized under this Article shall be
23    distributed as follows:
24            (A) 65% shall be distributed to the metropolitan
25        enforcement group, local, municipal, county, or State
26        law enforcement agency or agencies which conducted or

 

 

HB0001 Engrossed- 151 -LRB099 00249 HEP 20254 b

1        participated in the investigation resulting in the
2        forfeiture. The distribution shall bear a reasonable
3        relationship to the degree of direct participation of
4        the law enforcement agency in the effort resulting in
5        the forfeiture, taking into account the total value of
6        the property forfeited and the total law enforcement
7        effort with respect to the violation of the law upon
8        which the forfeiture is based. Amounts distributed to
9        the agency or agencies shall be used for the
10        enforcement of laws.
11            (B)(i) 12.5% shall be distributed to the Office of
12        the State's Attorney of the county in which the
13        prosecution resulting in the forfeiture was
14        instituted, deposited in a special fund in the county
15        treasury and appropriated to the State's Attorney for
16        use in the enforcement of laws. In counties over
17        3,000,000 population, 25% shall be distributed to the
18        Office of the State's Attorney for use in the
19        enforcement of laws. If the prosecution is undertaken
20        solely by the Attorney General, the portion provided
21        hereunder shall be distributed to the Attorney General
22        for use in the enforcement of laws.
23                (ii) 12.5% shall be distributed to the Office
24            of the State's Attorneys Appellate Prosecutor and
25            deposited in the Narcotics Profit Forfeiture Fund
26            of that office to be used for additional expenses

 

 

HB0001 Engrossed- 152 -LRB099 00249 HEP 20254 b

1            incurred in the investigation, prosecution and
2            appeal of cases arising under laws. The Office of
3            the State's Attorneys Appellate Prosecutor shall
4            not receive distribution from cases brought in
5            counties with over 3,000,000 population.
6            (C) 10% shall be retained by the Department of
7        State Police for expenses related to the
8        administration and sale of seized and forfeited
9        property.
10        Moneys and the sale proceeds distributed to the
11    Department of State Police under this Article shall be
12    deposited in the Money Laundering Asset Recovery Fund
13    created in the State treasury and shall be used by the
14    Department of State Police for State law enforcement
15    purposes.
16        (7) All moneys and sale proceeds of property forfeited
17    and seized under this Article and distributed according to
18    paragraph (6) may also be used to purchase opioid
19    antagonists as defined in Section 5-23 of the Alcoholism
20    and Other Drug Abuse and Dependency Act.
21    (i) Notice to owner or interest holder.
22        (1) Whenever notice of pending forfeiture or service of
23    an in rem complaint is required under the provisions of
24    this Article, such notice or service shall be given as
25    follows:
26            (A) If the owner's or interest holder's name and

 

 

HB0001 Engrossed- 153 -LRB099 00249 HEP 20254 b

1        current address are known, then by either personal
2        service or mailing a copy of the notice by certified
3        mail, return receipt requested, to that address. For
4        purposes of notice under this Section, if a person has
5        been arrested for the conduct giving rise to the
6        forfeiture, then the address provided to the arresting
7        agency at the time of arrest shall be deemed to be that
8        person's known address. Provided, however, if an owner
9        or interest holder's address changes prior to the
10        effective date of the notice of pending forfeiture, the
11        owner or interest holder shall promptly notify the
12        seizing agency of the change in address or, if the
13        owner or interest holder's address changes subsequent
14        to the effective date of the notice of pending
15        forfeiture, the owner or interest holder shall
16        promptly notify the State's Attorney of the change in
17        address; or
18            (B) If the property seized is a conveyance, to the
19        address reflected in the office of the agency or
20        official in which title or interest to the conveyance
21        is required by law to be recorded, then by mailing a
22        copy of the notice by certified mail, return receipt
23        requested, to that address; or
24            (C) If the owner's or interest holder's address is
25        not known, and is not on record as provided in
26        paragraph (B), then by publication for 3 successive

 

 

HB0001 Engrossed- 154 -LRB099 00249 HEP 20254 b

1        weeks in a newspaper of general circulation in the
2        county in which the seizure occurred.
3        (2) Notice served under this Article is effective upon
4    personal service, the last date of publication, or the
5    mailing of written notice, whichever is earlier.
6    (j) Notice to State's Attorney. The law enforcement agency
7seizing property for forfeiture under this Article shall,
8within 90 days after seizure, notify the State's Attorney for
9the county, either where an act or omission giving rise to the
10forfeiture occurred or where the property was seized, of the
11seizure of the property and the facts and circumstances giving
12rise to the seizure and shall provide the State's Attorney with
13the inventory of the property and its estimated value. When the
14property seized for forfeiture is a vehicle, the law
15enforcement agency seizing the property shall immediately
16notify the Secretary of State that forfeiture proceedings are
17pending regarding such vehicle.
18    (k) Non-judicial forfeiture. If non-real property that
19exceeds $20,000 in value excluding the value of any conveyance,
20or if real property is seized under the provisions of this
21Article, the State's Attorney shall institute judicial in rem
22forfeiture proceedings as described in subsection (l) of this
23Section within 45 days from receipt of notice of seizure from
24the seizing agency under subsection (j) of this Section.
25However, if non-real property that does not exceed $20,000 in
26value excluding the value of any conveyance is seized, the

 

 

HB0001 Engrossed- 155 -LRB099 00249 HEP 20254 b

1following procedure shall be used:
2        (1) If, after review of the facts surrounding the
3    seizure, the State's Attorney is of the opinion that the
4    seized property is subject to forfeiture, then within 45
5    days after the receipt of notice of seizure from the
6    seizing agency, the State's Attorney shall cause notice of
7    pending forfeiture to be given to the owner of the property
8    and all known interest holders of the property in
9    accordance with subsection (i) of this Section.
10        (2) The notice of pending forfeiture must include a
11    description of the property, the estimated value of the
12    property, the date and place of seizure, the conduct giving
13    rise to forfeiture or the violation of law alleged, and a
14    summary of procedures and procedural rights applicable to
15    the forfeiture action.
16        (3)(A) Any person claiming an interest in property
17    which is the subject of notice under paragraph (1) of this
18    subsection (k), must, in order to preserve any rights or
19    claims to the property, within 45 days after the effective
20    date of notice as described in subsection (i) of this
21    Section, file a verified claim with the State's Attorney
22    expressing his or her interest in the property. The claim
23    must set forth:
24            (i) the caption of the proceedings as set forth on
25        the notice of pending forfeiture and the name of the
26        claimant;

 

 

HB0001 Engrossed- 156 -LRB099 00249 HEP 20254 b

1            (ii) the address at which the claimant will accept
2        mail;
3            (iii) the nature and extent of the claimant's
4        interest in the property;
5            (iv) the date, identity of the transferor, and
6        circumstances of the claimant's acquisition of the
7        interest in the property;
8            (v) the name and address of all other persons known
9        to have an interest in the property;
10            (vi) the specific provision of law relied on in
11        asserting the property is not subject to forfeiture;
12            (vii) all essential facts supporting each
13        assertion; and
14            (viii) the relief sought.
15        (B) If a claimant files the claim and deposits with the
16    State's Attorney a cost bond, in the form of a cashier's
17    check payable to the clerk of the court, in the sum of 10%
18    of the reasonable value of the property as alleged by the
19    State's Attorney or the sum of $100, whichever is greater,
20    upon condition that, in the case of forfeiture, the
21    claimant must pay all costs and expenses of forfeiture
22    proceedings, then the State's Attorney shall institute
23    judicial in rem forfeiture proceedings and deposit the cost
24    bond with the clerk of the court as described in subsection
25    (l) of this Section within 45 days after receipt of the
26    claim and cost bond. In lieu of a cost bond, a person

 

 

HB0001 Engrossed- 157 -LRB099 00249 HEP 20254 b

1    claiming interest in the seized property may file, under
2    penalty of perjury, an indigency affidavit which has been
3    approved by a circuit court judge.
4        (C) If none of the seized property is forfeited in the
5    judicial in rem proceeding, the clerk of the court shall
6    return to the claimant, unless the court orders otherwise,
7    90% of the sum which has been deposited and shall retain as
8    costs 10% of the money deposited. If any of the seized
9    property is forfeited under the judicial forfeiture
10    proceeding, the clerk of the court shall transfer 90% of
11    the sum which has been deposited to the State's Attorney
12    prosecuting the civil forfeiture to be applied to the costs
13    of prosecution and the clerk shall retain as costs 10% of
14    the sum deposited.
15        (4) If no claim is filed or bond given within the 45
16    day period as described in paragraph (3) of this subsection
17    (k), the State's Attorney shall declare the property
18    forfeited and shall promptly notify the owner and all known
19    interest holders of the property and the Director of State
20    Police of the declaration of forfeiture and the Director
21    shall dispose of the property in accordance with law.
22    (l) Judicial in rem procedures. If property seized under
23the provisions of this Article is non-real property that
24exceeds $20,000 in value excluding the value of any conveyance,
25or is real property, or a claimant has filed a claim and a cost
26bond under paragraph (3) of subsection (k) of this Section, the

 

 

HB0001 Engrossed- 158 -LRB099 00249 HEP 20254 b

1following judicial in rem procedures shall apply:
2        (1) If, after a review of the facts surrounding the
3    seizure, the State's Attorney is of the opinion that the
4    seized property is subject to forfeiture, then within 45
5    days of the receipt of notice of seizure by the seizing
6    agency or the filing of the claim and cost bond, whichever
7    is later, the State's Attorney shall institute judicial
8    forfeiture proceedings by filing a verified complaint for
9    forfeiture and, if the claimant has filed a claim and cost
10    bond, by depositing the cost bond with the clerk of the
11    court. When authorized by law, a forfeiture must be ordered
12    by a court on an action in rem brought by a State's
13    Attorney under a verified complaint for forfeiture.
14        (2) During the probable cause portion of the judicial
15    in rem proceeding wherein the State presents its
16    case-in-chief, the court must receive and consider, among
17    other things, all relevant hearsay evidence and
18    information. The laws of evidence relating to civil actions
19    apply to all other portions of the judicial in rem
20    proceeding.
21        (3) Only an owner of or interest holder in the property
22    may file an answer asserting a claim against the property
23    in the action in rem. For purposes of this Section, the
24    owner or interest holder shall be referred to as claimant.
25    Upon motion of the State, the court shall first hold a
26    hearing, wherein any claimant must establish by a

 

 

HB0001 Engrossed- 159 -LRB099 00249 HEP 20254 b

1    preponderance of the evidence, that he or she has a lawful,
2    legitimate ownership interest in the property and that it
3    was obtained through a lawful source.
4        (4) The answer must be signed by the owner or interest
5    holder under penalty of perjury and must set forth:
6            (A) the caption of the proceedings as set forth on
7        the notice of pending forfeiture and the name of the
8        claimant;
9            (B) the address at which the claimant will accept
10        mail;
11            (C) the nature and extent of the claimant's
12        interest in the property;
13            (D) the date, identity of transferor, and
14        circumstances of the claimant's acquisition of the
15        interest in the property;
16            (E) the name and address of all other persons known
17        to have an interest in the property;
18            (F) all essential facts supporting each assertion;
19        and
20            (G) the precise relief sought.
21        (5) The answer must be filed with the court within 45
22    days after service of the civil in rem complaint.
23        (6) The hearing must be held within 60 days after
24    filing of the answer unless continued for good cause.
25        (7) The State shall show the existence of probable
26    cause for forfeiture of the property. If the State shows

 

 

HB0001 Engrossed- 160 -LRB099 00249 HEP 20254 b

1    probable cause, the claimant has the burden of showing by a
2    preponderance of the evidence that the claimant's interest
3    in the property is not subject to forfeiture.
4        (8) If the State does not show existence of probable
5    cause, the court shall order the interest in the property
6    returned or conveyed to the claimant and shall order all
7    other property forfeited to the State. If the State does
8    show existence of probable cause, the court shall order all
9    property forfeited to the State.
10        (9) A defendant convicted in any criminal proceeding is
11    precluded from later denying the essential allegations of
12    the criminal offense of which the defendant was convicted
13    in any proceeding under this Article regardless of the
14    pendency of an appeal from that conviction. However,
15    evidence of the pendency of an appeal is admissible.
16        (10) An acquittal or dismissal in a criminal proceeding
17    does not preclude civil proceedings under this Article;
18    however, for good cause shown, on a motion by the State's
19    Attorney, the court may stay civil forfeiture proceedings
20    during the criminal trial for a related criminal indictment
21    or information alleging a money laundering violation. Such
22    a stay shall not be available pending an appeal. Property
23    subject to forfeiture under this Article shall not be
24    subject to return or release by a court exercising
25    jurisdiction over a criminal case involving the seizure of
26    such property unless such return or release is consented to

 

 

HB0001 Engrossed- 161 -LRB099 00249 HEP 20254 b

1    by the State's Attorney.
2        (11) All property declared forfeited under this
3    Article vests in this State on the commission of the
4    conduct giving rise to forfeiture together with the
5    proceeds of the property after that time. Any such property
6    or proceeds subsequently transferred to any person remain
7    subject to forfeiture and thereafter shall be ordered
8    forfeited.
9        (12) A civil action under this Article must be
10    commenced within 5 years after the last conduct giving rise
11    to forfeiture became known or should have become known or 5
12    years after the forfeitable property is discovered,
13    whichever is later, excluding any time during which either
14    the property or claimant is out of the State or in
15    confinement or during which criminal proceedings relating
16    to the same conduct are in progress.
17    (m) Stay of time periods. If property is seized for
18evidence and for forfeiture, the time periods for instituting
19judicial and non-judicial forfeiture proceedings shall not
20begin until the property is no longer necessary for evidence.
21    (n) Settlement of claims. Notwithstanding other provisions
22of this Article, the State's Attorney and a claimant of seized
23property may enter into an agreed-upon settlement concerning
24the seized property in such an amount and upon such terms as
25are set out in writing in a settlement agreement.
26    (o) Property constituting attorney fees. Nothing in this

 

 

HB0001 Engrossed- 162 -LRB099 00249 HEP 20254 b

1Article applies to property which constitutes reasonable bona
2fide attorney's fees paid to an attorney for services rendered
3or to be rendered in the forfeiture proceeding or criminal
4proceeding relating directly thereto where such property was
5paid before its seizure, before the issuance of any seizure
6warrant or court order prohibiting transfer of the property and
7where the attorney, at the time he or she received the property
8did not know that it was property subject to forfeiture under
9this Article.
10    (p) Construction. It is the intent of the General Assembly
11that the forfeiture provisions of this Article be liberally
12construed so as to effect their remedial purpose. The
13forfeiture of property and other remedies hereunder shall be
14considered to be in addition to, and not exclusive of, any
15sentence or other remedy provided by law.
16    (q) Judicial review. If property has been declared
17forfeited under subsection (k) of this Section, any person who
18has an interest in the property declared forfeited may, within
1930 days after the effective date of the notice of the
20declaration of forfeiture, file a claim and cost bond as
21described in paragraph (3) of subsection (k) of this Section.
22If a claim and cost bond is filed under this Section, then the
23procedures described in subsection (l) of this Section apply.
24    (r) Burden of proof of exemption or exception. It is not
25necessary for the State to negate any exemption or exception in
26this Article in any complaint, information, indictment or other

 

 

HB0001 Engrossed- 163 -LRB099 00249 HEP 20254 b

1pleading or in any trial, hearing, or other proceeding under
2this Article. The burden of proof of any exemption or exception
3is upon the person claiming it.
4    (s) Review of administrative decisions. All administrative
5findings, rulings, final determinations, findings, and
6conclusions of the State's Attorney's Office under this Article
7are final and conclusive decisions of the matters involved. Any
8person aggrieved by the decision may obtain review of the
9decision pursuant to the provisions of the Administrative
10Review Law and the rules adopted pursuant to that Law. Pending
11final decision on such review, the administrative acts, orders,
12and rulings of the State's Attorney's Office remain in full
13force and effect unless modified or suspended by order of court
14pending final judicial decision. Pending final decision on such
15review, the acts, orders, and rulings of the State's Attorney's
16Office remain in full force and effect, unless stayed by order
17of court. However, no stay of any decision of the
18administrative agency shall issue unless the person aggrieved
19by the decision establishes by a preponderance of the evidence
20that good cause exists for the stay. In determining good cause,
21the court shall find that the aggrieved party has established a
22substantial likelihood of prevailing on the merits and that
23granting the stay will not have an injurious effect on the
24general public.
25(Source: P.A. 96-275, eff. 8-11-09; 96-710, eff. 1-1-10;
2696-1000, eff. 7-2-10; 96-1234, eff. 7-23-10.)
 

 

 

HB0001 Engrossed- 164 -LRB099 00249 HEP 20254 b

1    Section 5-95. The Cannabis Control Act is amended by
2changing Section 10 as follows:
 
3    (720 ILCS 550/10)  (from Ch. 56 1/2, par. 710)
4    Sec. 10. (a) Whenever any person who has not previously
5been convicted of, or placed on probation or court supervision
6for, any offense under this Act or any law of the United States
7or of any State relating to cannabis, or controlled substances
8as defined in the Illinois Controlled Substances Act, pleads
9guilty to or is found guilty of violating Sections 4(a), 4(b),
104(c), 5(a), 5(b), 5(c) or 8 of this Act, the court may, without
11entering a judgment and with the consent of such person,
12sentence him to probation.
13    (b) When a person is placed on probation, the court shall
14enter an order specifying a period of probation of 24 months,
15and shall defer further proceedings in the case until the
16conclusion of the period or until the filing of a petition
17alleging violation of a term or condition of probation.
18    (c) The conditions of probation shall be that the person:
19(1) not violate any criminal statute of any jurisdiction; (2)
20refrain from possession of a firearm or other dangerous weapon;
21(3) submit to periodic drug testing at a time and in a manner
22as ordered by the court, but no less than 3 times during the
23period of the probation, with the cost of the testing to be
24paid by the probationer; and (4) perform no less than 30 hours

 

 

HB0001 Engrossed- 165 -LRB099 00249 HEP 20254 b

1of community service, provided community service is available
2in the jurisdiction and is funded and approved by the county
3board.
4    (d) The court may, in addition to other conditions, require
5that the person:
6        (1) make a report to and appear in person before or
7    participate with the court or such courts, person, or
8    social service agency as directed by the court in the order
9    of probation;
10        (2) pay a fine and costs;
11        (3) work or pursue a course of study or vocational
12    training;
13        (4) undergo medical or psychiatric treatment; or
14    treatment for drug addiction or alcoholism;
15        (5) attend or reside in a facility established for the
16    instruction or residence of defendants on probation;
17        (6) support his dependents;
18        (7) refrain from possessing a firearm or other
19    dangerous weapon;
20        (7-5) refrain from having in his or her body the
21    presence of any illicit drug prohibited by the Cannabis
22    Control Act, the Illinois Controlled Substances Act, or the
23    Methamphetamine Control and Community Protection Act,
24    unless prescribed by a physician, and submit samples of his
25    or her blood or urine or both for tests to determine the
26    presence of any illicit drug;

 

 

HB0001 Engrossed- 166 -LRB099 00249 HEP 20254 b

1        (8) and in addition, if a minor:
2            (i) reside with his parents or in a foster home;
3            (ii) attend school;
4            (iii) attend a non-residential program for youth;
5            (iv) contribute to his own support at home or in a
6        foster home.
7    (e) Upon violation of a term or condition of probation, the
8court may enter a judgment on its original finding of guilt and
9proceed as otherwise provided.
10    (f) Upon fulfillment of the terms and conditions of
11probation, the court shall discharge such person and dismiss
12the proceedings against him.
13    (g) A disposition of probation is considered to be a
14conviction for the purposes of imposing the conditions of
15probation and for appeal, however, discharge and dismissal
16under this Section is not a conviction for purposes of
17disqualification or disabilities imposed by law upon
18conviction of a crime (including the additional penalty imposed
19for subsequent offenses under Section 4(c), 4(d), 5(c) or 5(d)
20of this Act).
21    (h) Discharge and dismissal under this Section, Section 410
22of the Illinois Controlled Substances Act, Section 70 of the
23Methamphetamine Control and Community Protection Act, Section
245-6-3.3 or 5-6-3.4 of the Unified Code of Corrections, or
25subsection (c) of Section 11-14 of the Criminal Code of 1961 or
26the Criminal Code of 2012 may occur only once with respect to

 

 

HB0001 Engrossed- 167 -LRB099 00249 HEP 20254 b

1any person.
2    (i) If a person is convicted of an offense under this Act,
3the Illinois Controlled Substances Act, or the Methamphetamine
4Control and Community Protection Act within 5 years subsequent
5to a discharge and dismissal under this Section, the discharge
6and dismissal under this Section shall be admissible in the
7sentencing proceeding for that conviction as a factor in
8aggravation.
9    (j) Notwithstanding subsection (a), before a person is
10sentenced to probation under this Section, the court may refer
11the person to the drug court established in that judicial
12circuit pursuant to Section 15 of the Drug Court Treatment Act.
13The drug court team shall evaluate the person's likelihood of
14successfully completing a sentence of probation under this
15Section and shall report the results of its evaluation to the
16court. If the drug court team finds that the person suffers
17from a substance abuse problem that makes him or her
18substantially unlikely to successfully complete a sentence of
19probation under this Section, then the drug court shall set
20forth its findings in the form of a written order, and the
21person shall not be sentenced to probation under this Section,
22but may be considered for the drug court program.
23(Source: P.A. 97-1118, eff. 1-1-13; 97-1150, eff. 1-25-13;
2498-164, eff. 1-1-14.)
 
25    Section 5-100. The Illinois Controlled Substances Act is

 

 

HB0001 Engrossed- 168 -LRB099 00249 HEP 20254 b

1amended by changing Sections 102, 301, 312, 314.5, 316, 317,
2318, 319, 320, 406, and 410 as follows:
 
3    (720 ILCS 570/102)  (from Ch. 56 1/2, par. 1102)
4    Sec. 102. Definitions. As used in this Act, unless the
5context otherwise requires:
6    (a) "Addict" means any person who habitually uses any drug,
7chemical, substance or dangerous drug other than alcohol so as
8to endanger the public morals, health, safety or welfare or who
9is so far addicted to the use of a dangerous drug or controlled
10substance other than alcohol as to have lost the power of self
11control with reference to his or her addiction.
12    (b) "Administer" means the direct application of a
13controlled substance, whether by injection, inhalation,
14ingestion, or any other means, to the body of a patient,
15research subject, or animal (as defined by the Humane
16Euthanasia in Animal Shelters Act) by:
17        (1) a practitioner (or, in his or her presence, by his
18    or her authorized agent),
19        (2) the patient or research subject pursuant to an
20    order, or
21        (3) a euthanasia technician as defined by the Humane
22    Euthanasia in Animal Shelters Act.
23    (c) "Agent" means an authorized person who acts on behalf
24of or at the direction of a manufacturer, distributor,
25dispenser, prescriber, or practitioner. It does not include a

 

 

HB0001 Engrossed- 169 -LRB099 00249 HEP 20254 b

1common or contract carrier, public warehouseman or employee of
2the carrier or warehouseman.
3    (c-1) "Anabolic Steroids" means any drug or hormonal
4substance, chemically and pharmacologically related to
5testosterone (other than estrogens, progestins,
6corticosteroids, and dehydroepiandrosterone), and includes:
7    (i) 3[beta],17-dihydroxy-5a-androstane, 
8    (ii) 3[alpha],17[beta]-dihydroxy-5a-androstane, 
9    (iii) 5[alpha]-androstan-3,17-dione, 
10    (iv) 1-androstenediol (3[beta], 
11        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
12    (v) 1-androstenediol (3[alpha], 
13        17[beta]-dihydroxy-5[alpha]-androst-1-ene), 
14    (vi) 4-androstenediol  
15        (3[beta],17[beta]-dihydroxy-androst-4-ene), 
16    (vii) 5-androstenediol  
17        (3[beta],17[beta]-dihydroxy-androst-5-ene), 
18    (viii) 1-androstenedione  
19        ([5alpha]-androst-1-en-3,17-dione), 
20    (ix) 4-androstenedione  
21        (androst-4-en-3,17-dione), 
22    (x) 5-androstenedione  
23        (androst-5-en-3,17-dione), 
24    (xi) bolasterone (7[alpha],17a-dimethyl-17[beta]- 
25        hydroxyandrost-4-en-3-one), 
26    (xii) boldenone (17[beta]-hydroxyandrost- 

 

 

HB0001 Engrossed- 170 -LRB099 00249 HEP 20254 b

1        1,4,-diene-3-one), 
2    (xiii) boldione (androsta-1,4- 
3        diene-3,17-dione), 
4    (xiv) calusterone (7[beta],17[alpha]-dimethyl-17 
5        [beta]-hydroxyandrost-4-en-3-one), 
6    (xv) clostebol (4-chloro-17[beta]- 
7        hydroxyandrost-4-en-3-one), 
8    (xvi) dehydrochloromethyltestosterone (4-chloro- 
9        17[beta]-hydroxy-17[alpha]-methyl- 
10        androst-1,4-dien-3-one), 
11    (xvii) desoxymethyltestosterone 
12        (17[alpha]-methyl-5[alpha]
13        -androst-2-en-17[beta]-ol)(a.k.a., madol), 
14    (xviii) [delta]1-dihydrotestosterone (a.k.a.  
15        '1-testosterone') (17[beta]-hydroxy- 
16        5[alpha]-androst-1-en-3-one), 
17    (xix) 4-dihydrotestosterone (17[beta]-hydroxy- 
18        androstan-3-one), 
19    (xx) drostanolone (17[beta]-hydroxy-2[alpha]-methyl- 
20        5[alpha]-androstan-3-one), 
21    (xxi) ethylestrenol (17[alpha]-ethyl-17[beta]- 
22        hydroxyestr-4-ene), 
23    (xxii) fluoxymesterone (9-fluoro-17[alpha]-methyl- 
24        1[beta],17[beta]-dihydroxyandrost-4-en-3-one), 
25    (xxiii) formebolone (2-formyl-17[alpha]-methyl-11[alpha], 
26        17[beta]-dihydroxyandrost-1,4-dien-3-one), 

 

 

HB0001 Engrossed- 171 -LRB099 00249 HEP 20254 b

1    (xxiv) furazabol (17[alpha]-methyl-17[beta]- 
2        hydroxyandrostano[2,3-c]-furazan), 
3    (xxv) 13[beta]-ethyl-17[beta]-hydroxygon-4-en-3-one) 
4    (xxvi) 4-hydroxytestosterone (4,17[beta]-dihydroxy- 
5        androst-4-en-3-one), 
6    (xxvii) 4-hydroxy-19-nortestosterone (4,17[beta]- 
7        dihydroxy-estr-4-en-3-one), 
8    (xxviii) mestanolone (17[alpha]-methyl-17[beta]- 
9        hydroxy-5-androstan-3-one), 
10    (xxix) mesterolone (1amethyl-17[beta]-hydroxy- 
11        [5a]-androstan-3-one), 
12    (xxx) methandienone (17[alpha]-methyl-17[beta]- 
13        hydroxyandrost-1,4-dien-3-one), 
14    (xxxi) methandriol (17[alpha]-methyl-3[beta],17[beta]- 
15        dihydroxyandrost-5-ene), 
16    (xxxii) methenolone (1-methyl-17[beta]-hydroxy- 
17        5[alpha]-androst-1-en-3-one), 
18    (xxxiii) 17[alpha]-methyl-3[beta], 17[beta]- 
19        dihydroxy-5a-androstane), 
20    (xxxiv) 17[alpha]-methyl-3[alpha],17[beta]-dihydroxy 
21        -5a-androstane), 
22    (xxxv) 17[alpha]-methyl-3[beta],17[beta]- 
23        dihydroxyandrost-4-ene), 
24    (xxxvi) 17[alpha]-methyl-4-hydroxynandrolone (17[alpha]- 
25        methyl-4-hydroxy-17[beta]-hydroxyestr-4-en-3-one), 
26    (xxxvii) methyldienolone (17[alpha]-methyl-17[beta]- 

 

 

HB0001 Engrossed- 172 -LRB099 00249 HEP 20254 b

1        hydroxyestra-4,9(10)-dien-3-one), 
2    (xxxviii) methyltrienolone (17[alpha]-methyl-17[beta]- 
3        hydroxyestra-4,9-11-trien-3-one), 
4    (xxxix) methyltestosterone (17[alpha]-methyl-17[beta]- 
5        hydroxyandrost-4-en-3-one), 
6    (xl) mibolerone (7[alpha],17a-dimethyl-17[beta]- 
7        hydroxyestr-4-en-3-one), 
8    (xli) 17[alpha]-methyl-[delta]1-dihydrotestosterone  
9        (17b[beta]-hydroxy-17[alpha]-methyl-5[alpha]- 
10        androst-1-en-3-one)(a.k.a. '17-[alpha]-methyl- 
11        1-testosterone'), 
12    (xlii) nandrolone (17[beta]-hydroxyestr-4-en-3-one), 
13    (xliii) 19-nor-4-androstenediol (3[beta], 17[beta]- 
14        dihydroxyestr-4-ene), 
15    (xliv) 19-nor-4-androstenediol (3[alpha], 17[beta]- 
16        dihydroxyestr-4-ene), 
17    (xlv) 19-nor-5-androstenediol (3[beta], 17[beta]- 
18        dihydroxyestr-5-ene), 
19    (xlvi) 19-nor-5-androstenediol (3[alpha], 17[beta]- 
20        dihydroxyestr-5-ene), 
21    (xlvii) 19-nor-4,9(10)-androstadienedione  
22        (estra-4,9(10)-diene-3,17-dione), 
23    (xlviii) 19-nor-4-androstenedione (estr-4- 
24        en-3,17-dione), 
25    (xlix) 19-nor-5-androstenedione (estr-5- 
26        en-3,17-dione), 

 

 

HB0001 Engrossed- 173 -LRB099 00249 HEP 20254 b

1    (l) norbolethone (13[beta], 17a-diethyl-17[beta]- 
2        hydroxygon-4-en-3-one), 
3    (li) norclostebol (4-chloro-17[beta]- 
4        hydroxyestr-4-en-3-one), 
5    (lii) norethandrolone (17[alpha]-ethyl-17[beta]- 
6        hydroxyestr-4-en-3-one), 
7    (liii) normethandrolone (17[alpha]-methyl-17[beta]- 
8        hydroxyestr-4-en-3-one), 
9    (liv) oxandrolone (17[alpha]-methyl-17[beta]-hydroxy- 
10        2-oxa-5[alpha]-androstan-3-one), 
11    (lv) oxymesterone (17[alpha]-methyl-4,17[beta]- 
12        dihydroxyandrost-4-en-3-one), 
13    (lvi) oxymetholone (17[alpha]-methyl-2-hydroxymethylene- 
14        17[beta]-hydroxy-(5[alpha]-androstan-3-one), 
15    (lvii) stanozolol (17[alpha]-methyl-17[beta]-hydroxy- 
16        (5[alpha]-androst-2-eno[3,2-c]-pyrazole), 
17    (lviii) stenbolone (17[beta]-hydroxy-2-methyl- 
18        (5[alpha]-androst-1-en-3-one), 
19    (lix) testolactone (13-hydroxy-3-oxo-13,17- 
20        secoandrosta-1,4-dien-17-oic 
21        acid lactone), 
22    (lx) testosterone (17[beta]-hydroxyandrost- 
23        4-en-3-one), 
24    (lxi) tetrahydrogestrinone (13[beta], 17[alpha]- 
25        diethyl-17[beta]-hydroxygon- 
26        4,9,11-trien-3-one), 

 

 

HB0001 Engrossed- 174 -LRB099 00249 HEP 20254 b

1    (lxii) trenbolone (17[beta]-hydroxyestr-4,9, 
2        11-trien-3-one). 
3    Any person who is otherwise lawfully in possession of an
4anabolic steroid, or who otherwise lawfully manufactures,
5distributes, dispenses, delivers, or possesses with intent to
6deliver an anabolic steroid, which anabolic steroid is
7expressly intended for and lawfully allowed to be administered
8through implants to livestock or other nonhuman species, and
9which is approved by the Secretary of Health and Human Services
10for such administration, and which the person intends to
11administer or have administered through such implants, shall
12not be considered to be in unauthorized possession or to
13unlawfully manufacture, distribute, dispense, deliver, or
14possess with intent to deliver such anabolic steroid for
15purposes of this Act.
16    (d) "Administration" means the Drug Enforcement
17Administration, United States Department of Justice, or its
18successor agency.
19    (d-5) "Clinical Director, Prescription Monitoring Program"
20means a Department of Human Services administrative employee
21licensed to either prescribe or dispense controlled substances
22who shall run the clinical aspects of the Department of Human
23Services Prescription Monitoring Program and its Prescription
24Information Library.
25    (d-10) "Compounding" means the preparation and mixing of
26components, excluding flavorings, (1) as the result of a

 

 

HB0001 Engrossed- 175 -LRB099 00249 HEP 20254 b

1prescriber's prescription drug order or initiative based on the
2prescriber-patient-pharmacist relationship in the course of
3professional practice or (2) for the purpose of, or incident
4to, research, teaching, or chemical analysis and not for sale
5or dispensing. "Compounding" includes the preparation of drugs
6or devices in anticipation of receiving prescription drug
7orders based on routine, regularly observed dispensing
8patterns. Commercially available products may be compounded
9for dispensing to individual patients only if both of the
10following conditions are met: (i) the commercial product is not
11reasonably available from normal distribution channels in a
12timely manner to meet the patient's needs and (ii) the
13prescribing practitioner has requested that the drug be
14compounded.
15    (e) "Control" means to add a drug or other substance, or
16immediate precursor, to a Schedule whether by transfer from
17another Schedule or otherwise.
18    (f) "Controlled Substance" means (i) a drug, substance, or
19immediate precursor in the Schedules of Article II of this Act
20or (ii) a drug or other substance, or immediate precursor,
21designated as a controlled substance by the Department through
22administrative rule. The term does not include distilled
23spirits, wine, malt beverages, or tobacco, as those terms are
24defined or used in the Liquor Control Act of 1934 and the
25Tobacco Products Tax Act of 1995.
26    (f-5) "Controlled substance analog" means a substance:

 

 

HB0001 Engrossed- 176 -LRB099 00249 HEP 20254 b

1        (1) the chemical structure of which is substantially
2    similar to the chemical structure of a controlled substance
3    in Schedule I or II;
4        (2) which has a stimulant, depressant, or
5    hallucinogenic effect on the central nervous system that is
6    substantially similar to or greater than the stimulant,
7    depressant, or hallucinogenic effect on the central
8    nervous system of a controlled substance in Schedule I or
9    II; or
10        (3) with respect to a particular person, which such
11    person represents or intends to have a stimulant,
12    depressant, or hallucinogenic effect on the central
13    nervous system that is substantially similar to or greater
14    than the stimulant, depressant, or hallucinogenic effect
15    on the central nervous system of a controlled substance in
16    Schedule I or II.
17    (g) "Counterfeit substance" means a controlled substance,
18which, or the container or labeling of which, without
19authorization bears the trademark, trade name, or other
20identifying mark, imprint, number or device, or any likeness
21thereof, of a manufacturer, distributor, or dispenser other
22than the person who in fact manufactured, distributed, or
23dispensed the substance.
24    (h) "Deliver" or "delivery" means the actual, constructive
25or attempted transfer of possession of a controlled substance,
26with or without consideration, whether or not there is an

 

 

HB0001 Engrossed- 177 -LRB099 00249 HEP 20254 b

1agency relationship.
2    (i) "Department" means the Illinois Department of Human
3Services (as successor to the Department of Alcoholism and
4Substance Abuse) or its successor agency.
5    (j) (Blank).
6    (k) "Department of Corrections" means the Department of
7Corrections of the State of Illinois or its successor agency.
8    (l) "Department of Financial and Professional Regulation"
9means the Department of Financial and Professional Regulation
10of the State of Illinois or its successor agency.
11    (m) "Depressant" means any drug that (i) causes an overall
12depression of central nervous system functions, (ii) causes
13impaired consciousness and awareness, and (iii) can be
14habit-forming or lead to a substance abuse problem, including
15but not limited to alcohol, cannabis and its active principles
16and their analogs, benzodiazepines and their analogs,
17barbiturates and their analogs, opioids (natural and
18synthetic) and their analogs, and chloral hydrate and similar
19sedative hypnotics.
20    (n) (Blank).
21    (o) "Director" means the Director of the Illinois State
22Police or his or her designated agents.
23    (p) "Dispense" means to deliver a controlled substance to
24an ultimate user or research subject by or pursuant to the
25lawful order of a prescriber, including the prescribing,
26administering, packaging, labeling, or compounding necessary

 

 

HB0001 Engrossed- 178 -LRB099 00249 HEP 20254 b

1to prepare the substance for that delivery.
2    (q) "Dispenser" means a practitioner who dispenses.
3    (r) "Distribute" means to deliver, other than by
4administering or dispensing, a controlled substance.
5    (s) "Distributor" means a person who distributes.
6    (t) "Drug" means (1) substances recognized as drugs in the
7official United States Pharmacopoeia, Official Homeopathic
8Pharmacopoeia of the United States, or official National
9Formulary, or any supplement to any of them; (2) substances
10intended for use in diagnosis, cure, mitigation, treatment, or
11prevention of disease in man or animals; (3) substances (other
12than food) intended to affect the structure of any function of
13the body of man or animals and (4) substances intended for use
14as a component of any article specified in clause (1), (2), or
15(3) of this subsection. It does not include devices or their
16components, parts, or accessories.
17    (t-3) "Electronic health record" or "EHR" means an
18electronic record of health-related information on an
19individual that is created, gathered, managed, and consulted by
20authorized health care clinicians and staff.
21    (t-5) "Euthanasia agency" means an entity certified by the
22Department of Financial and Professional Regulation for the
23purpose of animal euthanasia that holds an animal control
24facility license or animal shelter license under the Animal
25Welfare Act. A euthanasia agency is authorized to purchase,
26store, possess, and utilize Schedule II nonnarcotic and

 

 

HB0001 Engrossed- 179 -LRB099 00249 HEP 20254 b

1Schedule III nonnarcotic drugs for the sole purpose of animal
2euthanasia.
3    (t-10) "Euthanasia drugs" means Schedule II or Schedule III
4substances (nonnarcotic controlled substances) that are used
5by a euthanasia agency for the purpose of animal euthanasia.
6    (u) "Good faith" means the prescribing or dispensing of a
7controlled substance by a practitioner in the regular course of
8professional treatment to or for any person who is under his or
9her treatment for a pathology or condition other than that
10individual's physical or psychological dependence upon or
11addiction to a controlled substance, except as provided herein:
12and application of the term to a pharmacist shall mean the
13dispensing of a controlled substance pursuant to the
14prescriber's order which in the professional judgment of the
15pharmacist is lawful. The pharmacist shall be guided by
16accepted professional standards including, but not limited to
17the following, in making the judgment:
18        (1) lack of consistency of prescriber-patient
19    relationship,
20        (2) frequency of prescriptions for same drug by one
21    prescriber for large numbers of patients,
22        (3) quantities beyond those normally prescribed,
23        (4) unusual dosages (recognizing that there may be
24    clinical circumstances where more or less than the usual
25    dose may be used legitimately),
26        (5) unusual geographic distances between patient,

 

 

HB0001 Engrossed- 180 -LRB099 00249 HEP 20254 b

1    pharmacist and prescriber,
2        (6) consistent prescribing of habit-forming drugs.
3    (u-0.5) "Hallucinogen" means a drug that causes markedly
4altered sensory perception leading to hallucinations of any
5type.
6    (u-1) "Home infusion services" means services provided by a
7pharmacy in compounding solutions for direct administration to
8a patient in a private residence, long-term care facility, or
9hospice setting by means of parenteral, intravenous,
10intramuscular, subcutaneous, or intraspinal infusion.
11    (u-5) "Illinois State Police" means the State Police of the
12State of Illinois, or its successor agency.
13    (v) "Immediate precursor" means a substance:
14        (1) which the Department has found to be and by rule
15    designated as being a principal compound used, or produced
16    primarily for use, in the manufacture of a controlled
17    substance;
18        (2) which is an immediate chemical intermediary used or
19    likely to be used in the manufacture of such controlled
20    substance; and
21        (3) the control of which is necessary to prevent,
22    curtail or limit the manufacture of such controlled
23    substance.
24    (w) "Instructional activities" means the acts of teaching,
25educating or instructing by practitioners using controlled
26substances within educational facilities approved by the State

 

 

HB0001 Engrossed- 181 -LRB099 00249 HEP 20254 b

1Board of Education or its successor agency.
2    (x) "Local authorities" means a duly organized State,
3County or Municipal peace unit or police force.
4    (y) "Look-alike substance" means a substance, other than a
5controlled substance which (1) by overall dosage unit
6appearance, including shape, color, size, markings or lack
7thereof, taste, consistency, or any other identifying physical
8characteristic of the substance, would lead a reasonable person
9to believe that the substance is a controlled substance, or (2)
10is expressly or impliedly represented to be a controlled
11substance or is distributed under circumstances which would
12lead a reasonable person to believe that the substance is a
13controlled substance. For the purpose of determining whether
14the representations made or the circumstances of the
15distribution would lead a reasonable person to believe the
16substance to be a controlled substance under this clause (2) of
17subsection (y), the court or other authority may consider the
18following factors in addition to any other factor that may be
19relevant:
20        (a) statements made by the owner or person in control
21    of the substance concerning its nature, use or effect;
22        (b) statements made to the buyer or recipient that the
23    substance may be resold for profit;
24        (c) whether the substance is packaged in a manner
25    normally used for the illegal distribution of controlled
26    substances;

 

 

HB0001 Engrossed- 182 -LRB099 00249 HEP 20254 b

1        (d) whether the distribution or attempted distribution
2    included an exchange of or demand for money or other
3    property as consideration, and whether the amount of the
4    consideration was substantially greater than the
5    reasonable retail market value of the substance.
6    Clause (1) of this subsection (y) shall not apply to a
7noncontrolled substance in its finished dosage form that was
8initially introduced into commerce prior to the initial
9introduction into commerce of a controlled substance in its
10finished dosage form which it may substantially resemble.
11    Nothing in this subsection (y) prohibits the dispensing or
12distributing of noncontrolled substances by persons authorized
13to dispense and distribute controlled substances under this
14Act, provided that such action would be deemed to be carried
15out in good faith under subsection (u) if the substances
16involved were controlled substances.
17    Nothing in this subsection (y) or in this Act prohibits the
18manufacture, preparation, propagation, compounding,
19processing, packaging, advertising or distribution of a drug or
20drugs by any person registered pursuant to Section 510 of the
21Federal Food, Drug, and Cosmetic Act (21 U.S.C. 360).
22    (y-1) "Mail-order pharmacy" means a pharmacy that is
23located in a state of the United States that delivers,
24dispenses or distributes, through the United States Postal
25Service or other common carrier, to Illinois residents, any
26substance which requires a prescription.

 

 

HB0001 Engrossed- 183 -LRB099 00249 HEP 20254 b

1    (z) "Manufacture" means the production, preparation,
2propagation, compounding, conversion or processing of a
3controlled substance other than methamphetamine, either
4directly or indirectly, by extraction from substances of
5natural origin, or independently by means of chemical
6synthesis, or by a combination of extraction and chemical
7synthesis, and includes any packaging or repackaging of the
8substance or labeling of its container, except that this term
9does not include:
10        (1) by an ultimate user, the preparation or compounding
11    of a controlled substance for his or her own use; or
12        (2) by a practitioner, or his or her authorized agent
13    under his or her supervision, the preparation,
14    compounding, packaging, or labeling of a controlled
15    substance:
16            (a) as an incident to his or her administering or
17        dispensing of a controlled substance in the course of
18        his or her professional practice; or
19            (b) as an incident to lawful research, teaching or
20        chemical analysis and not for sale.
21    (z-1) (Blank).
22    (z-5) "Medication shopping" means the conduct prohibited
23under subsection (a) of Section 314.5 of this Act.
24    (z-10) "Mid-level practitioner" means (i) a physician
25assistant who has been delegated authority to prescribe through
26a written delegation of authority by a physician licensed to

 

 

HB0001 Engrossed- 184 -LRB099 00249 HEP 20254 b

1practice medicine in all of its branches, in accordance with
2Section 7.5 of the Physician Assistant Practice Act of 1987,
3(ii) an advanced practice nurse who has been delegated
4authority to prescribe through a written delegation of
5authority by a physician licensed to practice medicine in all
6of its branches or by a podiatric physician, in accordance with
7Section 65-40 of the Nurse Practice Act, (iii) an animal
8euthanasia agency, or (iv) a prescribing psychologist.
9    (aa) "Narcotic drug" means any of the following, whether
10produced directly or indirectly by extraction from substances
11of vegetable origin, or independently by means of chemical
12synthesis, or by a combination of extraction and chemical
13synthesis:
14        (1) opium, opiates, derivatives of opium and opiates,
15    including their isomers, esters, ethers, salts, and salts
16    of isomers, esters, and ethers, whenever the existence of
17    such isomers, esters, ethers, and salts is possible within
18    the specific chemical designation; however the term
19    "narcotic drug" does not include the isoquinoline
20    alkaloids of opium;
21        (2) (blank);
22        (3) opium poppy and poppy straw;
23        (4) coca leaves, except coca leaves and extracts of
24    coca leaves from which substantially all of the cocaine and
25    ecgonine, and their isomers, derivatives and salts, have
26    been removed;

 

 

HB0001 Engrossed- 185 -LRB099 00249 HEP 20254 b

1        (5) cocaine, its salts, optical and geometric isomers,
2    and salts of isomers;
3        (6) ecgonine, its derivatives, their salts, isomers,
4    and salts of isomers;
5        (7) any compound, mixture, or preparation which
6    contains any quantity of any of the substances referred to
7    in subparagraphs (1) through (6).
8    (bb) "Nurse" means a registered nurse licensed under the
9Nurse Practice Act.
10    (cc) (Blank).
11    (dd) "Opiate" means any substance having an addiction
12forming or addiction sustaining liability similar to morphine
13or being capable of conversion into a drug having addiction
14forming or addiction sustaining liability.
15    (ee) "Opium poppy" means the plant of the species Papaver
16somniferum L., except its seeds.
17    (ee-5) "Oral dosage" means a tablet, capsule, elixir, or
18solution or other liquid form of medication intended for
19administration by mouth, but the term does not include a form
20of medication intended for buccal, sublingual, or transmucosal
21administration.
22    (ff) "Parole and Pardon Board" means the Parole and Pardon
23Board of the State of Illinois or its successor agency.
24    (gg) "Person" means any individual, corporation,
25mail-order pharmacy, government or governmental subdivision or
26agency, business trust, estate, trust, partnership or

 

 

HB0001 Engrossed- 186 -LRB099 00249 HEP 20254 b

1association, or any other entity.
2    (hh) "Pharmacist" means any person who holds a license or
3certificate of registration as a registered pharmacist, a local
4registered pharmacist or a registered assistant pharmacist
5under the Pharmacy Practice Act.
6    (ii) "Pharmacy" means any store, ship or other place in
7which pharmacy is authorized to be practiced under the Pharmacy
8Practice Act.
9    (ii-5) "Pharmacy shopping" means the conduct prohibited
10under subsection (b) of Section 314.5 of this Act.
11    (ii-10) "Physician" (except when the context otherwise
12requires) means a person licensed to practice medicine in all
13of its branches.
14    (jj) "Poppy straw" means all parts, except the seeds, of
15the opium poppy, after mowing.
16    (kk) "Practitioner" means a physician licensed to practice
17medicine in all its branches, dentist, optometrist, podiatric
18physician, veterinarian, scientific investigator, pharmacist,
19physician assistant, advanced practice nurse, licensed
20practical nurse, registered nurse, hospital, laboratory, or
21pharmacy, or other person licensed, registered, or otherwise
22lawfully permitted by the United States or this State to
23distribute, dispense, conduct research with respect to,
24administer or use in teaching or chemical analysis, a
25controlled substance in the course of professional practice or
26research.

 

 

HB0001 Engrossed- 187 -LRB099 00249 HEP 20254 b

1    (ll) "Pre-printed prescription" means a written
2prescription upon which the designated drug has been indicated
3prior to the time of issuance; the term does not mean a written
4prescription that is individually generated by machine or
5computer in the prescriber's office.
6    (mm) "Prescriber" means a physician licensed to practice
7medicine in all its branches, dentist, optometrist,
8prescribing psychologist licensed under Section 4.2 of the
9Clinical Psychologist Licensing Act with prescriptive
10authority delegated under Section 4.3 of the Clinical
11Psychologist Licensing Act, podiatric physician, or
12veterinarian who issues a prescription, a physician assistant
13who issues a prescription for a controlled substance in
14accordance with Section 303.05, a written delegation, and a
15written supervision agreement required under Section 7.5 of the
16Physician Assistant Practice Act of 1987, or an advanced
17practice nurse with prescriptive authority delegated under
18Section 65-40 of the Nurse Practice Act and in accordance with
19Section 303.05, a written delegation, and a written
20collaborative agreement under Section 65-35 of the Nurse
21Practice Act.
22    (nn) "Prescription" means a written, facsimile, or oral
23order, or an electronic order that complies with applicable
24federal requirements, of a physician licensed to practice
25medicine in all its branches, dentist, podiatric physician or
26veterinarian for any controlled substance, of an optometrist

 

 

HB0001 Engrossed- 188 -LRB099 00249 HEP 20254 b

1for a Schedule II, III, IV, or V controlled substance in
2accordance with Section 15.1 of the Illinois Optometric
3Practice Act of 1987, of a prescribing psychologist licensed
4under Section 4.2 of the Clinical Psychologist Licensing Act
5with prescriptive authority delegated under Section 4.3 of the
6Clinical Psychologist Licensing Act, of a physician assistant
7for a controlled substance in accordance with Section 303.05, a
8written delegation, and a written supervision agreement
9required under Section 7.5 of the Physician Assistant Practice
10Act of 1987, or of an advanced practice nurse with prescriptive
11authority delegated under Section 65-40 of the Nurse Practice
12Act who issues a prescription for a controlled substance in
13accordance with Section 303.05, a written delegation, and a
14written collaborative agreement under Section 65-35 of the
15Nurse Practice Act when required by law.
16    (nn-5) "Prescription Information Library" (PIL) means an
17electronic library that contains reported controlled substance
18data.
19    (nn-10) "Prescription Monitoring Program" (PMP) means the
20entity that collects, tracks, and stores reported data on
21controlled substances and select drugs pursuant to Section 316.
22    (oo) "Production" or "produce" means manufacture,
23planting, cultivating, growing, or harvesting of a controlled
24substance other than methamphetamine.
25    (pp) "Registrant" means every person who is required to
26register under Section 302 of this Act.

 

 

HB0001 Engrossed- 189 -LRB099 00249 HEP 20254 b

1    (qq) "Registry number" means the number assigned to each
2person authorized to handle controlled substances under the
3laws of the United States and of this State.
4    (qq-5) "Secretary" means, as the context requires, either
5the Secretary of the Department or the Secretary of the
6Department of Financial and Professional Regulation, and the
7Secretary's designated agents.
8    (rr) "State" includes the State of Illinois and any state,
9district, commonwealth, territory, insular possession thereof,
10and any area subject to the legal authority of the United
11States of America.
12    (rr-5) "Stimulant" means any drug that (i) causes an
13overall excitation of central nervous system functions, (ii)
14causes impaired consciousness and awareness, and (iii) can be
15habit-forming or lead to a substance abuse problem, including
16but not limited to amphetamines and their analogs,
17methylphenidate and its analogs, cocaine, and phencyclidine
18and its analogs.
19    (ss) "Ultimate user" means a person who lawfully possesses
20a controlled substance for his or her own use or for the use of
21a member of his or her household or for administering to an
22animal owned by him or her or by a member of his or her
23household.
24(Source: P.A. 97-334, eff. 1-1-12; 98-214, eff. 8-9-13; 98-668,
25eff. 6-25-14; 98-756, eff. 7-16-14; 98-1111, eff. 8-26-14;
26revised 10-1-14.)
 

 

 

HB0001 Engrossed- 190 -LRB099 00249 HEP 20254 b

1    (720 ILCS 570/301)  (from Ch. 56 1/2, par. 1301)
2    Sec. 301. The Department of Financial and Professional
3Regulation shall promulgate rules and charge reasonable fees
4and fines relating to the registration and control of the
5manufacture, distribution, and dispensing of controlled
6substances within this State. The Department shall request a
7contact email address in its application for a new or renewed
8license to dispense controlled substances. All moneys received
9by the Department of Financial and Professional Regulation
10under this Act shall be deposited into the respective
11professional dedicated funds in like manner as the primary
12professional licenses.
13    A pharmacy, manufacturer of controlled substances, or
14wholesale distributor of controlled substances that is
15regulated under this Act and owned and operated by the State is
16exempt from fees required under this Act. Pharmacists and
17pharmacy technicians working in facilities owned and operated
18by the State are not exempt from the payment of fees required
19by this Act and any rules adopted under this Act. Nothing in
20this Section shall be construed to prohibit the Department of
21Financial and Professional Regulation from imposing any fine or
22other penalty allowed under this Act.
23(Source: P.A. 97-334, eff. 1-1-12.)
 
24    (720 ILCS 570/312)  (from Ch. 56 1/2, par. 1312)

 

 

HB0001 Engrossed- 191 -LRB099 00249 HEP 20254 b

1    Sec. 312. Requirements for dispensing controlled
2substances.
3    (a) A practitioner, in good faith, may dispense a Schedule
4II controlled substance, which is a narcotic drug listed in
5Section 206 of this Act; or which contains any quantity of
6amphetamine or methamphetamine, their salts, optical isomers
7or salts of optical isomers; phenmetrazine and its salts; or
8pentazocine; and Schedule III, IV, or V controlled substances
9to any person upon a written or electronic prescription of any
10prescriber, dated and signed by the person prescribing (or
11electronically validated in compliance with Section 311.5) on
12the day when issued and bearing the name and address of the
13patient for whom, or the owner of the animal for which the
14controlled substance is dispensed, and the full name, address
15and registry number under the laws of the United States
16relating to controlled substances of the prescriber, if he or
17she is required by those laws to be registered. If the
18prescription is for an animal it shall state the species of
19animal for which it is ordered. The practitioner filling the
20prescription shall, unless otherwise permitted, write the date
21of filling and his or her own signature on the face of the
22written prescription or, alternatively, shall indicate such
23filling using a unique identifier as defined in paragraph (v)
24of Section 3 of the Pharmacy Practice Act. The written
25prescription shall be retained on file by the practitioner who
26filled it or pharmacy in which the prescription was filled for

 

 

HB0001 Engrossed- 192 -LRB099 00249 HEP 20254 b

1a period of 2 years, so as to be readily accessible for
2inspection or removal by any officer or employee engaged in the
3enforcement of this Act. Whenever the practitioner's or
4pharmacy's copy of any prescription is removed by an officer or
5employee engaged in the enforcement of this Act, for the
6purpose of investigation or as evidence, such officer or
7employee shall give to the practitioner or pharmacy a receipt
8in lieu thereof. If the specific prescription is machine or
9computer generated and printed at the prescriber's office, the
10date does not need to be handwritten. A prescription for a
11Schedule II controlled substance shall not be issued for more
12than a 30 day supply, except as provided in subsection (a-5),
13and shall be valid for up to 90 days after the date of
14issuance. A written prescription for Schedule III, IV or V
15controlled substances shall not be filled or refilled more than
166 months after the date thereof or refilled more than 5 times
17unless renewed, in writing, by the prescriber. A pharmacy shall
18maintain a policy regarding the type of identification
19necessary, if any, to receive a prescription in accordance with
20State and federal law. The pharmacy must post such information
21where prescriptions are filled.
22    (a-5) Physicians may issue multiple prescriptions (3
23sequential 30-day supplies) for the same Schedule II controlled
24substance, authorizing up to a 90-day supply. Before
25authorizing a 90-day supply of a Schedule II controlled
26substance, the physician must meet both of the following

 

 

HB0001 Engrossed- 193 -LRB099 00249 HEP 20254 b

1conditions:
2        (1) Each separate prescription must be issued for a
3    legitimate medical purpose by an individual physician
4    acting in the usual course of professional practice.
5        (2) The individual physician must provide written
6    instructions on each prescription (other than the first
7    prescription, if the prescribing physician intends for the
8    prescription to be filled immediately) indicating the
9    earliest date on which a pharmacy may fill that
10    prescription.
11        (3) The physician shall document in the medical record
12    of a patient the medical necessity for the amount and
13    duration of the 3 sequential 30-day prescriptions for
14    Schedule II narcotics.
15    (b) In lieu of a written prescription required by this
16Section, a pharmacist, in good faith, may dispense Schedule
17III, IV, or V substances to any person either upon receiving a
18facsimile of a written, signed prescription transmitted by the
19prescriber or the prescriber's agent or upon a lawful oral
20prescription of a prescriber which oral prescription shall be
21reduced promptly to writing by the pharmacist and such written
22memorandum thereof shall be dated on the day when such oral
23prescription is received by the pharmacist and shall bear the
24full name and address of the ultimate user for whom, or of the
25owner of the animal for which the controlled substance is
26dispensed, and the full name, address, and registry number

 

 

HB0001 Engrossed- 194 -LRB099 00249 HEP 20254 b

1under the law of the United States relating to controlled
2substances of the prescriber prescribing if he or she is
3required by those laws to be so registered, and the pharmacist
4filling such oral prescription shall write the date of filling
5and his or her own signature on the face of such written
6memorandum thereof. The facsimile copy of the prescription or
7written memorandum of the oral prescription shall be retained
8on file by the proprietor of the pharmacy in which it is filled
9for a period of not less than two years, so as to be readily
10accessible for inspection by any officer or employee engaged in
11the enforcement of this Act in the same manner as a written
12prescription. The facsimile copy of the prescription or oral
13prescription and the written memorandum thereof shall not be
14filled or refilled more than 6 months after the date thereof or
15be refilled more than 5 times, unless renewed, in writing, by
16the prescriber.
17    (c) Except for any non-prescription targeted
18methamphetamine precursor regulated by the Methamphetamine
19Precursor Control Act, a controlled substance included in
20Schedule V shall not be distributed or dispensed other than for
21a medical purpose and not for the purpose of evading this Act,
22and then:
23        (1) only personally by a person registered to dispense
24    a Schedule V controlled substance and then only to his or
25    her patients, or
26        (2) only personally by a pharmacist, and then only to a

 

 

HB0001 Engrossed- 195 -LRB099 00249 HEP 20254 b

1    person over 21 years of age who has identified himself or
2    herself to the pharmacist by means of 2 positive documents
3    of identification.
4        (3) the dispenser shall record the name and address of
5    the purchaser, the name and quantity of the product, the
6    date and time of the sale, and the dispenser's signature.
7        (4) no person shall purchase or be dispensed more than
8    120 milliliters or more than 120 grams of any Schedule V
9    substance which contains codeine, dihydrocodeine, or any
10    salts thereof, or ethylmorphine, or any salts thereof, in
11    any 96 hour period. The purchaser shall sign a form,
12    approved by the Department of Financial and Professional
13    Regulation, attesting that he or she has not purchased any
14    Schedule V controlled substances within the immediately
15    preceding 96 hours.
16        (5) (Blank).
17        (6) all records of purchases and sales shall be
18    maintained for not less than 2 years.
19        (7) no person shall obtain or attempt to obtain within
20    any consecutive 96 hour period any Schedule V substances of
21    more than 120 milliliters or more than 120 grams containing
22    codeine, dihydrocodeine or any of its salts, or
23    ethylmorphine or any of its salts. Any person obtaining any
24    such preparations or combination of preparations in excess
25    of this limitation shall be in unlawful possession of such
26    controlled substance.

 

 

HB0001 Engrossed- 196 -LRB099 00249 HEP 20254 b

1        (8) a person qualified to dispense controlled
2    substances under this Act and registered thereunder shall
3    at no time maintain or keep in stock a quantity of Schedule
4    V controlled substances in excess of 4.5 liters for each
5    substance; a pharmacy shall at no time maintain or keep in
6    stock a quantity of Schedule V controlled substances as
7    defined in excess of 4.5 liters for each substance, plus
8    the additional quantity of controlled substances necessary
9    to fill the largest number of prescription orders filled by
10    that pharmacy for such controlled substances in any one
11    week in the previous year. These limitations shall not
12    apply to Schedule V controlled substances which Federal law
13    prohibits from being dispensed without a prescription.
14        (9) no person shall distribute or dispense butyl
15    nitrite for inhalation or other introduction into the human
16    body for euphoric or physical effect.
17    (d) Every practitioner shall keep a record or log of
18controlled substances received by him or her and a record of
19all such controlled substances administered, dispensed or
20professionally used by him or her otherwise than by
21prescription. It shall, however, be sufficient compliance with
22this paragraph if any practitioner utilizing controlled
23substances listed in Schedules III, IV and V shall keep a
24record of all those substances dispensed and distributed by him
25or her other than those controlled substances which are
26administered by the direct application of a controlled

 

 

HB0001 Engrossed- 197 -LRB099 00249 HEP 20254 b

1substance, whether by injection, inhalation, ingestion, or any
2other means to the body of a patient or research subject. A
3practitioner who dispenses, other than by administering, a
4controlled substance in Schedule II, which is a narcotic drug
5listed in Section 206 of this Act, or which contains any
6quantity of amphetamine or methamphetamine, their salts,
7optical isomers or salts of optical isomers, pentazocine, or
8methaqualone shall do so only upon the issuance of a written
9prescription blank or electronic prescription issued by a
10prescriber.
11    (e) Whenever a manufacturer distributes a controlled
12substance in a package prepared by him or her, and whenever a
13wholesale distributor distributes a controlled substance in a
14package prepared by him or her or the manufacturer, he or she
15shall securely affix to each package in which that substance is
16contained a label showing in legible English the name and
17address of the manufacturer, the distributor and the quantity,
18kind and form of controlled substance contained therein. No
19person except a pharmacist and only for the purposes of filling
20a prescription under this Act, shall alter, deface or remove
21any label so affixed.
22    (f) Whenever a practitioner dispenses any controlled
23substance except a non-prescription Schedule V product or a
24non-prescription targeted methamphetamine precursor regulated
25by the Methamphetamine Precursor Control Act, he or she shall
26affix to the container in which such substance is sold or

 

 

HB0001 Engrossed- 198 -LRB099 00249 HEP 20254 b

1dispensed, a label indicating the date of initial filling, the
2practitioner's name and address, the name of the patient, the
3name of the prescriber, the directions for use and cautionary
4statements, if any, contained in any prescription or required
5by law, the proprietary name or names or the established name
6of the controlled substance, and the dosage and quantity,
7except as otherwise authorized by regulation by the Department
8of Financial and Professional Regulation. No person shall
9alter, deface or remove any label so affixed as long as the
10specific medication remains in the container.
11    (g) A person to whom or for whose use any controlled
12substance has been prescribed or dispensed by a practitioner,
13or other persons authorized under this Act, and the owner of
14any animal for which such substance has been prescribed or
15dispensed by a veterinarian, may lawfully possess such
16substance only in the container in which it was delivered to
17him or her by the person dispensing such substance.
18    (h) The responsibility for the proper prescribing or
19dispensing of controlled substances that are under the
20prescriber's direct control is upon the prescriber. The
21responsibility for the proper filling of a prescription for
22controlled substance drugs rests with the pharmacist. An order
23purporting to be a prescription issued to any individual, which
24is not in the regular course of professional treatment nor part
25of an authorized methadone maintenance program, nor in
26legitimate and authorized research instituted by any

 

 

HB0001 Engrossed- 199 -LRB099 00249 HEP 20254 b

1accredited hospital, educational institution, charitable
2foundation, or federal, state or local governmental agency, and
3which is intended to provide that individual with controlled
4substances sufficient to maintain that individual's or any
5other individual's physical or psychological addiction,
6habitual or customary use, dependence, or diversion of that
7controlled substance is not a prescription within the meaning
8and intent of this Act; and the person issuing it, shall be
9subject to the penalties provided for violations of the law
10relating to controlled substances.
11    (i) A prescriber shall not pre-print preprint or cause to
12be pre-printed preprinted a prescription for any controlled
13substance; nor shall any practitioner issue, fill or cause to
14be issued or filled, a pre-printed preprinted prescription for
15any controlled substance.
16    (i-5) A prescriber may use a machine or electronic device
17to individually generate a printed prescription, but the
18prescriber is still required to affix his or her manual
19signature.
20    (j) No person shall manufacture, dispense, deliver,
21possess with intent to deliver, prescribe, or administer or
22cause to be administered under his or her direction any
23anabolic steroid, for any use in humans other than the
24treatment of disease in accordance with the order of a
25physician licensed to practice medicine in all its branches for
26a valid medical purpose in the course of professional practice.

 

 

HB0001 Engrossed- 200 -LRB099 00249 HEP 20254 b

1The use of anabolic steroids for the purpose of hormonal
2manipulation that is intended to increase muscle mass, strength
3or weight without a medical necessity to do so, or for the
4intended purpose of improving physical appearance or
5performance in any form of exercise, sport, or game, is not a
6valid medical purpose or in the course of professional
7practice.
8    (k) Controlled substances may be mailed if all of the
9following conditions are met:
10        (1) The controlled substances are not outwardly
11    dangerous and are not likely, of their own force, to cause
12    injury to a person's life or health.
13        (2) The inner container of a parcel containing
14    controlled substances must be marked and sealed as required
15    under this Act and its rules, and be placed in a plain
16    outer container or securely wrapped in plain paper.
17        (3) If the controlled substances consist of
18    prescription medicines, the inner container must be
19    labeled to show the name and address of the pharmacy or
20    practitioner dispensing the prescription.
21        (4) The outside wrapper or container must be free of
22    markings that would indicate the nature of the contents.
23(Source: P.A. 96-166, eff. 1-1-10; 97-334, eff. 1-1-12; revised
2412-10-14.)
 
25    (720 ILCS 570/314.5)

 

 

HB0001 Engrossed- 201 -LRB099 00249 HEP 20254 b

1    Sec. 314.5. Medication shopping; pharmacy shopping.
2    (a) It shall be unlawful for any person knowingly or
3intentionally to fraudulently obtain or fraudulently seek to
4obtain any controlled substance or prescription for a
5controlled substance from a prescriber or dispenser while being
6supplied with any controlled substance or prescription for a
7controlled substance by another prescriber or dispenser,
8without disclosing the fact of the existing controlled
9substance or prescription for a controlled substance to the
10prescriber or dispenser from whom the subsequent controlled
11substance or prescription for a controlled substance is sought.
12    (b) It shall be unlawful for a person knowingly or
13intentionally to fraudulently obtain or fraudulently seek to
14obtain any controlled substance from a pharmacy while being
15supplied with any controlled substance by another pharmacy,
16without disclosing the fact of the existing controlled
17substance to the pharmacy from which the subsequent controlled
18substance is sought.
19    (c) A person may be in violation of Section 3.23 of the
20Illinois Food, Drug and Cosmetic Act or Section 406 of this Act
21when medication shopping or pharmacy shopping, or both.
22    (d) When a person has been identified as having 3 6 or more
23prescribers or 3 6 or more pharmacies, or both, that do not
24utilize a common electronic file as specified in Section 20 of
25the Pharmacy Practice Act for controlled substances within the
26course of a continuous 30-day period, the Prescription

 

 

HB0001 Engrossed- 202 -LRB099 00249 HEP 20254 b

1Monitoring Program may issue an unsolicited report to the
2prescribers, dispensers, and their designees informing them of
3the potential medication shopping.
4    (e) Nothing in this Section shall be construed to create a
5requirement that any prescriber, dispenser, or pharmacist
6request any patient medication disclosure, report any patient
7activity, or prescribe or refuse to prescribe or dispense any
8medications.
9    (f) This Section shall not be construed to apply to
10inpatients or residents at hospitals or other institutions or
11to institutional pharmacies.
12    (g) Any patient feedback, including grades, ratings, or
13written or verbal statements, in opposition to a clinical
14decision that the prescription of a controlled substance is not
15medically necessary shall not be the basis of any adverse
16action, evaluation, or any other type of negative
17credentialing, contracting, licensure, or employment action
18taken against a prescriber or dispenser.
19(Source: P.A. 97-334, eff. 1-1-12.)
 
20    (720 ILCS 570/316)
21    Sec. 316. Prescription monitoring program.
22    (a) The Department must provide for a prescription
23monitoring program for Schedule II, III, IV, and V controlled
24substances that includes the following components and
25requirements:

 

 

HB0001 Engrossed- 203 -LRB099 00249 HEP 20254 b

1        (1) The dispenser must transmit to the central
2    repository, in a form and manner specified by the
3    Department, the following information:
4            (A) The recipient's name and address.
5            (B) The recipient's date of birth and gender
6        address.
7            (C) The national drug code number of the controlled
8        substance dispensed.
9            (D) The date the controlled substance is
10        dispensed.
11            (E) The quantity of the controlled substance
12        dispensed and days supply.
13            (F) The dispenser's United States Drug Enforcement
14        Administration registration number.
15            (G) The prescriber's United States Drug
16        Enforcement Administration registration number.
17            (H) The dates the controlled substance
18        prescription is filled.
19            (I) The payment type used to purchase the
20        controlled substance (i.e. Medicaid, cash, third party
21        insurance).
22            (J) The patient location code (i.e. home, nursing
23        home, outpatient, etc.) for the controlled substances
24        other than those filled at a retail pharmacy.
25            (K) Any additional information that may be
26        required by the department by administrative rule,

 

 

HB0001 Engrossed- 204 -LRB099 00249 HEP 20254 b

1        including but not limited to information required for
2        compliance with the criteria for electronic reporting
3        of the American Society for Automation and Pharmacy or
4        its successor.
5        (2) The information required to be transmitted under
6    this Section must be transmitted not later more than the
7    end of the next business day 7 days after the date on which
8    a controlled substance is dispensed, or at such other time
9    as may be required by the Department by administrative
10    rule.
11        (3) A dispenser must transmit the information required
12    under this Section by:
13            (A) an electronic device compatible with the
14        receiving device of the central repository;
15            (B) a computer diskette;
16            (C) a magnetic tape; or
17            (D) a pharmacy universal claim form or Pharmacy
18        Inventory Control form;
19        (4) The Department may impose a civil fine of up to
20    $100 per day for willful failure to report controlled
21    substance dispensing to the Prescription Monitoring
22    Program. The fine shall be calculated on no more than the
23    number of days from the time the report was required to be
24    made until the time the problem was resolved, and shall be
25    payable to the Prescription Monitoring Program.
26    (b) The Department, by rule, may include in the monitoring

 

 

HB0001 Engrossed- 205 -LRB099 00249 HEP 20254 b

1program certain other select drugs that are not included in
2Schedule II, III, IV, or V. The prescription monitoring program
3does not apply to controlled substance prescriptions as
4exempted under Section 313.
5    (c) The collection of data on select drugs and scheduled
6substances by the Prescription Monitoring Program may be used
7as a tool for addressing oversight requirements of long-term
8care institutions as set forth by Public Act 96-1372. Long-term
9care pharmacies shall transmit patient medication profiles to
10the Prescription Monitoring Program monthly or more frequently
11as established by administrative rule.
12    (d) The Department of Human Services shall appoint a
13full-time Clinical Director of the Prescription Monitoring
14Program.
15    (e) Within one year of the effective date of this
16amendatory Act of the 99th General Assembly, the Department
17shall adopt rules establishing pilot initiatives involving a
18cross-section of hospitals in this State to increase electronic
19integration of a hospital's electronic health record with the
20Prescription Monitoring Program on or before January 1, 2019 to
21ensure all providers have timely access to relevant
22prescription information during the treatment of their
23patients. These rules shall also establish pilots that enhance
24the electronic integration of outpatient pharmacy records with
25the Prescription Monitoring Program to allow for faster
26transmission of the information required under this Section. In

 

 

HB0001 Engrossed- 206 -LRB099 00249 HEP 20254 b

1collaboration with the Department of Human Services, the
2Prescription Monitoring Program Advisory Committee shall
3identify funding sources to support the pilot projects in this
4Section and distribution of funds shall be based on voluntary
5and incentive-based models. The rules adopted by the Department
6shall also ensure that the Department continues to monitor
7updates in Electronic Health Record Technology and how other
8states have integrated their prescription monitoring databases
9with Electronic Health Records.
10(Source: P.A. 97-334, eff. 1-1-12.)
 
11    (720 ILCS 570/317)
12    Sec. 317. Central repository for collection of
13information.
14    (a) The Department must designate a central repository for
15the collection of information transmitted under Section 316 and
16former Section 321.
17    (b) The central repository must do the following:
18        (1) Create a database for information required to be
19    transmitted under Section 316 in the form required under
20    rules adopted by the Department, including search
21    capability for the following:
22            (A) A recipient's name and address.
23            (B) A recipient's date of birth and gender address.
24            (C) The national drug code number of a controlled
25        substance dispensed.

 

 

HB0001 Engrossed- 207 -LRB099 00249 HEP 20254 b

1            (D) The dates a controlled substance is dispensed.
2            (E) The quantities and days supply of a controlled
3        substance dispensed.
4            (F) A dispenser's Administration registration
5        number.
6            (G) A prescriber's Administration registration
7        number.
8            (H) The dates the controlled substance
9        prescription is filled.
10            (I) The payment type used to purchase the
11        controlled substance (i.e. Medicaid, cash, third party
12        insurance).
13            (J) The patient location code (i.e. home, nursing
14        home, outpatient, etc.) for controlled substance
15        prescriptions other than those filled at a retail
16        pharmacy.
17        (2) Provide the Department with a database maintained
18    by the central repository. The Department of Financial and
19    Professional Regulation must provide the Department with
20    electronic access to the license information of a
21    prescriber or dispenser.
22        (3) Secure the information collected by the central
23    repository and the database maintained by the central
24    repository against access by unauthorized persons.
25    All prescribers shall designate one or more medical
26specialties or fields of medical care and treatment for which

 

 

HB0001 Engrossed- 208 -LRB099 00249 HEP 20254 b

1the prescriber prescribes controlled substances when
2registering with the Prescription Monitoring Program.
3    No fee shall be charged for access by a prescriber or
4dispenser.
5(Source: P.A. 97-334, eff. 1-1-12.)
 
6    (720 ILCS 570/318)
7    Sec. 318. Confidentiality of information.
8    (a) Information received by the central repository under
9Section 316 and former Section 321 is confidential.
10    (b) The Department must carry out a program to protect the
11confidentiality of the information described in subsection
12(a). The Department may disclose the information to another
13person only under subsection (c), (d), or (f) and may charge a
14fee not to exceed the actual cost of furnishing the
15information.
16    (c) The Department may disclose confidential information
17described in subsection (a) to any person who is engaged in
18receiving, processing, or storing the information.
19    (d) The Department may release confidential information
20described in subsection (a) to the following persons:
21        (1) A governing body that licenses practitioners and is
22    engaged in an investigation, an adjudication, or a
23    prosecution of a violation under any State or federal law
24    that involves a controlled substance.
25        (2) An investigator for the Consumer Protection

 

 

HB0001 Engrossed- 209 -LRB099 00249 HEP 20254 b

1    Division of the office of the Attorney General, a
2    prosecuting attorney, the Attorney General, a deputy
3    Attorney General, or an investigator from the office of the
4    Attorney General, who is engaged in any of the following
5    activities involving controlled substances:
6            (A) an investigation;
7            (B) an adjudication; or
8            (C) a prosecution of a violation under any State or
9        federal law that involves a controlled substance.
10        (3) A law enforcement officer who is:
11            (A) authorized by the Illinois State Police or the
12        office of a county sheriff or State's Attorney or
13        municipal police department of Illinois to receive
14        information of the type requested for the purpose of
15        investigations involving controlled substances; or
16            (B) approved by the Department to receive
17        information of the type requested for the purpose of
18        investigations involving controlled substances; and
19            (C) engaged in the investigation or prosecution of
20        a violation under any State or federal law that
21        involves a controlled substance.
22    (e) Before the Department releases confidential
23information under subsection (d), the applicant must
24demonstrate in writing to the Department that:
25        (1) the applicant has reason to believe that a
26    violation under any State or federal law that involves a

 

 

HB0001 Engrossed- 210 -LRB099 00249 HEP 20254 b

1    controlled substance has occurred; and
2        (2) the requested information is reasonably related to
3    the investigation, adjudication, or prosecution of the
4    violation described in subdivision (1).
5    (f) The Department may receive and release prescription
6record information under Section 316 and former Section 321 to:
7        (1) a governing body that licenses practitioners;
8        (2) an investigator for the Consumer Protection
9    Division of the office of the Attorney General, a
10    prosecuting attorney, the Attorney General, a deputy
11    Attorney General, or an investigator from the office of the
12    Attorney General;
13        (3) any Illinois law enforcement officer who is:
14            (A) authorized to receive the type of information
15        released; and
16            (B) approved by the Department to receive the type
17        of information released; or
18        (4) prescription monitoring entities in other states
19    per the provisions outlined in subsection (g) and (h)
20    below;
21confidential prescription record information collected under
22Sections 316 and 321 (now repealed) that identifies vendors or
23practitioners, or both, who are prescribing or dispensing large
24quantities of Schedule II, III, IV, or V controlled substances
25outside the scope of their practice, pharmacy, or business, as
26determined by the Advisory Committee created by Section 320.

 

 

HB0001 Engrossed- 211 -LRB099 00249 HEP 20254 b

1    (g) The information described in subsection (f) may not be
2released until it has been reviewed by an employee of the
3Department who is licensed as a prescriber or a dispenser and
4until that employee has certified that further investigation is
5warranted. However, failure to comply with this subsection (g)
6does not invalidate the use of any evidence that is otherwise
7admissible in a proceeding described in subsection (h).
8    (h) An investigator or a law enforcement officer receiving
9confidential information under subsection (c), (d), or (f) may
10disclose the information to a law enforcement officer or an
11attorney for the office of the Attorney General for use as
12evidence in the following:
13        (1) A proceeding under any State or federal law that
14    involves a controlled substance.
15        (2) A criminal proceeding or a proceeding in juvenile
16    court that involves a controlled substance.
17    (i) The Department may compile statistical reports from the
18information described in subsection (a). The reports must not
19include information that identifies, by name, license or
20address, any practitioner, dispenser, ultimate user, or other
21person administering a controlled substance.
22    (j) Based upon federal, initial and maintenance funding, a
23prescriber and dispenser inquiry system shall be developed to
24assist the health care community in its goal of effective
25clinical practice and to prevent patients from diverting or
26abusing medications.

 

 

HB0001 Engrossed- 212 -LRB099 00249 HEP 20254 b

1        (1) An inquirer shall have read-only access to a
2    stand-alone database which shall contain records for the
3    previous 12 months.
4        (2) Dispensers may, upon positive and secure
5    identification, make an inquiry on a patient or customer
6    solely for a medical purpose as delineated within the
7    federal HIPAA law.
8        (3) The Department shall provide a one-to-one secure
9    link and encrypted software necessary to establish the link
10    between an inquirer and the Department. Technical
11    assistance shall also be provided.
12        (4) Written inquiries are acceptable but must include
13    the fee and the requestor's Drug Enforcement
14    Administration license number and submitted upon the
15    requestor's business stationery.
16        (5) As directed by the Prescription Monitoring Program
17    Advisory Committee and the Clinical Director for the
18    Prescription Monitoring Program, aggregate data that does
19    not indicate any prescriber, practitioner, dispenser, or
20    patient may be used for clinical studies.
21        (6) Tracking analysis shall be established and used per
22    administrative rule.
23        (7) Nothing in this Act or Illinois law shall be
24    construed to require a prescriber or dispenser to make use
25    of this inquiry system.
26        (8) If there is an adverse outcome because of a

 

 

HB0001 Engrossed- 213 -LRB099 00249 HEP 20254 b

1    prescriber or dispenser making an inquiry, which is
2    initiated in good faith, the prescriber or dispenser shall
3    be held harmless from any civil liability.
4    (k) The Department shall establish, by rule, the process by
5which to evaluate possible erroneous association of
6prescriptions to any licensed prescriber or end user of the
7Illinois Prescription Information Library (PIL).
8    (l) The Prescription Monitoring Program Advisory Committee
9is authorized to evaluate the need for and method of
10establishing a patient specific identifier.
11    (m) Patients who identify prescriptions attributed to them
12that were not obtained by them shall be given access to their
13personal prescription history pursuant to the validation
14process as set forth by administrative rule.
15    (n) The Prescription Monitoring Program is authorized to
16develop operational push reports to entities with compatible
17electronic medical records. The process shall be covered within
18administrative rule established by the Department.
19    (o) Hospital emergency departments and freestanding
20healthcare facilities providing healthcare to walk-in patients
21may obtain, for the purpose of improving patient care, a unique
22identifier for each shift to utilize the PIL system.
23    (p) The Prescription Monitoring Program shall
24automatically create a log-in to the inquiry system when a
25prescriber or dispenser obtains or renews his or her controlled
26substance license. The Department of Financial and

 

 

HB0001 Engrossed- 214 -LRB099 00249 HEP 20254 b

1Professional Regulation must provide the Prescription
2Monitoring Program with electronic access to the license
3information of a prescriber or dispenser to facilitate the
4creation of this profile. The Prescription Monitoring Program
5shall send the prescriber or dispenser information regarding
6the inquiry system, including instructions on how to log into
7the system, instructions on how to use the system to promote
8effective clinical practice, and opportunities for continuing
9education for the prescribing of controlled substances. The
10Prescription Monitoring Program shall also send to all enrolled
11prescribers, dispensers, and designees information regarding
12the unsolicited reports produced pursuant to Section 314.5 of
13this Act.
14    (q) A prescriber or dispenser may authorize a designee to
15consult the inquiry system established by the Department under
16this subsection on his or her behalf, provided that all the
17following conditions are met:
18        (1) the designee so authorized is employed by the same
19    hospital or health care system; is employed by the same
20    professional practice; or is under contract with such
21    practice, hospital, or health care system;
22        (2) the prescriber or dispenser takes reasonable steps
23    to ensure that such designee is sufficiently competent in
24    the use of the inquiry system;
25        (3) the prescriber or dispenser remains responsible
26    for ensuring that access to the inquiry system by the

 

 

HB0001 Engrossed- 215 -LRB099 00249 HEP 20254 b

1    designee is limited to authorized purposes and occurs in a
2    manner that protects the confidentiality of the
3    information obtained from the inquiry system, and remains
4    responsible for any breach of confidentiality; and
5        (4) the ultimate decision as to whether or not to
6    prescribe or dispense a controlled substance remains with
7    the prescriber or dispenser.
8    The Prescription Monitoring Program shall send to
9registered designees information regarding the inquiry system,
10including instructions on how to log onto the system.
11    (r) The Prescription Monitoring Program shall maintain an
12Internet website in conjunction with its prescriber and
13dispenser inquiry system. This website shall include, at a
14minimum, the following information:
15        (1) current clinical guidelines developed by health
16    care professional organizations on the prescribing of
17    opioids or other controlled substances as determined by the
18    Advisory Committee;
19        (2) accredited continuing education programs related
20    to prescribing of controlled substances;
21        (3) programs or information developed by health care
22    professionals that may be used to assess patients or help
23    ensure compliance with prescriptions;
24        (4) updates from the Food and Drug Administration, the
25    Centers for Disease Control and Prevention, and other
26    public and private organizations which are relevant to

 

 

HB0001 Engrossed- 216 -LRB099 00249 HEP 20254 b

1    prescribing;
2        (5) relevant medical studies related to prescribing;
3        (6) other information regarding the prescription of
4    controlled substances; and
5        (7) information regarding prescription drug disposal
6    events, including take-back programs or other disposal
7    options or events.
8    The content of the Internet website shall be periodically
9reviewed by the Prescription Monitoring Program Advisory
10Committee as set forth in Section 320 and updated in accordance
11with the recommendation of the advisory committee.
12    (s) The Prescription Monitoring Program shall regularly
13send electronic updates to the registered users of the Program.
14The Prescription Monitoring Program Advisory Committee shall
15review any communications sent to registered users and also
16make recommendations for communications as set forth in Section
17320. These updates shall include the following information:
18        (1) opportunities for accredited continuing education
19    programs related to prescribing of controlled substances;
20        (2) current clinical guidelines developed by health
21    care professional organizations on the prescribing of
22    opioids or other drugs as determined by the Advisory
23    Committee;
24        (3) programs or information developed by health care
25    professionals that may be used to assess patients or help
26    ensure compliance with prescriptions;

 

 

HB0001 Engrossed- 217 -LRB099 00249 HEP 20254 b

1        (4) updates from the Food and Drug Administration, the
2    Centers for Disease Control and Prevention, and other
3    public and private organizations which are relevant to
4    prescribing;
5        (5) relevant medical studies related to prescribing;
6        (6) other information regarding prescribing of
7    controlled substances;
8        (7) information regarding prescription drug disposal
9    events, including take-back programs or other disposal
10    options or events; and
11        (8) reminders that the Prescription Monitoring Program
12    is a useful clinical tool.
13(Source: P.A. 97-334, eff. 1-1-12; 97-813, eff. 7-13-12.)
 
14    (720 ILCS 570/319)
15    Sec. 319. Rules. The Department shall must adopt rules
16under the Illinois Administrative Procedure Act to implement
17Sections 316 through 321, including the following:
18        (1) Information collection and retrieval procedures
19    for the central repository, including the controlled
20    substances to be included in the program required under
21    Section 316 and Section 321 (now repealed).
22        (2) Design for the creation of the database required
23    under Section 317.
24        (3) Requirements for the development and installation
25    of on-line electronic access by the Department to

 

 

HB0001 Engrossed- 218 -LRB099 00249 HEP 20254 b

1    information collected by the central repository.
2(Source: P.A. 97-334, eff. 1-1-12.)
 
3    (720 ILCS 570/320)
4    Sec. 320. Advisory committee.
5    (a) There is created a Prescription Monitoring Program
6Advisory Committee The Secretary of the Department of Human
7Services must appoint an advisory committee to assist the
8Department of Human Services in implementing the Prescription
9Monitoring Program controlled substance prescription
10monitoring program created by this Article and to advise the
11Department on the professional performance of prescribers and
12dispensers and other matters germane to the advisory
13committee's field of competence Section 316 and former Section
14321 of this Act. The Advisory Committee consists of prescribers
15and dispensers.
16    (b) The Clinical Director of the Prescription Monitoring
17Program shall appoint Secretary of the Department of Human
18Services or his or her designee must determine the number of
19members to serve on the advisory committee. The advisory
20committee shall be composed of prescribers and dispensers as
21follows: 4 physicians licensed to practice medicine in all its
22branches; one advanced practice nurse; one physician
23assistant; one optometrist; one dentist; one podiatric
24physician; and 3 pharmacists. The Clinical Director of the
25Prescription Monitoring Program may appoint a representative

 

 

HB0001 Engrossed- 219 -LRB099 00249 HEP 20254 b

1of an organization representing a profession required to be
2appointed. The Clinical Director of the Prescription
3Monitoring Program shall serve as the chair of the committee.
4The Secretary must choose one of the members of the advisory
5committee to serve as chair of the committee.
6    (c) The advisory committee may appoint its other officers
7as it deems appropriate.
8    (d) The members of the advisory committee shall receive no
9compensation for their services as members of the advisory
10committee but may be reimbursed for their actual expenses
11incurred in serving on the advisory committee.
12    (e) The advisory committee shall:
13        (1) provide a uniform approach to reviewing this Act in
14    order to determine whether changes should be recommended to
15    the General Assembly; .
16        (2) review current drug schedules in order to manage
17    changes to the administrative rules pertaining to the
18    utilization of this Act; .
19        (3) review the following: current clinical guidelines
20    developed by health care professional organizations on the
21    prescribing of opioids or other controlled substances;
22    accredited continuing education programs related to
23    prescribing and dispensing; programs or information
24    developed by health care professional organizations that
25    may be used to assess patients or help ensure compliance
26    with prescriptions; updates from the Food and Drug

 

 

HB0001 Engrossed- 220 -LRB099 00249 HEP 20254 b

1    Administration, the Centers for Disease Control and
2    Prevention, and other public and private organizations
3    which are relevant to prescribing and dispensing; relevant
4    medical studies; and other publications which involve the
5    prescription of controlled substances;
6        (4) make recommendations for inclusion of these
7    materials or other studies which may be effective resources
8    for prescribers and dispensers on the Internet website of
9    the inquiry system established under Section 318;
10        (5) on at least a quarterly basis, review the content
11    of the Internet website of the inquiry system established
12    pursuant to Section 318 to ensure this Internet website has
13    the most current available information;
14        (6) on at least a quarterly basis, review opportunities
15    for federal grants and other forms of funding to support
16    projects which will increase the number of pilot programs
17    which integrate the inquiry system with electronic health
18    records; and
19        (7) on at least a quarterly basis, review communication
20    to be sent to all registered users of the inquiry system
21    established pursuant to Section 318, including
22    recommendations for relevant accredited continuing
23    education and information regarding prescribing and
24    dispensing.
25    (f) The Clinical Director of the Prescription Monitoring
26Program shall select 5 members, 3 physicians and 2 pharmacists,

 

 

HB0001 Engrossed- 221 -LRB099 00249 HEP 20254 b

1of the Prescription Monitoring Program Advisory Committee to
2serve as members of the peer review subcommittee. The purpose
3of the peer review subcommittee is to advise the Program on
4matters germane to the advisory committee's field of
5competence, establish a formal peer review of professional
6performance of prescribers and dispensers, and develop
7communications to transmit to prescribers and dispensers. The
8deliberations, information, and communications of the peer
9review subcommittee are privileged and confidential and shall
10not be disclosed in any manner except in accordance with
11current law.
12        (1) The peer review subcommittee shall periodically
13    review the data contained within the prescription
14    monitoring program to identify those prescribers or
15    dispensers who may be prescribing or dispensing outside the
16    currently accepted standards in the course of their
17    professional practice.
18        (2) The peer review subcommittee may identify
19    prescribers or dispensers who may be prescribing outside
20    the currently accepted medical standards in the course of
21    their professional practice and send the identified
22    prescriber or dispenser a request for information
23    regarding their prescribing or dispensing practices. This
24    request for information shall be sent via certified mail,
25    return receipt requested. A prescriber or dispenser shall
26    have 30 days to respond to the request for information.

 

 

HB0001 Engrossed- 222 -LRB099 00249 HEP 20254 b

1        (3) The peer review subcommittee shall refer a
2    prescriber or a dispenser to the Department of Financial
3    and Professional Regulation in the following situations:
4            (i) if a prescriber or dispenser does not respond
5        to three successive requests for information;
6            (ii) in the opinion of a majority of members of the
7        peer review subcommittee, the prescriber or dispenser
8        does not have a satisfactory explanation for the
9        practices identified by the peer review subcommittee
10        in its request for information; or
11            (iii) following communications with the peer
12        review subcommittee, the prescriber or dispenser does
13        not sufficiently rectify the practices identified in
14        the request for information in the opinion of a
15        majority of the members of the peer review
16        subcommittee.
17        (4) The Department of Financial and Professional
18    Regulation may initiate an investigation and discipline in
19    accordance with current laws and rules for any prescriber
20    or dispenser referred by the peer review subcommittee.
21        (5) The peer review subcommittee shall prepare an
22    annual report starting on July 1, 2017. This report shall
23    contain the following information: the number of times the
24    peer review subcommittee was convened; the number of
25    prescribers or dispensers who were reviewed by the peer
26    review committee; the number of requests for information

 

 

HB0001 Engrossed- 223 -LRB099 00249 HEP 20254 b

1    sent out by the peer review subcommittee; and the number of
2    prescribers or dispensers referred to the Department of
3    Financial and Professional Regulation. The annual report
4    shall be delivered electronically to the Department and to
5    the General Assembly. The report prepared by the peer
6    review subcommittee shall not identify any prescriber,
7    dispenser, or patient.
8(Source: P.A. 97-334, eff. 1-1-12.)
 
9    (720 ILCS 570/406)  (from Ch. 56 1/2, par. 1406)
10    Sec. 406. (a) It is unlawful for any person:
11        (1) who is subject to Article III knowingly to
12    distribute or dispense a controlled substance in violation
13    of Sections 308 through 314.5 of this Act; or
14        (2) who is a registrant, to manufacture a controlled
15    substance not authorized by his or her registration, or to
16    distribute or dispense a controlled substance not
17    authorized by his or her registration to another registrant
18    or other authorized person; or
19        (3) to refuse or fail to make, keep or furnish any
20    record, notification, order form, statement, invoice or
21    information required under this Act; or
22        (4) to refuse an entry into any premises for any
23    inspection authorized by this Act; or
24        (5) knowingly to keep or maintain any store, shop,
25    warehouse, dwelling, building, vehicle, boat, aircraft, or

 

 

HB0001 Engrossed- 224 -LRB099 00249 HEP 20254 b

1    other structure or place, which is resorted to by a person
2    unlawfully possessing controlled substances, or which is
3    used for possessing, manufacturing, dispensing or
4    distributing controlled substances in violation of this
5    Act.
6    Any person who violates this subsection (a) is guilty of a
7Class A misdemeanor for the first offense and a Class 4 felony
8for each subsequent offense. The fine for each subsequent
9offense shall not be more than $100,000. In addition, any
10practitioner who is found guilty of violating this subsection
11(a) is subject to suspension and revocation of his or her
12professional license, in accordance with such procedures as are
13provided by law for the taking of disciplinary action with
14regard to the license of said practitioner's profession.
15    (b) It is unlawful for any person knowingly:
16        (1) to distribute, as a registrant, a controlled
17    substance classified in Schedule I or II, except pursuant
18    to an order form as required by Section 307 of this Act; or
19        (2) to use, in the course of the manufacture or
20    distribution of a controlled substance, a registration
21    number which is fictitious, revoked, suspended, or issued
22    to another person; or
23        (3) to acquire or obtain, or attempt to acquire or
24    obtain, possession of a controlled substance by
25    misrepresentation, fraud, forgery, deception or
26    subterfuge; or

 

 

HB0001 Engrossed- 225 -LRB099 00249 HEP 20254 b

1        (3.1) to withhold information requested from a
2    practitioner, with the intent to obtain a controlled
3    substance that has not been prescribed, by
4    misrepresentation, fraud, forgery, deception, subterfuge,
5    or concealment of a material fact; or
6        (4) to furnish false or fraudulent material
7    information in, or omit any material information from, any
8    application, report or other document required to be kept
9    or filed under this Act, or any record required to be kept
10    by this Act; or
11        (5) to make, distribute or possess any punch, die,
12    plate, stone or other thing designed to print, imprint or
13    reproduce the trademark, trade name or other identifying
14    mark, imprint or device of another, or any likeness of any
15    of the foregoing, upon any controlled substance or
16    container or labeling thereof so as to render the drug a
17    counterfeit substance; or
18        (6) (blank); or
19        (7) (blank).
20    Any person who violates this subsection (b) is guilty of a
21Class 4 felony for the first offense and a Class 3 felony for
22each subsequent offense. The fine for the first offense shall
23be not more than $100,000. The fine for each subsequent offense
24shall not be more than $200,000.
25    (c) A person who knowingly or intentionally violates
26Section 316, 317, 318, or 319 is guilty of a Class A

 

 

HB0001 Engrossed- 226 -LRB099 00249 HEP 20254 b

1misdemeanor.
2(Source: P.A. 97-334, eff. 1-1-12.)
 
3    (720 ILCS 570/410)  (from Ch. 56 1/2, par. 1410)
4    Sec. 410. (a) Whenever any person who has not previously
5been convicted of, or placed on probation or court supervision
6for any offense under this Act or any law of the United States
7or of any State relating to cannabis or controlled substances,
8pleads guilty to or is found guilty of possession of a
9controlled or counterfeit substance under subsection (c) of
10Section 402 or of unauthorized possession of prescription form
11under Section 406.2, the court, without entering a judgment and
12with the consent of such person, may sentence him or her to
13probation.
14    (b) When a person is placed on probation, the court shall
15enter an order specifying a period of probation of 24 months
16and shall defer further proceedings in the case until the
17conclusion of the period or until the filing of a petition
18alleging violation of a term or condition of probation.
19    (c) The conditions of probation shall be that the person:
20(1) not violate any criminal statute of any jurisdiction; (2)
21refrain from possessing a firearm or other dangerous weapon;
22(3) submit to periodic drug testing at a time and in a manner
23as ordered by the court, but no less than 3 times during the
24period of the probation, with the cost of the testing to be
25paid by the probationer; and (4) perform no less than 30 hours

 

 

HB0001 Engrossed- 227 -LRB099 00249 HEP 20254 b

1of community service, provided community service is available
2in the jurisdiction and is funded and approved by the county
3board.
4    (d) The court may, in addition to other conditions, require
5that the person:
6        (1) make a report to and appear in person before or
7    participate with the court or such courts, person, or
8    social service agency as directed by the court in the order
9    of probation;
10        (2) pay a fine and costs;
11        (3) work or pursue a course of study or vocational
12    training;
13        (4) undergo medical or psychiatric treatment; or
14    treatment or rehabilitation approved by the Illinois
15    Department of Human Services;
16        (5) attend or reside in a facility established for the
17    instruction or residence of defendants on probation;
18        (6) support his or her dependents;
19        (6-5) refrain from having in his or her body the
20    presence of any illicit drug prohibited by the Cannabis
21    Control Act, the Illinois Controlled Substances Act, or the
22    Methamphetamine Control and Community Protection Act,
23    unless prescribed by a physician, and submit samples of his
24    or her blood or urine or both for tests to determine the
25    presence of any illicit drug;
26        (7) and in addition, if a minor:

 

 

HB0001 Engrossed- 228 -LRB099 00249 HEP 20254 b

1            (i) reside with his or her parents or in a foster
2        home;
3            (ii) attend school;
4            (iii) attend a non-residential program for youth;
5            (iv) contribute to his or her own support at home
6        or in a foster home.
7    (e) Upon violation of a term or condition of probation, the
8court may enter a judgment on its original finding of guilt and
9proceed as otherwise provided.
10    (f) Upon fulfillment of the terms and conditions of
11probation, the court shall discharge the person and dismiss the
12proceedings against him or her.
13    (g) A disposition of probation is considered to be a
14conviction for the purposes of imposing the conditions of
15probation and for appeal, however, discharge and dismissal
16under this Section is not a conviction for purposes of this Act
17or for purposes of disqualifications or disabilities imposed by
18law upon conviction of a crime.
19    (h) There may be only one discharge and dismissal under
20this Section, Section 10 of the Cannabis Control Act, Section
2170 of the Methamphetamine Control and Community Protection Act,
22Section 5-6-3.3 or 5-6-3.4 of the Unified Code of Corrections,
23or subsection (c) of Section 11-14 of the Criminal Code of 1961
24or the Criminal Code of 2012 with respect to any person.
25    (i) If a person is convicted of an offense under this Act,
26the Cannabis Control Act, or the Methamphetamine Control and

 

 

HB0001 Engrossed- 229 -LRB099 00249 HEP 20254 b

1Community Protection Act within 5 years subsequent to a
2discharge and dismissal under this Section, the discharge and
3dismissal under this Section shall be admissible in the
4sentencing proceeding for that conviction as evidence in
5aggravation.
6    (j) Notwithstanding subsection (a), before a person is
7sentenced to probation under this Section, the court may refer
8the person to the drug court established in that judicial
9circuit pursuant to Section 15 of the Drug Court Treatment Act.
10The drug court team shall evaluate the person's likelihood of
11successfully completing a sentence of probation under this
12Section and shall report the results of its evaluation to the
13court. If the drug court team finds that the person suffers
14from a substance abuse problem that makes him or her
15substantially unlikely to successfully complete a sentence of
16probation under this Section, then the drug court shall set
17forth its findings in the form of a written order, and the
18person shall not be sentenced to probation under this Section,
19but may be considered for the drug court program.
20(Source: P.A. 97-334, eff. 1-1-12; 97-1118, eff. 1-1-13;
2197-1150, eff. 1-25-13; 98-164, eff. 1-1-14.)
 
22    Section 5-105. The Methamphetamine Control and Community
23Protection Act is amended by changing Section 70 as follows:
 
24    (720 ILCS 646/70)

 

 

HB0001 Engrossed- 230 -LRB099 00249 HEP 20254 b

1    Sec. 70. Probation.
2    (a) Whenever any person who has not previously been
3convicted of, or placed on probation or court supervision for
4any offense under this Act, the Illinois Controlled Substances
5Act, the Cannabis Control Act, or any law of the United States
6or of any state relating to cannabis or controlled substances,
7pleads guilty to or is found guilty of possession of less than
815 grams of methamphetamine under paragraph (1) or (2) of
9subsection (b) of Section 60 of this Act, the court, without
10entering a judgment and with the consent of the person, may
11sentence him or her to probation.
12    (b) When a person is placed on probation, the court shall
13enter an order specifying a period of probation of 24 months
14and shall defer further proceedings in the case until the
15conclusion of the period or until the filing of a petition
16alleging violation of a term or condition of probation.
17    (c) The conditions of probation shall be that the person:
18        (1) not violate any criminal statute of any
19    jurisdiction;
20        (2) refrain from possessing a firearm or other
21    dangerous weapon;
22        (3) submit to periodic drug testing at a time and in a
23    manner as ordered by the court, but no less than 3 times
24    during the period of the probation, with the cost of the
25    testing to be paid by the probationer; and
26        (4) perform no less than 30 hours of community service,

 

 

HB0001 Engrossed- 231 -LRB099 00249 HEP 20254 b

1    if community service is available in the jurisdiction and
2    is funded and approved by the county board.
3    (d) The court may, in addition to other conditions, require
4that the person take one or more of the following actions:
5        (1) make a report to and appear in person before or
6    participate with the court or such courts, person, or
7    social service agency as directed by the court in the order
8    of probation;
9        (2) pay a fine and costs;
10        (3) work or pursue a course of study or vocational
11    training;
12        (4) undergo medical or psychiatric treatment; or
13    treatment or rehabilitation approved by the Illinois
14    Department of Human Services;
15        (5) attend or reside in a facility established for the
16    instruction or residence of defendants on probation;
17        (6) support his or her dependents;
18        (7) refrain from having in his or her body the presence
19    of any illicit drug prohibited by this Act, the Cannabis
20    Control Act, or the Illinois Controlled Substances Act,
21    unless prescribed by a physician, and submit samples of his
22    or her blood or urine or both for tests to determine the
23    presence of any illicit drug; or
24        (8) if a minor:
25            (i) reside with his or her parents or in a foster
26        home;

 

 

HB0001 Engrossed- 232 -LRB099 00249 HEP 20254 b

1            (ii) attend school;
2            (iii) attend a non-residential program for youth;
3        or
4            (iv) contribute to his or her own support at home
5        or in a foster home.
6    (e) Upon violation of a term or condition of probation, the
7court may enter a judgment on its original finding of guilt and
8proceed as otherwise provided.
9    (f) Upon fulfillment of the terms and conditions of
10probation, the court shall discharge the person and dismiss the
11proceedings against the person.
12    (g) A disposition of probation is considered to be a
13conviction for the purposes of imposing the conditions of
14probation and for appeal, however, discharge and dismissal
15under this Section is not a conviction for purposes of this Act
16or for purposes of disqualifications or disabilities imposed by
17law upon conviction of a crime.
18    (h) There may be only one discharge and dismissal under
19this Section, Section 410 of the Illinois Controlled Substances
20Act, Section 10 of the Cannabis Control Act, Section 5-6-3.3 or
215-6-3.4 of the Unified Code of Corrections, or subsection (c)
22of Section 11-14 of the Criminal Code of 1961 or the Criminal
23Code of 2012 with respect to any person.
24    (i) If a person is convicted of an offense under this Act,
25the Cannabis Control Act, or the Illinois Controlled Substances
26Act within 5 years subsequent to a discharge and dismissal

 

 

HB0001 Engrossed- 233 -LRB099 00249 HEP 20254 b

1under this Section, the discharge and dismissal under this
2Section are admissible in the sentencing proceeding for that
3conviction as evidence in aggravation.
4    (j) Notwithstanding subsection (a), before a person is
5sentenced to probation under this Section, the court may refer
6the person to the drug court established in that judicial
7circuit pursuant to Section 15 of the Drug Court Treatment Act.
8The drug court team shall evaluate the person's likelihood of
9successfully completing a sentence of probation under this
10Section and shall report the results of its evaluation to the
11court. If the drug court team finds that the person suffers
12from a substance abuse problem that makes him or her
13substantially unlikely to successfully complete a sentence of
14probation under this Section, then the drug court shall set
15forth its findings in the form of a written order, and the
16person shall not be sentenced to probation under this Section,
17but may be considered for the drug court program.
18(Source: P.A. 97-1118, eff. 1-1-13; 97-1150, eff. 1-25-13;
1998-164, eff. 1-1-14.)
 
20    Section 5-110. The Unified Code of Corrections is amended
21by changing Sections 5-6-3.3, 5-6-3.4, 5-9-1.1, and 5-9-1.1-5
22as follows:
 
23    (730 ILCS 5/5-6-3.3)
24    Sec. 5-6-3.3. Offender Initiative Program.

 

 

HB0001 Engrossed- 234 -LRB099 00249 HEP 20254 b

1    (a) Statement of purpose. The General Assembly seeks to
2continue other successful programs that promote public safety,
3conserve valuable resources, and reduce recidivism by
4defendants who can lead productive lives by creating the
5Offender Initiative Program.
6    (a-1) Whenever any person who has not previously been
7convicted of, or placed on probation or conditional discharge
8for, any felony offense under the laws of this State, the laws
9of any other state, or the laws of the United States, is
10arrested for and charged with a probationable felony offense of
11theft, retail theft, forgery, possession of a stolen motor
12vehicle, burglary, possession of burglary tools, possession of
13cannabis, possession of a controlled substance, or possession
14of methamphetamine, the court, with the consent of the
15defendant and the State's Attorney, may continue this matter to
16allow a defendant to participate and complete the Offender
17Initiative Program.
18    (a-2) Exemptions. A defendant shall not be eligible for
19this Program if the offense he or she has been arrested for and
20charged with is a violent offense. For purposes of this
21Program, a "violent offense" is any offense where bodily harm
22was inflicted or where force was used against any person or
23threatened against any person, any offense involving sexual
24conduct, sexual penetration, or sexual exploitation, any
25offense of domestic violence, domestic battery, violation of an
26order of protection, stalking, hate crime, driving under the

 

 

HB0001 Engrossed- 235 -LRB099 00249 HEP 20254 b

1influence of drugs or alcohol, and any offense involving the
2possession of a firearm or dangerous weapon. A defendant shall
3not be eligible for this Program if he or she has previously
4been adjudicated a delinquent minor for the commission of a
5violent offense as defined in this subsection.
6    (b) When a defendant is placed in the Program, after both
7the defendant and State's Attorney waive preliminary hearing
8pursuant to Section 109-3 of the Code of Criminal Procedure of
91963, the court shall enter an order specifying that the
10proceedings shall be suspended while the defendant is
11participating in a Program of not less 12 months.
12    (c) The conditions of the Program shall be that the
13defendant:
14        (1) not violate any criminal statute of this State or
15    any other jurisdiction;
16        (2) refrain from possessing a firearm or other
17    dangerous weapon;
18        (3) make full restitution to the victim or property
19    owner pursuant to Section 5-5-6 of this Code;
20        (4) obtain employment or perform not less than 30 hours
21    of community service, provided community service is
22    available in the county and is funded and approved by the
23    county board; and
24        (5) attend educational courses designed to prepare the
25    defendant for obtaining a high school diploma or to work
26    toward passing high school equivalency testing or to work

 

 

HB0001 Engrossed- 236 -LRB099 00249 HEP 20254 b

1    toward completing a vocational training program.
2    (d) The court may, in addition to other conditions, require
3that the defendant:
4        (1) undergo medical or psychiatric treatment, or
5    treatment or rehabilitation approved by the Illinois
6    Department of Human Services;
7        (2) refrain from having in his or her body the presence
8    of any illicit drug prohibited by the Methamphetamine
9    Control and Community Protection Act, the Cannabis Control
10    Act or the Illinois Controlled Substances Act, unless
11    prescribed by a physician, and submit samples of his or her
12    blood or urine or both for tests to determine the presence
13    of any illicit drug;
14        (3) submit to periodic drug testing at a time, manner,
15    and frequency as ordered by the court;
16        (4) pay fines, fees and costs; and
17        (5) in addition, if a minor:
18            (i) reside with his or her parents or in a foster
19        home;
20            (ii) attend school;
21            (iii) attend a non-residential program for youth;
22        or
23            (iv) contribute to his or her own support at home
24        or in a foster home.
25    (e) When the State's Attorney makes a factually specific
26offer of proof that the defendant has failed to successfully

 

 

HB0001 Engrossed- 237 -LRB099 00249 HEP 20254 b

1complete the Program or has violated any of the conditions of
2the Program, the court shall enter an order that the defendant
3has not successfully completed the Program and continue the
4case for arraignment pursuant to Section 113-1 of the Code of
5Criminal Procedure of 1963 for further proceedings as if the
6defendant had not participated in the Program.
7    (f) Upon fulfillment of the terms and conditions of the
8Program, the State's Attorney shall dismiss the case or the
9court shall discharge the person and dismiss the proceedings
10against the person.
11    (g) There may be only one discharge and dismissal under
12this Section with respect to any person.
13    (h) Notwithstanding subsection (a-1), if the court finds
14that the defendant suffers from a substance abuse problem, then
15before the person participates in the Program under this
16Section, the court may refer the person to the drug court
17established in that judicial circuit pursuant to Section 15 of
18the Drug Court Treatment Act. The drug court team shall
19evaluate the person's likelihood of successfully fulfilling
20the terms and conditions of the Program under this Section and
21shall report the results of its evaluation to the court. If the
22drug court team finds that the person suffers from a substance
23abuse problem that makes him or her substantially unlikely to
24successfully fulfill the terms and conditions of the Program,
25then the drug court shall set forth its findings in the form of
26a written order, and the person shall be ineligible to

 

 

HB0001 Engrossed- 238 -LRB099 00249 HEP 20254 b

1participate in the Program under this Section, but may be
2considered for the drug court program.
3(Source: P.A. 97-1118, eff. 1-1-13; 98-718, eff. 1-1-15.)
 
4    (730 ILCS 5/5-6-3.4)
5    Sec. 5-6-3.4. Second Chance Probation.
6    (a) Whenever any person who has not previously been
7convicted of, or placed on probation or conditional discharge
8for, any felony offense under the laws of this State, the laws
9of any other state, or the laws of the United States, including
10probation under Section 410 of the Illinois Controlled
11Substances Act, Section 70 of the Methamphetamine Control and
12Community Protection Act, Section 10 of the Cannabis Control
13Act, subsection (c) of Section 11-14 of the Criminal Code of
142012, Treatment Alternatives for Criminal Justice Clients
15(TASC) under Article 40 of the Alcoholism and Other Drug Abuse
16and Dependency Act, or prior successful completion of the
17Offender Initiative Program under Section 5-6-3.3 of this Code,
18and pleads guilty to, or is found guilty of, a probationable
19felony offense of possession of a controlled substance that is
20punishable as a Class 4 felony; possession of methamphetamine
21that is punishable as a Class 4 felony; theft that is
22punishable as a Class 3 felony based on the value of the
23property or punishable as a Class 4 felony if the theft was
24committed in a school or place of worship or if the theft was
25of governmental property; retail theft that is punishable as a

 

 

HB0001 Engrossed- 239 -LRB099 00249 HEP 20254 b

1Class 3 felony based on the value of the property; criminal
2damage to property that is punishable as a Class 4 felony;
3criminal damage to government supported property that is
4punishable as a Class 4 felony; or possession of cannabis which
5is punishable as a Class 4 felony, the court, with the consent
6of the defendant and the State's Attorney, may, without
7entering a judgment, sentence the defendant to probation under
8this Section.
9    (a-1) Exemptions. A defendant is not eligible for this
10probation if the offense he or she pleads guilty to, or is
11found guilty of, is a violent offense, or he or she has
12previously been convicted of a violent offense. For purposes of
13this probation, a "violent offense" is any offense where bodily
14harm was inflicted or where force was used against any person
15or threatened against any person, any offense involving sexual
16conduct, sexual penetration, or sexual exploitation, any
17offense of domestic violence, domestic battery, violation of an
18order of protection, stalking, hate crime, driving under the
19influence of drugs or alcohol, and any offense involving the
20possession of a firearm or dangerous weapon. A defendant shall
21not be eligible for this probation if he or she has previously
22been adjudicated a delinquent minor for the commission of a
23violent offense as defined in this subsection.
24    (b) When a defendant is placed on probation, the court
25shall enter an order specifying a period of probation of not
26less than 24 months and shall defer further proceedings in the

 

 

HB0001 Engrossed- 240 -LRB099 00249 HEP 20254 b

1case until the conclusion of the period or until the filing of
2a petition alleging violation of a term or condition of
3probation.
4    (c) The conditions of probation shall be that the
5defendant:
6        (1) not violate any criminal statute of this State or
7    any other jurisdiction;
8        (2) refrain from possessing a firearm or other
9    dangerous weapon;
10        (3) make full restitution to the victim or property
11    owner under Section 5-5-6 of this Code;
12        (4) obtain or attempt to obtain employment;
13        (5) pay fines and costs;
14        (6) attend educational courses designed to prepare the
15    defendant for obtaining a high school diploma or to work
16    toward passing high school equivalency testing or to work
17    toward completing a vocational training program;
18        (7) submit to periodic drug testing at a time and in a
19    manner as ordered by the court, but no less than 3 times
20    during the period of probation, with the cost of the
21    testing to be paid by the defendant; and
22        (8) perform a minimum of 30 hours of community service.
23    (d) The court may, in addition to other conditions, require
24that the defendant:
25        (1) make a report to and appear in person before or
26    participate with the court or such courts, person, or

 

 

HB0001 Engrossed- 241 -LRB099 00249 HEP 20254 b

1    social service agency as directed by the court in the order
2    of probation;
3        (2) undergo medical or psychiatric treatment, or
4    treatment or rehabilitation approved by the Illinois
5    Department of Human Services;
6        (3) attend or reside in a facility established for the
7    instruction or residence of defendants on probation;
8        (4) support his or her dependents; or
9        (5) refrain from having in his or her body the presence
10    of any illicit drug prohibited by the Methamphetamine
11    Control and Community Protection Act, the Cannabis Control
12    Act, or the Illinois Controlled Substances Act, unless
13    prescribed by a physician, and submit samples of his or her
14    blood or urine or both for tests to determine the presence
15    of any illicit drug.
16    (e) Upon violation of a term or condition of probation, the
17court may enter a judgment on its original finding of guilt and
18proceed as otherwise provided by law.
19    (f) Upon fulfillment of the terms and conditions of
20probation, the court shall discharge the person and dismiss the
21proceedings against the person.
22    (g) A disposition of probation is considered to be a
23conviction for the purposes of imposing the conditions of
24probation and for appeal; however, a discharge and dismissal
25under this Section is not a conviction for purposes of this
26Code or for purposes of disqualifications or disabilities

 

 

HB0001 Engrossed- 242 -LRB099 00249 HEP 20254 b

1imposed by law upon conviction of a crime.
2    (h) There may be only one discharge and dismissal under
3this Section, Section 410 of the Illinois Controlled Substances
4Act, Section 70 of the Methamphetamine Control and Community
5Protection Act, Section 10 of the Cannabis Control Act,
6Treatment Alternatives for Criminal Justice Clients (TASC)
7under Article 40 of the Alcoholism and Other Drug Abuse and
8Dependency Act, the Offender Initiative Program under Section
95-6-3.3 of this Code, and subsection (c) of Section 11-14 of
10the Criminal Code of 2012 with respect to any person.
11    (i) If a person is convicted of any offense which occurred
12within 5 years subsequent to a discharge and dismissal under
13this Section, the discharge and dismissal under this Section
14shall be admissible in the sentencing proceeding for that
15conviction as evidence in aggravation.
16    (j) Notwithstanding subsection (a), if the court finds that
17the defendant suffers from a substance abuse problem, then
18before the person is placed on probation under this Section,
19the court may refer the person to the drug court established in
20that judicial circuit pursuant to Section 15 of the Drug Court
21Treatment Act. The drug court team shall evaluate the person's
22likelihood of successfully fulfilling the terms and conditions
23of probation under this Section and shall report the results of
24its evaluation to the court. If the drug court team finds that
25the person suffers from a substance abuse problem that makes
26him or her substantially unlikely to successfully fulfill the

 

 

HB0001 Engrossed- 243 -LRB099 00249 HEP 20254 b

1terms and conditions of probation under this Section, then the
2drug court shall set forth its findings in the form of a
3written order, and the person shall be ineligible to be placed
4on probation under this Section, but may be considered for the
5drug court program.
6(Source: P.A. 98-164, eff. 1-1-14; 98-718, eff. 1-1-15.)
 
7    (730 ILCS 5/5-9-1.1)  (from Ch. 38, par. 1005-9-1.1)
8    (Text of Section from P.A. 94-550, 96-132, 96-402, 96-1234,
997-545, and 98-537)
10    Sec. 5-9-1.1. Drug related offenses.
11    (a) When a person has been adjudged guilty of a drug
12related offense involving possession or delivery of cannabis or
13possession or delivery of a controlled substance, other than
14methamphetamine, as defined in the Cannabis Control Act, as
15amended, or the Illinois Controlled Substances Act, as amended,
16in addition to any other penalty imposed, a fine shall be
17levied by the court at not less than the full street value of
18the cannabis or controlled substances seized.
19    "Street value" shall be determined by the court on the
20basis of testimony of law enforcement personnel and the
21defendant as to the amount seized and such testimony as may be
22required by the court as to the current street value of the
23cannabis or controlled substance seized.
24    (b) In addition to any penalty imposed under subsection (a)
25of this Section, a fine of $100 shall be levied by the court,

 

 

HB0001 Engrossed- 244 -LRB099 00249 HEP 20254 b

1the proceeds of which shall be collected by the Circuit Clerk
2and remitted to the State Treasurer under Section 27.6 of the
3Clerks of Courts Act for deposit into the Trauma Center Fund
4for distribution as provided under Section 3.225 of the
5Emergency Medical Services (EMS) Systems Act.
6    (c) In addition to any penalty imposed under subsection (a)
7of this Section, a fee of $5 shall be assessed by the court,
8the proceeds of which shall be collected by the Circuit Clerk
9and remitted to the State Treasurer under Section 27.6 of the
10Clerks of Courts Act for deposit into the Spinal Cord Injury
11Paralysis Cure Research Trust Fund. This additional fee of $5
12shall not be considered a part of the fine for purposes of any
13reduction in the fine for time served either before or after
14sentencing.
15    (d) In addition to any penalty imposed under subsection (a)
16of this Section for a drug related offense involving possession
17or delivery of cannabis or possession or delivery of a
18controlled substance as defined in the Cannabis Control Act,
19the Illinois Controlled Substances Act, or the Methamphetamine
20Control and Community Protection Act, a fee of $50 shall be
21assessed by the court, the proceeds of which shall be collected
22by the Circuit Clerk and remitted to the State Treasurer under
23Section 27.6 of the Clerks of Courts Act for deposit into the
24Performance-enhancing Substance Testing Fund. This additional
25fee of $50 shall not be considered a part of the fine for
26purposes of any reduction in the fine for time served either

 

 

HB0001 Engrossed- 245 -LRB099 00249 HEP 20254 b

1before or after sentencing. The provisions of this subsection
2(d), other than this sentence, are inoperative after June 30,
32011.
4    (e) In addition to any penalty imposed under subsection (a)
5of this Section, a $25 assessment shall be assessed by the
6court, the proceeds of which shall be collected by the Circuit
7Clerk and remitted to the State Treasurer for deposit into the
8Criminal Justice Information Projects Fund. The moneys
9deposited into the Criminal Justice Information Projects Fund
10under this Section shall be appropriated to and administered by
11the Illinois Criminal Justice Information Authority for
12funding of drug task forces and Metropolitan Enforcement
13Groups.
14    (f) In addition to any penalty imposed under subsection (a)
15of this Section, a $40 $20 assessment shall be assessed by the
16court, the proceeds of which shall be collected by the Circuit
17Clerk. Of the collected proceeds, (i) 90% shall be remitted to
18the State Treasurer for deposit into the Prescription Pill and
19Drug Disposal Fund; (ii) 5% shall be remitted for deposit into
20the Criminal Justice Information Projects Fund, for use by the
21Illinois Criminal Justice Information Authority for the costs
22associated with making grants from the Prescription Pill and
23Drug Disposal Fund; and (iii) the Circuit Clerk shall retain 5%
24for deposit into the Circuit Court Clerk Operation and
25Administrative Fund for the costs associated with
26administering this subsection.

 

 

HB0001 Engrossed- 246 -LRB099 00249 HEP 20254 b

1(Source: P.A. 97-545, eff. 1-1-12; 98-537, eff. 8-23-13.)
 
2    (Text of Section from P.A. 94-556, 96-132, 96-402, 96-1234,
397-545, and 98-537)
4    Sec. 5-9-1.1. Drug related offenses.
5    (a) When a person has been adjudged guilty of a drug
6related offense involving possession or delivery of cannabis or
7possession or delivery of a controlled substance as defined in
8the Cannabis Control Act, the Illinois Controlled Substances
9Act, or the Methamphetamine Control and Community Protection
10Act, in addition to any other penalty imposed, a fine shall be
11levied by the court at not less than the full street value of
12the cannabis or controlled substances seized.
13    "Street value" shall be determined by the court on the
14basis of testimony of law enforcement personnel and the
15defendant as to the amount seized and such testimony as may be
16required by the court as to the current street value of the
17cannabis or controlled substance seized.
18    (b) In addition to any penalty imposed under subsection (a)
19of this Section, a fine of $100 shall be levied by the court,
20the proceeds of which shall be collected by the Circuit Clerk
21and remitted to the State Treasurer under Section 27.6 of the
22Clerks of Courts Act for deposit into the Trauma Center Fund
23for distribution as provided under Section 3.225 of the
24Emergency Medical Services (EMS) Systems Act.
25    (c) In addition to any penalty imposed under subsection (a)

 

 

HB0001 Engrossed- 247 -LRB099 00249 HEP 20254 b

1of this Section, a fee of $5 shall be assessed by the court,
2the proceeds of which shall be collected by the Circuit Clerk
3and remitted to the State Treasurer under Section 27.6 of the
4Clerks of Courts Act for deposit into the Spinal Cord Injury
5Paralysis Cure Research Trust Fund. This additional fee of $5
6shall not be considered a part of the fine for purposes of any
7reduction in the fine for time served either before or after
8sentencing.
9    (d) In addition to any penalty imposed under subsection (a)
10of this Section for a drug related offense involving possession
11or delivery of cannabis or possession or delivery of a
12controlled substance as defined in the Cannabis Control Act,
13the Illinois Controlled Substances Act, or the Methamphetamine
14Control and Community Protection Act, a fee of $50 shall be
15assessed by the court, the proceeds of which shall be collected
16by the Circuit Clerk and remitted to the State Treasurer under
17Section 27.6 of the Clerks of Courts Act for deposit into the
18Performance-enhancing Substance Testing Fund. This additional
19fee of $50 shall not be considered a part of the fine for
20purposes of any reduction in the fine for time served either
21before or after sentencing. The provisions of this subsection
22(d), other than this sentence, are inoperative after June 30,
232011.
24    (e) In addition to any penalty imposed under subsection (a)
25of this Section, a $25 assessment shall be assessed by the
26court, the proceeds of which shall be collected by the Circuit

 

 

HB0001 Engrossed- 248 -LRB099 00249 HEP 20254 b

1Clerk and remitted to the State Treasurer for deposit into the
2Criminal Justice Information Projects Fund. The moneys
3deposited into the Criminal Justice Information Projects Fund
4under this Section shall be appropriated to and administered by
5the Illinois Criminal Justice Information Authority for
6funding of drug task forces and Metropolitan Enforcement
7Groups.
8    (f) In addition to any penalty imposed under subsection (a)
9of this Section, a $40 $20 assessment shall be assessed by the
10court, the proceeds of which shall be collected by the Circuit
11Clerk. Of the collected proceeds, (i) 90% shall be remitted to
12the State Treasurer for deposit into the Prescription Pill and
13Drug Disposal Fund; (ii) 5% shall be remitted for deposit into
14the Criminal Justice Information Projects Fund, for use by the
15Illinois Criminal Justice Information Authority for the costs
16associated with making grants from the Prescription Pill and
17Drug Disposal Fund; and (iii) the Circuit Clerk shall retain 5%
18for deposit into the Circuit Court Clerk Operation and
19Administrative Fund for the costs associated with
20administering this subsection.
21(Source: P.A. 97-545, eff. 1-1-12; 98-537, eff. 8-23-13.)
 
22    (730 ILCS 5/5-9-1.1-5)
23    Sec. 5-9-1.1-5. Methamphetamine related offenses.
24    (a) When a person has been adjudged guilty of a
25methamphetamine related offense involving possession or

 

 

HB0001 Engrossed- 249 -LRB099 00249 HEP 20254 b

1delivery of methamphetamine or any salt of an optical isomer of
2methamphetamine or possession of a methamphetamine
3manufacturing material as set forth in Section 10 of the
4Methamphetamine Control and Community Protection Act with the
5intent to manufacture a substance containing methamphetamine
6or salt of an optical isomer of methamphetamine, in addition to
7any other penalty imposed, a fine shall be levied by the court
8at not less than the full street value of the methamphetamine
9or salt of an optical isomer of methamphetamine or
10methamphetamine manufacturing materials seized.
11    "Street value" shall be determined by the court on the
12basis of testimony of law enforcement personnel and the
13defendant as to the amount seized and such testimony as may be
14required by the court as to the current street value of the
15methamphetamine or salt of an optical isomer of methamphetamine
16or methamphetamine manufacturing materials seized.
17    (b) In addition to any penalty imposed under subsection (a)
18of this Section, a fine of $100 shall be levied by the court,
19the proceeds of which shall be collected by the Circuit Clerk
20and remitted to the State Treasurer under Section 27.6 of the
21Clerks of Courts Act for deposit into the Methamphetamine Law
22Enforcement Fund and allocated as provided in subsection (d) of
23Section 5-9-1.2.
24    (c) In addition to any penalty imposed under subsection (a)
25of this Section, a $25 assessment shall be assessed by the
26court, the proceeds of which shall be collected by the Circuit

 

 

HB0001 Engrossed- 250 -LRB099 00249 HEP 20254 b

1Clerk and remitted to the State Treasurer for deposit into the
2Criminal Justice Information Projects Fund. The moneys
3deposited into the Criminal Justice Information Projects Fund
4under this Section shall be appropriated to and administered by
5the Illinois Criminal Justice Information Authority for
6funding of drug task forces and Metropolitan Enforcement
7Groups.
8    (d) In addition to any penalty imposed under subsection (a)
9of this Section, a $40 $20 assessment shall be assessed by the
10court, the proceeds of which shall be collected by the Circuit
11Clerk. Of the collected proceeds, (i) 90% shall be remitted to
12the State Treasurer for deposit into the Prescription Pill and
13Drug Disposal Fund; (ii) 5% shall be remitted for deposit into
14the Criminal Justice Information Projects Fund, for use by the
15Illinois Criminal Justice Information Authority for the costs
16associated with making grants from the Prescription Pill and
17Drug Disposal Fund; and (iii) the Circuit Clerk shall retain 5%
18for deposit into the Circuit Court Clerk Operation and
19Administrative Fund for the costs associated with
20administering this subsection.
21(Source: P.A. 97-545, eff. 1-1-12; 98-537, eff. 8-23-13.)
 
22    Section 5-115. The Drug Court Treatment Act is amended by
23changing Section 20 and by adding Sections 45 and 50 as
24follows:
 

 

 

HB0001 Engrossed- 251 -LRB099 00249 HEP 20254 b

1    (730 ILCS 166/20)
2    Sec. 20. Eligibility.
3    (a) A defendant may be admitted into a drug court program
4only upon the agreement of the prosecutor and the defendant and
5with the approval of the court.
6    (b) A defendant shall be excluded from a drug court program
7if any of one of the following apply:
8        (1) The crime is a crime of violence as set forth in
9    clause (4) of this subsection (b).
10        (2) The defendant denies his or her use of or addiction
11    to drugs.
12        (3) The defendant does not demonstrate a willingness to
13    participate in a treatment program.
14        (4) The defendant has been convicted of a crime of
15    violence within the past 10 years excluding incarceration
16    time. As used in this Section, "crime of violence" means ,
17    including but not limited to: first degree murder, second
18    degree murder, predatory criminal sexual assault of a
19    child, aggravated criminal sexual assault, criminal sexual
20    assault, armed robbery, aggravated arson, arson,
21    aggravated kidnaping, kidnaping, aggravated battery
22    resulting in great bodily harm or permanent disability,
23    stalking, aggravated stalking, or any offense involving
24    the discharge of a firearm.
25    (c) Notwithstanding subsection (a), the defendant may be
26admitted into a drug court program only upon the agreement of

 

 

HB0001 Engrossed- 252 -LRB099 00249 HEP 20254 b

1the prosecutor if:
2        (1) the defendant is charged with a Class 2 or greater
3    felony violation of:
4            (A) Section 401, 401.1, 405, or 405.2 of the
5        Illinois Controlled Substances Act;
6            (B) Section 5, 5.1, or 5.2 of the Cannabis Control
7        Act;
8            (C) Section 15, 20, 25, 30, 35, 40, 45, 50, 55, 56,
9        or 65 of the Methamphetamine Control and Community
10        Protection Act; or
11        (2) the defendant has previously, on 3 or more
12    occasions, either completed a drug court program, been
13    discharged from a drug court program, or been terminated
14    from a drug court program.
15        (5) The defendant has previously completed or has been
16    discharged from a drug court program.
17(Source: P.A. 92-58, eff. 1-1-02.)
 
18    (730 ILCS 166/45 new)
19    Sec. 45. Education seminars for drug court prosecutors.
20Subject to appropriation, the Office of the State's Attorneys
21Appellate Prosecutor shall conduct mandatory education
22seminars on the subjects of substance abuse and addiction for
23all drug court prosecutors throughout the State.
 
24    (730 ILCS 166/50 new)

 

 

HB0001 Engrossed- 253 -LRB099 00249 HEP 20254 b

1    Sec. 50. Education seminars for public defenders. Subject
2to appropriation, the Office of the State Appellate Defender
3shall conduct mandatory education seminars on the subjects of
4substance abuse and addiction for all public defenders and
5assistant public defenders practicing in drug courts
6throughout the State.
 
7    Section 5-120. The Veterans and Servicemembers Court
8Treatment Act is amended by changing Section 20 as follows:
 
9    (730 ILCS 167/20)
10    Sec. 20. Eligibility. Veterans and Servicemembers are
11eligible for Veterans and Servicemembers Courts, provided the
12following:
13    (a) A defendant, who is eligible for probation based on the
14nature of the crime convicted of and in consideration of his or
15her criminal background, if any, may be admitted into a
16Veterans and Servicemembers Court program only upon the
17agreement of the prosecutor and the defendant and with the
18approval of the Court.
19    (b) A defendant shall be excluded from Veterans and
20Servicemembers Court program if any of one of the following
21applies:
22        (1) The crime is a crime of violence as set forth in
23    clause (3) of this subsection (b).
24        (2) The defendant does not demonstrate a willingness to

 

 

HB0001 Engrossed- 254 -LRB099 00249 HEP 20254 b

1    participate in a treatment program.
2        (3) The defendant has been convicted of a crime of
3    violence within the past 10 years excluding incarceration
4    time. As used in this Section, "crime of violence" means ,
5    including but not limited to: first degree murder, second
6    degree murder, predatory criminal sexual assault of a
7    child, aggravated criminal sexual assault, criminal sexual
8    assault, armed robbery, aggravated arson, arson,
9    aggravated kidnapping and kidnapping, aggravated battery
10    resulting in great bodily harm or permanent disability,
11    stalking, aggravated stalking, or any offense involving
12    the discharge of a firearm or where occurred serious bodily
13    injury or death to any person.
14        (4) (Blank).
15        (5) The crime for which the defendant has been
16    convicted is non-probationable.
17        (6) The sentence imposed on the defendant, whether the
18    result of a plea or a finding of guilt, renders the
19    defendant ineligible for probation.
20(Source: P.A. 97-946, eff. 8-13-12; 98-152, eff. 1-1-14.)
 
21    Section 5-125. The Good Samaritan Act is amended by adding
22Section 36 and by changing Section 70 as follows:
 
23    (745 ILCS 49/36 new)
24    Sec. 36. Pharmacists; exemptions from civil liability for

 

 

HB0001 Engrossed- 255 -LRB099 00249 HEP 20254 b

1the dispensing of an opioid antagonist to individuals who may
2or may not be at risk for an opioid overdose. Any person
3licensed as a pharmacist in Illinois or any other state or
4territory of the United States who in good faith dispenses or
5administers an opioid antagonist as defined in Section 5-23 of
6the Alcoholism and Other Drug Abuse and Dependency Act in
7compliance with the procedures or protocols developed under
8Section 19.1 of the Pharmacy Practice Act, or the standing
9order of any person licensed under the Medical Practice Act of
101987, without fee or compensation in any way, shall not, as a
11result of her or his acts or omissions, except for willful or
12wanton misconduct on the part of the person, in dispensing the
13drug or administering the drug, be liable for civil damages.
 
14    (745 ILCS 49/70)
15    Sec. 70. Law enforcement officers, firemen, Emergency
16Medical Technicians (EMTs) and First Responders; exemption
17from civil liability for emergency care. Any law enforcement
18officer or fireman as defined in Section 2 of the Line of Duty
19Compensation Act, any "emergency medical technician (EMT)" as
20defined in Section 3.50 of the Emergency Medical Services (EMS)
21Systems Act, and any "first responder" as defined in Section
223.60 of the Emergency Medical Services (EMS) Systems Act, who
23in good faith provides emergency care, including the
24administration of an opioid antagonist as defined in Section
255-23 of the Alcoholism and Other Drug Abuse and Dependency Act,

 

 

HB0001 Engrossed- 256 -LRB099 00249 HEP 20254 b

1without fee or compensation to any person shall not, as a
2result of his or her acts or omissions, except willful and
3wanton misconduct on the part of the person, in providing the
4care, be liable to a person to whom such care is provided for
5civil damages.
6(Source: P.A. 93-1047, eff. 10-18-04; 94-826, eff. 1-1-07.)
 
7    Section 999. Effective date. This Act takes effect upon
8becoming law.